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Abstract 
IgA nephropathy (IgAN) is recognised as the commonest cause of glomerulonephritis 
worldwide. It is a heterogeneous condition with two major subtypes: primary and 
secondary IgAN, the latter being most commonly associated with liver disease. The 
aetiology of IgAN remains obscure. Much of the early research into its pathogenesis 
focused on alterations in the IgA metabolism as well as its interactions with putative 
food, infective, and auto-antigens. More recently abnormalities of IgAl 0- 
glycosylation have attracted attention as a possible key to IgA deposition. The 
contradictory results of IgAN research mirror its variable clinical features. 
The aim of this thesis is to assess: (i) the IgA I 0-glycosylation pattern; (ii) monocyte 
Fc a-receptor expression; (iii) in vitro IgA production; and (iv) IgA isotype and sub- 
class profile in patients with primary and hepatic IgAN, their appropriate renal and 
hepatic controls, as well as normal controls. 
Ile hinge glycopeptide of purified serum IgAl was analysed by MALDI mass 
spectrometry. IgAl was under-sialylated in all our patient groups when compared 
with normal controls. Patients with primary IgAN also had a small decrease in their 
galactose and GaINAc content as well as a number of highly abnormal species which 
were specific to this group. 
Levels of serum and supernatant IgA from cultured peripheral blood mononuclear 
cells were measured using ELISA. Total serum IgA levels (but not supernatant) were 
raised in all four diseased groups. Serum IgAl and IgA2 levels were both increased in 
primary IgAN. Polymeric IgA levels measured by size exclusion chromatography 
were only elevated in the ciffhosis group. There was no difference in monocyte Fca 
receptor expression in any of the groups by flow cytometry. 
In summary, we found significant changes in IgAl 0-glycosylation in all our patient 
groups and their diseased controls. These results suggest that altered glycosylation is 
not specific to primary IgAN. Further characterisation of the highly abnormal 
glycoforms specific to IgAN and their interactions is warranted. Despite elevated 
serum IgA levels in IgAN, we found no IgA immune system over-activity and no 
alterations in monocyte FcaR expression. 
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Chapter 1: Immunoglobulin A Nephropathies 
1.1 Introduction 
The French pathologists Berger and Hinglais (1967) first described the syndrome of 
primary IgA nephropathy (PIgAN) in the 1960s as a glomerulonephritis characterised 
by mesangial IgA deposits. Since then it has been recognised as the commonest cause 
of glomerulonephritis (GN) in parts of the world where renal biopsies are routinely 
performed (Julian et al 1988). The disease accounts for 10% of patients on dialysis for 
end-stage renal disease (ESRD) (d'Amico 1987). Since the condition mainly affects 
young adults, it incurs a high cost on individuals and society. 
Alcoholic liver disease is the commonest cause of secondary IgAN and manifests 
mainly as hepatic IgAN (HIgAN) (Van de Wiel et al 1987). When comparing their 
natural histories, unlike primary IgAN, HIgAN is deemed a more benign condition, 
having rarely been reported to progress to ESRD (Newell 1987). Mesangial IgA 
deposits and altered serum IgA profiles are common to both primary and secondary 
IgAN's (Galla 1995). As such, IgA nephropathies are unique in that the diagnosis 
depends on the presence of IgA immune deposits on immunofluorescence (EF) 
studies, rather than histological appearance or a distinct clinical syndrome. 
There is no effective specific treatment for IgAN and the absence of satisfactory 
animal models and ethical limitations to human experiments restrict our 
understanding of their aetiology (Feehally 1997). Hepatic IgAN, where renal and IgA 
system pathology co-exist, may provide a valuable model for examining the 
pathogenesis and determinants of disease progression in IgAN. Research aiming 
towards elucidation of the pathogenesis of IgAN may through consequent design of 
specific therapies, have a positive influence on the treatment and prognosis of this 
group of patients. 
1.2 Aims of this thesis 
Despite much research interest over the years into the pathogenesis of IgA 
nephropathies, many questions remain unanswered. None of the information we have 
learnt as a result of the studies I have reviewed in this thesis has led to a clear 
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understanding of the aetiology or brought about changes in the therapies for IgAN. 
The structure of the IgAl molecule has become increasingly central to the 
understanding of the pathogenesis of IgAN. Alterations of the IgAl glycosylation 
potentially affect all its interactions with binding sites involved in its homeostasis as 
well as the renal mesangium. The latter may have a crucial role in determining 
whether deposited IgA is cleared or sets up an inflammatory process. Glycobiology 
has become a burgeoning science in the diagnosis and treatment of a wide range of 
diseases. As such, it has the potential to make a positive impact on our understanding 
of the pathogenesis of IgAN and to create tailor-made therapies to prevent disease 
progression in IgAN. 
With this background in mind we set out to investigate the features of IgA biology 
which we believe may hold the key to understanding the pathogenesis of IgA 
nephropathies. We hypothesise that abnormalities in either IgAl 0-glycosylation or 
IgA production and the consequent effect on the interaction between IgA and its 
receptors may explain the aetiology of IgAN. Furthermore, comparisons between 
different types of IgAN may shed light on some of the different factors that may play 
a role in disease progression in this heterogeneous condition. The specific aims of this 
project therefore are: 
1. Optimal characterisation of the glycan structure of IgAl from patients with 
primary and hepatic IgAN and their controls by devising an improved mass 
spectrometric technique. 
2. To study and compare the biological characteristics of serum IgA in the 
patient groups and their controls. 
3. To study the production of IgA using cultured peripheral blood mononuclear 
cells (PBMCs) from our different subject groups. 
4. To assess the clearance of IgA from the circulation by studying the expression 
of Fca-I receptors (CD89) on circulating monocytes and neutrophils by flow 
cytometry. 
19 
1.3 Human IgA Biology 
1.3.1 IgA system compartments 
IgA is the most abundantly produced immunoglobulin in man with a unique 
heterogeneity in its molecular form and distribution (Delacroix et al 1982). It is the 
predominant immunoglobulin in the mucosal secretions of the body, forming the first 
line of defence against potentially invasive pathogens. It is also present in the serum 
making up 15% of the total circulating immunoglobulins (Mestecky 1988). Around 
66 ing of IgA per kg body weight is synthesised each day which approximates to 
twice the amount of IgG and IgM produced by the body per day (Conley and 
Delacroix 1987). IgA exists as two isotypes, IgAl and IgA2 (Kerr 1990). 90% of 
serum IgA is monomeric IgAl produced in the bone marrow, lymph nodes, tonsils, 
and spleen. A small proportion of circulating IgA is dimeric and even less commonly 
polymeric. In contrast, secretory IgA produced at mucosal surfaces is predominantly 
dimeric with some IgA present in the polymeric form. The ratios of IgAl to IgA2 
vary depending on the mucosal site (Mestecky and McGhee 1987). 
The mucosal and systemic IgA immune systems were initially regarded as separate 
compartments under separate control. In studies where either a mucosal antigen or 
systemic antigen were used to challenge the IgA immune system, the production of 
serum IgA without induction of secretory IgA and vice versa supported this notion. 
Although understanding the dynamics of such a system has been challenging there are 
suggestions that some degree of 'cross talk' may in fact occur between the two. The 
majority of this evidence comes from animal studies (Pabst and Reynolds 1987) 
although limited support has been found for trafficking of cells controlling IgA 
synthesis fornýiing a kind of mucosal-marrow axis in humans (de FitJer et al 1996). 
The majority of the human studies have concentrated on oral tolerance and the 
immune responses to immunisation via mucosal or systemic challenges with specific 
antigens. Such links suggest that the mucosal and systemically produced IgA whilst 
discrete, exist as intimately linked systems. 
1.3.2 Structure 
Human IgA is a heavily glycosylated glycoprotein which exists as a heterogeneous 
population of different isoforms. However, all the different forms of IgA are made of 
two heavy (H) ot chains of approximately 60 kDa, and two light (L) chains (25 kDa) 
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producing the Fab arms and Fc region common to all immunoglobulins (Kerr 1990). 
Each heavy chain is folded into the N-terminal variable domain (VH), followed by the 
constant domains Cott (CH09 Ca2 (CH2), and CO (CH3). IgAl has a flexible hinge 
region between the Cccl and C(x2 domains. The light chains are composed of two 
domains, VL and CL. The code for the IgA constant heavy chain is located on the a 
genes on chromosome 14 (Flannagan and Rabbitts 1982). There are two (X genes, al 
and a2, with a2 existing in two allotypic forms cc2 m(l) and a2 m(2). Human IgA 
therefore exists as two isotypic forms, IgA, and IgA2 (Fig 1.1), with IgA2 existing in 
two allotypic forms IgA2 m(l) and IgA2 m(2). 
1.3.2.1 IgAl and IgA2 The two isotypes of IgA differ only in the amino acid 
constitution of their heavy chains, predominantly arising from the absence of 13 
amino acids in IgA2 between the CHI and CH2 domains. Both have N-linked 
glycosylation sites but IgAl alone is distinct in having O-linked carbohydrates at its 
hinge region (Keff 1990). The 13 amino acid hinge region of the al-chain comprises a 
repeating sequence of proline, serine, and threonine residues, the latter two being 
variably glycosylated by carrying simple O-linked oligosaccharides as shown in 
Figures 1.2 and 2.5. The a2-chain lacks such a structure which may confer important 
biological advantages in rendering IgA2 resistant to cleavage by released bacterial 
proteases (Senior et al 199 1). 
The allotypes of IgA2 differ in the structure of their inter-chain disulphide bonds. 
A2m(l) lacks the di-sulphide bridge that connects the heavy and light chains, instead 
the light chains di-sulphide bond with each other via their tenninal cysteines. Ue 
A2m(l) has an alpha chain which is a hybrid of Al and A2m(2) in that its CH3 is 
identical to that in the alpha I chain and the CHI and CH2 are like that of A2m(2) 






Figure 1.1 Theoretical schemes of the monomeric IgA I and IgA2 showing the 
heavy and light chains as well as the tail piece in each molecule. The human IgAl 
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Figurel. 2 Schematic diagramme of the theoretical structure of human IgA L The hinge region 
is the heavily glycosylated structure which distinguishes human IgA I from IgA2 which is 
lacking in this region. Otherwise, both subtypes are formed of a pair of heavy chains (H) and 
light chains (L), each of which consists of one variable (V) and 3 constant (C) regions. Each 
molecule is divided into the Fab and Fc portions. The variable portion of the molecule is 
highly specific for interactions with their respective antigens and antigen presenting cells. The 
linear extensions or tailpieces at the C-termini of the heavy chains are also glycosylated. 
Image reproduced courtesy of Dr Alice Smith. 
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1.3.2.2 Monomeric and polymeric IgA: Both subtypes of IgA may be found in 
monomeric (molecular weight (MW) 160kDa), dimeric (MW 385kDa), or polymeric 
forms. Polymeric IgA is formed when 3 or more monomers are linked by a cysteine- 
rich 21 kDa J-chain (Figure 1.3). The systemic IgA is predominantly of the 
monomeric type. The IgA in mucosal secretions (secretory IgA) is mainly in the 
polymeric form with the addition of a secretory component (SC) (Figure 1.4). Both 
the SC and the J-chain are linked to the Fc portion of the constant heavy chains via a 
di-sulphide link. The SC is complexed with the molecule during the process of 
secretion. It originates from the polymeric immunoglobulin (1g) receptor on the 
basolateral surface of the mucosal epithelial cells, which facilitates the transcytosis of 
polymeric IgA and IgM and attaches to the molecules by recognising the J-chain. The 
SC is heavily glycosylated. These glycans regulate its interactions with antigens and 
cell surface receptors. They serve a two-fold function, on the one hand prolonging its 
half-life in the mucosal sites by increasing its solubility and protecting it from 
proteolysis, and on the other hand facilitating its clearance (Montreuil et al 1982; Lis 
and Sharon 1993). 
1.3.3 IgA production 
Mucosae are rich in IgA and IgA producing cells. The body produces more IgA than 
all the other immunoglobulins put together the majority being produced by the 
mucosal surfaces of the gut (Mestecky 1988). Serum IgA is derived from dedicated 
plasma cells in the marrow that produce predominantly monomeric IgAl. By contrast, 
plasma cells in the mucosal areas secrete polymeric IgAl and IgA2 which reach the 
mucosal fluids by translocation through the epithelial cells via the polymeric Ig 
receptor where they become secretory IgA. Very little of this secretory IgA enters the 
systemic side. Both IgA subclasses are produced at the mucosal surfaces in varying 
proportions depending on the site of production. 
IgA production is under the control of complex cytokine pathways and regulatory 
lymphocytes, abnormalities of which can lead to IgA over-production, tissue 
deposition and damage. The control mechanisms of systernic IgA production are 
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Figure 1.3 Theoretical structure of dimeric IgA2 m(l). This model shows the Fc 
regions of the two IgA molecules crossed over with J chain linked to the tailpiece 
cysteine residues of one pair of heavy chains. The heavy chains are also linked by 
cysteine residues in the CH2 domains to the tailpiece cysteines of the other pair of 
heavy chains. Image reproduced courtesy of Dr Alice Smith. 
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Secretory Component (SC) 
\ 
SC domain 5 SC domain 1 
Figure 1.4 Theoretical structure of secretory IgA2 m(l). This model shows 
secretory component (SC) interacting with CH2 and CH3 domains of both pairs of 
heavy chains. The fifth domain of SC is disulphide-linked to the CH2 domain of one of 
the IgA monomers. Image reproduced courtesy of Dr Alice Smith 
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similar to IgG production. One study has shown TH2 cells via IL-4,5, and 6 to cause 
B cell class switching to IgA production (Lycke 1998). IgA production was also 
found to be promoted by 11,10 and TGF-P in an earlier study (Defrance et al 1992). 
The control of mucosal IgA production is less well understood although there is 
evidence for similar TH2 mediated control mechanisms (Abreu-Martin and Targan 
1996). 
1.3.4 IM clearance 
A diverse range of cells in the reticulo-endothelial system are responsible for IgA 
clearance. The asialoglycoprotein receptor (ASGP-R) (or the human hepatic lectin) 
found on hepatocytes and the Fca-receptor (FcccR) on Kupffer cells represent the 
hepatic routes of clearance (Rocatello et al 1993). Fc(xRI on myeloid cells represents a 
further route of IgA removal from the circulation (Monteiro et al 2002). 
1.3.4.1 Hepatic route Ile liver is the major site in humans for IgA and IgA- 
containing immune complex clearance from the circulation (Tomana et al 1988). 
Hepatocytes express an ASGP-R that binds IgAl prior to endocytosis and 
presentation to the lysosomes for degradation (Lis and Sharon 1993). This is a C-type, 
calcium-dependent lectin with a high affinity for terminal galactose or GaINAc 
residues. The human ASGP-R is a non-covalent hetero-oligomeric integral membrane 
glycoprotein with 2 sub-units. Each sub-unit is a single spanning membrane protein 
with one extra-cellular domain containing the C-type carbohydrate recognition 
domain. This domain has an amino acid sequence highly conserved for GaINAc and 
galactose recognition (lobst and Drickamer 1996; Drickamer 1996; Kolatkar et al 
1998). IgAl is the principal glycoprotein cleared via this receptor. Factors favouring 
this route of clearance are tight clustering of GaINAc and galactose residues 
especially as a polymer or as part of an immune complex. IgA2 is not thought to be 
recognised by this receptor in humans, as the hinge region is not present in this 
isotype. 
Kupffer cells express a receptor for the constant (Fc) portion of IgA (FcocR) which 
represents a further route of IgAl and IgA2 clearance (Silvain et al 1995). Little is 
know about the characteristics and function of the Kupffer cell Fc-alpha receptors. It 
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can be postulated though, that impaired clearance via these receptors and elevated IgA 
levels can theoretically lead to tissue deposition, inflammation and damage. 
1.3.4.2 Myeloid cells Circulating blood cells also express an FcaR which binds the 
IgA molecule. These have been detected on myeloid cells (neutrophils, monocytes, 
macrophages and eosinophils), erythrocytes and some types of lymphocytes. These 
receptors can recognise both secretory and serum IgAl, IgA2 both in the monomeric 
and polymeric form as well as IgA bound in immune complexes. Fc receptors for IgA 
are less well understood compared to Fc receptors for other immunoglobulins. The 
development of monoclonal antibodies against the myeloid FcotR, its characterisation 
and cloning has generated a higher level of interest in its characteristics. 
The FcaRI is expressed on myeloid cells and is encoded by a single gene mapping to 
chromosome l9ql3A It is an integral type I transmembrane glycoprotein of the FcR 
family and the Ig gene super family (Williams and Barclay 1988). It is a 55-75 kDa 
protein on polymorphonuclear cells and monocyte/macrophages (Monteiro et al 
1990). This receptor was designated CD89 at the 5 th Leucocyte Typing Workshop. 
Quantitative data suggest equal numbers of CD89 receptors on monocytes and 
neutrophils. Fc-alpha receptors isolated from neutrophils, monocytes and U937 cells 
run a similar broad band on SDS-PAGE with a molecular weight of between 50-70 
kDa depending on the glycosylation. The molecules are heavily N-glycosylated 
(Monteiro et al 1992). A panel of monoclonal antibodies against CD89 exist: A3, 
A57, A62, A77, and My43 with only the latter being able to block IgA binding to 
Fc(xRl. 
The direct binding of IgA via the Fc portion of the molecule to leukocytes and 
myeloid cell lines has been demonstrated extensively by a range of techniques in 
particular flow cytometry (reviewed by Kerr 1990). FcaRI has a medium affinity for 
IgAl and IgA2 and binds both serum and secretory IgA well (Kerr and Woof 1999). 
As with the ASGP-R, IgA glycosylation can influence binding to the FcaRI, with 
excessively sialylated IgA having a lower binding capacity to the receptor (Basset et 
al 1999). After binding to its receptor, IgA can stimulate or inhibit a variety of 
myeloid cell functions. At the mucosal surfaces IgA cross-linking of FcccRI initiate 
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the myeloid cell responses such as opsonisation or phagocytosis. Fc(XRI-mediated 
responses enable the orchestration of local cytokine and inflammatory mediators 
action, promoting the recruitment of effector cells. 'Me role of the Fc(xRI in the 
systemic side of the IgA immune system is not so clear. One possible role is that of 
IgA clearance through pinocytosis and lysosomal catabolism. 
1.3.5 IgA Function 
While the role of IgA in the mucosa as the first line of defence against pathogens is 
clear, the function of IgA in the maintenance of systemic immunity is less well 
understood. 
1.3.5.1 Serum IgA No clear role has been ascribed to serum IgA. Evidence regarding 
the ability of IgA to trigger phagocytosis (Blackburn et aI 1995) and cell-mediated 
cytotoxicity (Dunne et al 1993) has contradicted the previously held belief that IgA 
acted as a 'discreet housekeeper' by dampening the systemic immune response to oral 
and environmental antigens. 
1.3.5.2 Secretory IgA The main role of IgA in the mucosal sites is to aggregate 
immobilise and consequently inhibit the adherence to and penetration of epithelial 
surfaces by pathogenic bacteria, viruses, and fungi (Underdown and Schiff 1986). The 
alternative complement pathway is also activated by aggregated secretory IgA 
(Lucisano Valim and Lachmann 1991). Both isotypes of IgA are capable of 
interacting with IgA receptors in myeloid cells at the mucosal sites, thus mediating 
phagocytosis, superoxide generation and the clearance of immune complexes. Other 
functions ascribed to SlgA are: neutralisation of biologically active antigens such as 
toxins, viral particles, and enzymes; enhancement of secretion of lactoferrin, 
peroxidase and other antibacterial factors in mucosal secretions; opsonisation for 
macrophages and neutrophils; and enhancing monocyte anti-bacterial activity 
(Mestecky 1988). Finally secretory IgA is thought to have a role in the prevention of 
food and environmental antigen absorption by binding and transporting them back 
into the lumen via the polymeric Ig receptor (Mostov and Kaetzel 1999). 
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1.4 Primary IgAN 
1.4.1 Epidemiology 
Although IgAN may develop at any age, it typically presents in young adults in the 
second and third decades of life and commonly in childhood and adolescence 
(d'Amico 1988). It is 2-3 times more common in men than in women (Schena 1990). 
There is marked geographical variation in the distribution of cases among and within 
countries. In developed countries where renal biopsies are routinely used, IgAN 
accounts for 30% of renal biopsies performed for the diagnosis of glomerular disease 
(Clarkson et al 1996). On a world-wide level, IgAN accounts for 30% of biopsy 
findings in Asia, 12% in Australia, 10% in Europe, and 5% in the USA (Levy and 
Berger 1988; Schena 1990). In North America, there are significant differences 
between individuals from diverse racial backgrounds. Whereas the disease is common 
amongst Native American Indians (35% of renal biopsies performed in that 
population) (Smith and Tung 1985), the white population has the same incidence as 
Europeans. Traditionally it has been thought that IgAN is least common (<5% of 
biopsy findings) in those of African extraction (Jennette et al 1985). More recently 
however it has been noted that IgAN is increasingly recognised in African Americans 
possibly due to racial admixture (Sehic et aI 1997). In Africa the disease is very 
uncommon (Galla et al 1984). The high incidence among the Native Americans may 
be related to high alcohol consumption and cirrhosis rates in this population, leading 
to increased cases of secondary IgAN. Therefore in quoting prevalence of the disease, 
the presence and influence of other co-morbid conditions should be taken into 
account. 
The quoted incidence of IgAN not only varies with geographical region but also with 
different screening policies and the frequency of renal biopsies. For example one 
explanation for the high rate of IgAN (approaching 50% of all glomerular diseases) in 
Japan is the vigorous urine screening of all school-aged children and their high biopsy 
rates (Ueda et al 1977). Autopsy and biopsy studies suggest that the quoted 
prevalence of IgAN is grossly underestimated. One study from Germany of 250 
consecutive autopsies discovered IgA deposits in 4.8% of cases (Waldherr et al 1989). 
Zero-time biopsies performed at the time of renal transplants have shown that latent 




Whilst consistent genetic markers for IgAN have not been found in population 
studies, there is little doubt that genetic factors are involved in the pathogenesis and 
clinical manifestation of IgAN. This is in evidence from cases of familial IgAN (Levy 
1993) and also changes in the IgA system biology in unaffected relations of patients 
with IgAN (Egido et al 1983a; Schena 1993). There are also reports of increased 
clinical renal abnormalities in relations of IgAN patients (Scolari et al 1992). A few 
groups have reported cases of familial clustering in IgAN although HLA associations 
have not been consistently identified. This may be partly due to the fact that the 
studies on HLA antigen associations have not had sufficient patient numbers to confer 
statistical power to their resuds (reviewed by Hsu et al 2000). 
These findings along with the racial variations in the incidence of IgAN have 
prompted a search for a genetic cause in at least some of these patients. Using 
genome-wide linkage analyses in multigenerational families with several members 
with biopsy proven IgAN, Gharavi et al showed linkage of IgAN to 6q22-23 now 
known as the IgANI gene (Gharavi et al 2000. ) They found 60% linkage between 
kindreds in a dominant model of transmission with incomplete penetrance and locus 
heterogeneity. Because of the high number of genes in this locus, the importance of 
this finding in relation to the pathogenesis of IgAN remains to be clarified. So far the 
analysis of polymorphic markers related to the immunoglobulin genes, MHC loci and 
genes identified for Fc-alpha receptors have not been found to show linkage. Further 
definition of the genes within the IgAN I locus is awaited. 
1.4.3 Clinical features of IgAN 
The syndrome of IgAN may present anywhere on a spectrum between asymptornatic 
urinary abnormalities to a rapidly progressing glornerulonephritis (Emancipator et al 
1985; d'Amico 1987). In 40-50% of cases it presents in adults in their 20s and 30s. 
Patients experience recurrent, self-limiting episodes of macroscopic haematuna 
associated with upper respiratory tract infections typically 24 hours after the onset of 
infective symptoms. The frequency of these episodes is higher in childhood and 
decreases with time (Schena 1990). Occasionally, infections of other IgA secreting 
tracts such as the urinary, gastrointestinal and bronchial mucus membranes may 
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predate the onset of haernaturia. The episodes of haernaturia last between 24 hours up 
to one week but microscopic haernaturia may be persistent. Occasionally patients 
complain of loin pain. 
About 30-40% of patients are asymptomatic, with microscopic haernaturia and 
occasional proteinuria as the most common feature at presentation. This is often 
picked up at routine screening and in countries such as Japan with widespread urinary 
screening practices, the percentage of patients picked up with microscopic haernaturia 
or chance proteinuria will be higher. 
Some 30% of patients have a less benign onset presenting with either hypertension, 
nephrotic syndrome (5%), acute on chronic renal failure, or acute nephritis. Nephrotic 
syndrome as the initial presentation is uncommon in adults but more frequent in 
childhood and adolescence (Hogg 1993). Of these 10% may present with oliguria and 
renal failure of which a quarter may require acute renal replacement therapy (Schena 
1990). 
Acute renal failure at presentation is very uncommon (<5% of cases) and may be a 
presenting feature of a severe, rapidly progressive crescentic glomerulonephritis 
(Nicholls et al 1985). Alternatively it may be caused by tubular obstruction through 
heavy glomerular haernaturia. The rest of the patients presenting with renal 
impairment have longstanding IgAN. Although hypertension is a common finding in 
all groups, it is only present in 5-10% of cases at the time of presentation (Clarkson et 
al 1977). 
1.4.4 Diagnosis 
Ile diagnosis of IgAN is a histological one based on positive mesangial IgA 
immunofluorescence. There are as yet no serological markers for IgAN. Serum IgA 
levels are elevated in a proportion of patients. In adults, serum total IgA is reported to 
be elevated in 30-50% and an even higher percentage of children with IgAN 
(d'Amico 1988). As serum IgA levels have not been measured serially or correlated 
with disease activity in a large population, this measurement is relatively unhelpful in 
either making the diagnosis or for following its course. Unlike normal serum where 
the ic isotype of the IgA light chain is predominant, high X isotype is found in IgAN 
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(Lai et a11988). Ilere are no distinctive changes in urinary immunoglobulins. Serum 
complement levels remain normal despite evidence of complement co-deposition in 
the mesangium. 
1.4.5 Patholoa 
As with the clinical features, the histological features of IgAN fall along a wide 
spectrum ranging from near normal glomerular morphology, through focal and 
segmental proliferative changes, to crescentic glomerulonephritis (GN) (d'Amico 
1987; Emancipator et al 1985). The diagnosis is defined by the presence of mesangial 
deposits of IgA on immunofluorescence. Figure 1.5 shows the light microscopic and 
EF features of a patient with IgAN. 
1.4.5.1 Histopathology Light microscopic changes may be minimal. The most 
common histological change on biopsy in about 60% of patients is glomerular matrix 
expansion and a diffuse and global mesangial cell proliferation confined to the 
mesangial compartment, without involving the capillary lumina. In some cases these 
changes may be focal. In 15% of cases, patients have focal endocapillary pr oliferation 
superimposed on the mesangial proliferative pattern. A further 10% have a more 
unusual pattern of injury including diffuse endocapillary proliferation causing 
occlusion of capillaries with inflammatory cells and mesangial matrix. 
Crescentic changes have also been described on the background of a diffuse 
mesangioproliferative GN. The type of cellular infiltrates depends on the severity of 
the disease with increasing mononuclear cell invasion as the lesions become more 
advanced. One study found that the degree of renal dysfunction and the presence of 
crescents correlate with the number of glomerular macrophages (Arima et al 1991). 
Tubulointerstitial and vascular changes are no different to those found in other forms 
of progressive renal parenchymal disease. The histological markers associated with 
disease progression appear to be the presence of glomerular sclerosis, interstitial 
fibrosis, and vascular changes rather than proliferative changes (d'Amico 2000). 
These are not specific to IgAN per se. 
Recently a revised grading system (H. S. Lee's grading system for IgAN) was 
assessed for correlation with clinical presentation and disease progression (Lee et al 
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2005). The grades are as follows: grade 1, normal or focal mesangial cell proliferation; 
grade II, diffuse mesangial cell proliferation, or <25% of glomeruli with crescent 
(Cr)/segmental sclerosis (SS)/global sclerosis (GS); grade 111,25-49% of glomeruli 
with Cr/SS/GS; grade IV, 50-75% of glomeruli with Cr/SS/GS; grade V, >75% of 
glomeruli with Cr/SS/GS. This grading system showed good correlation with clinical 
features of the biopsied patients. 
1.4.5.2 Immunofluorescence Mesangial IgA is the hallmark of IgA nephropathies. It is 
the sole immunoglobulin in only 15% of biopsies and co-deposited in 50-70% of 
cases with IgG. IgM and C3 staining (but not Clq) is also found in 31-66% of cases 
(Emancipator and Lamm 1989). The deposits are polymeric IgAl and they stain more 
strongly for ). rather than ic light chains. The deposits are diffuse and global and may 
extend into the glomerular capillaries. This is associated with a worse prognosis. The 
deposits may be present before the appearance of any light microscopic changes and 
re-biopsy studies in children suggest the IgA deposits can regress whilst in clinical 
remission (Yoshikawa et al 1990). 71be intensity of IgA staining has not been found to 
correlate with the severity of the disease (Jennette 1988). 
1.4.5.3 Electron microscopy Dense deposits of IgA and varying amounts of IgG, IgM 
and C3 are found in the mesangial and paramesangial structures. They have also been 
identified in the glomerular capillaries at either subendothelial, intramembranous, or 
sub-epithelial spaces. Other features are those of mesangiolysis presumed to be due to 
chronic mesangial overload by IgA deposits, glomerular basement membrane 
thinning, splitting, as well as the duplication of the lamina densa. These GBM 
changes are associated with heavy proteinuria and severe glomerular disease, such as 
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Figure 1.5 Photornicrographs of the histological and immunofluorescence features of IgAN. 
The photograph on the left shows a low power image of the glomerulus in IgAN with the 
typical proliferative changes in a hypercellular mesangium with increased matrix deposition. 
The picture on the right is the image of the linear immunofluorescence pattern of IgA in the 
renal glornerulus of it patient with IgAN. Photornicrographs are courtesy of Dr Patrick 
O'Donnell. 
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1.4.6 Natural Hia ýo 
IgA nephropathy is thought to carry a benign prognosis for around one third of 
diagnosed patients who do not suffer any long-term problems. A French series which 
included the original Berger group of patients showed that after a follow up period of 
10 years, 30% were in remission with normal renal funtion, blood pressure and 
complete resolution of their urinary abnormalities (Chauveau and Droz 1993). In a 
significant number of patients the disease progresses slowly over 20-25 years with 25- 
30% reaching ESRF (Clarkson et al 1984). About one third develop chronic renal 
failure (CRF) and its complications in particular renal hypertension. Patients 
presenting with proteinuria, hypertension and renal failure progress more rapidly to 
ESRD (Chauveau and Droz 1993). The picture is a variable one with a proportion of 
patients in whom there is no tendency towards progression and others in whom a 
fulminant course results in rapid deterioration in renal function resulting in ESRD 
(Nicholls et al 1985). For this reason several studies have examined prognostic 
features which predict a poor outcome. 
Up until recently the presence of renal impairment, proteinuria of greater than 
lg/24hrs, and hypertension as well as the presence of tubulo-interstitial damage and 
glomerular sclerosis were thought of as markers of poor prognosis. None of these 
factors are specific to IgAN. A study from Toronto on a large cohort of patients with 
long term follow up, found that mean arterial pressure and severity of proteinuria over 
time are the most important prognostic predictors of IgAN (Bartosik et al 2001). 
A number of gene polymorphisms have also been the subject of studies in relation to 
disease progression in IgAN. The results of these studies have been conflicting due in 
part to differences in the prevalence of different polymorphisms, in different 
populations and races (Marden et al 1995; Suzuki et al 2000). Iberefore such results 
may not be readily extrapolated from one population to another. Nevertheless a recent 
study of angiotensin converting enzyme (ACE) gene polymorphisms has found that 
the II allele (as opposed to the ID or DD) is associated with good prognosis in IgAN, 
the D allele being most likely to be linked with disease progression (SyrJonen et al 
2000). Other alleles such as the 1235 variant of the angiotensinogen gene have been 
associated with disease progression through their hypertensive effects. Other gene 
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polymorphisms such as TNF-(x, IL-1 receptor antagonist, uteroglobin, endothelial cell 
NO synthase, and neuropeptide Y have been studied in this context with different 
conclusions regarding their significance in disease progression. 
Given the lack of consistency in these findings, the significance of these concepts is in 
doubt and far from proven. These studies have been reviewed in an article by 
Mustonen et al (2001). Further studies using large cohorts from various ethnic groups, 
followed up over a long period and with more refined methods of assessing disease 
activity are necessary to acquire data, which accommodate different patient cohorts in 
their analysis and will define those at higher risk of disease progression. 
1.4.7 Treatment 
In the absence of a clear understanding of the pathogenesis of IgAN, it has not been 
possible to develop treatments tailored to IgAN itself. In those with minimal 
proteinuria and preserved renal function, no treatment is required. In others the 
mainstay of therapy is aimed at controlling hypertension and proteinuria as both these 
complications are associated with poor outcome (Bartosik et al 2001). 
Immunosuppression has been used in an attempt to alter the course of the disease as 
well as reduce proteinuria (Laville and Alamartine 2004). Use of immunosuppressive 
therapies such as corticosteriods has produced inconsistent results in early trials 
(Julian and Barker 1993; Kobayashi et al 1986; Kobayashi et al 1988; Kobayashi et al 
1996; Lai et al 1986; Shoji et al 2000; Waldo et al 1993; Welch et al 1992). Ibis is 
due to small numbers of patients with different ages (including children) being 
employed. The cohorts studied were not all homogeneous in the severity of renal 
failure or degree of proteinuria. Not surprisingly these trials have not produced 
convincing benefits of interventions in the long-term especially in light of the very 
chronic nature of IgAN and its slow progress over many years. As a result, the 
treatment of this condition remains highly empirical in nature. 
More recently a number of trials have assessed the role of steroids in the treatment of 
proteinuria and renal function in better-defined cohorts of IgAN patients and over 
longer periods of time (Pozzi et al 1999; Pozzi et al 2004). There seems to be more 
benefit from the use of steroids in stemming heavy proteinuria than preventing 
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deterioration in renal function except in the case of children with IgAN. One 
particular group of adults that do benefit from steroids represent the minority of 
patients, i. e. those presenting with nephrotic syndrome and minimal histological 
changes and normal creatinine. Long-term follow up has shown that the use of 
corticosteriods in this group does preserve renal function. When taken together, a 
meta-analysis of the results of various trials points to a significant effect with steroids 
on proteinuria and preservation of renal function (Strippoli et al 2003). This is true in 
non-nephrotic range proteinuria and in those patients with a relatively high risk of 
disease progression. The effect also seems to be most apparent early in the course of 
treatment. Only when sufficiently high doses are administered can this effect be 
sustained for up to 5 years. One must however exercise caution when drawing 
conclusions from meta-analyses in a heterogeneous condition such as IgAN. 
Cyclosporin, cyclophosphamide, mycophenolate mofetil, azathioprine, intravenous 
immunoglobulin, and plasma exchange have all been used in a number of small, 
retrospective trials, some showing a beneficial effect on proteinuria as well as GFR 
over a short period. The most convincing report of a positive effect on renal outcome 
by cytotoxics came from Ballardie et al (2002). They showed remarkable preservation 
of renal function in a group of IgAN patients with a moderate risk of disease 
progression using prednisolone, cyclophosphamide and azathioprine. There are on- 
going studies assessing the efficacy of these therapies but so far most have been 
inconclusive. 
Other treatment strategies include: (i) antigen elimination through use of antibiotics, 
tonsillectomies (currently being assessed in a new Japanese multi-centred randomised. 
control trial), gluten and antigen free diets; (ii) anti-coagulation; (iii) dietary therapies 
such as fish oils, low protein diets, and Vitamin E supplementation; (iv) phenytoin, 
danazol, and dapsone. For a review of therapeutics in IgAN see Mustonen et al. 
(2001). 
ACE inhibitors and angiotensin H receptor blocking agents are increasingly used both 
separately and in combination. They are accepted as effective modulators of 
glomerular haemodynamics and as such minimize glomerular injury by effectively 
reducing proteinuria. One study of biopsy proven IgAN with good prognostic features 
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treated with enalapril versus other anti-hypertensives showed significant decline in 
protein excretion in the patient group as well as good preservation of renal function 
(Praga et al 2003). These drugs may therefore be considered as the first-line treatment 
in proteinuric IgAN patients with normal or slightly impaired renal function. 
Finally transplantation for patients with ESRD is not only effective as a treatment but 
has also afforded insights into the pathogenesis of IgAN. Transplanted patients with 
IgAN develop mesangial deposits within months but without any overt clinical 
manifestations in the majority of patients. Although IgA mesangial deposits appear in 
50% of patients after renal transplantation (Floege et al 1998), there had been 
relatively few case reports of recurrence of disease and graft loss in the literature 
(Berger 1988). With increasing graft survival, the number of reports of patients with 
recurrent disease is becoming more commonplace (Floege 2004). On the other hand, 
inadvertent transplantation of a kidney from an asymptornatic IgAN donor into a 
patient with another renal disease has resulted in the resolution of mesangial deposits 
in subsequent biopsies (Silva et al 1982, Cuevas et al 1987). This suggests that IgAN 
is not due to intrinsic renal disease, rather it is the kidney that appears to be an 
'innocent bystander' in a host that is susceptible to abnormalities of the IgAl immune 
system. When removed from such a pathogenic milieu, the kidney loses the features 
of IgAN. 
1.5 Pathogenesis of IgAN 
1.5.1 Introduction 
The pathogenesis of IgAN is complex and involves both factors which are specific to 
the condition and those which are common to all renal glomerular diseases. These 
elements may influence the course of the condition in any of the phases of its 
development. The main contributing factor to the initiation of the disease process is 
the production of IgA with characteristics that render it more liable to deposition and 
triggering an inflammatory process. Secondly, the response of the mesangial cells and 
tissue to such deposition may be a factor in whether the condition takes hold or 
resolves. There may be differences between cases where the capacity to dampen 
inflammation in response to deposition of IgA is greater than the propensity to mount 
and maintain a potentially damaging inflammatory response. Thus the unfolding of 
the disease process may vary from individual to individual where genetic 
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susceptibility may affect every aspect of the pathogenesis of the condition. Figure 1.6 
summarises the interactions of factors believed to be important in the development of 
IgA nephropathy. 
It must be said at the outset that IgAN is a morphological diagnosis and perhaps as 
such does not correlate to a unified clinical entity with a singular pathogenesis. The 
contradictory findings in the literature, the diversity of clinical presentations and 
outcomes make it more likely that IgAN comprises a phenotypically heterogeneous 
group of conditions which arise as a result of different pathogenic processes and 
pathways leading to the common finding of IgA deposits. Through a systematic study 
of these different mechanisms, we may learn about not just the pathogenesis of this 
group of conditions but also to revise our classification of them. 
1.5.2 Research Models 
Research into the aetiology of IgAN has been hampered by the absence of a good 
animal model. This has arisen for a number of reasons. Firstly there are few animal 
species in which the structure of IgA (in particular IgAl) is similar to the human. The 
IgA in rodents are more similar to IgA2 therefore rendering the study of IgAl 
mesangial deposition meaningless. Rabbits have 13 different IgA isotypes also 
limiting their use. Most rodent models of IgAN provide information about specific 
antigen-antibody associated nephropathy in contrast to humans where no specific 
antigen for the disease has been isolated and the condition appears to be more 
complex than a pure immune-complex mediated disease. IgA deposits in these models 
are usually benign and require further manipulation to trigger renal inflammation and 
damage (Montinaro 1991). The compartmentalisation and handling of IgA between 
the systemic and mucosal systems is also distinct in humans as compared to animals. 
The clearance mechanisms in rodents differ from humans in that the latter lack the 
hepato-biliary re-circulation of IgA from the gut (Mestecky 1988). 
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Mucosal and systemic 
antigen exposure 
Altered Systemic IgA Response 
oHyper reactive IgA system 
*Increased polymeric IgAl 
*Underglycosylation of IgA I 
*Increased Anionic IgA/IgA X 
Mesangial Deposition 
Initiation of glomerulonephritis 
eMesangial cell mediated 




eFactors generic to all GN 
*High BP/proteinufia/renal failure 
*Renal scarring 
Figure 1.6 Different factors thought to play a role in the development of IgAN. The 
interactions between the different elements are all modulated by the genetic 
predispositions of the individual. The key points in the unfolding of the disease are the 
preseance of IgA with altered properties. It is serum IgA with these specific 
characterisitics that is deposited in the renal mesangium. A small proportion of the 
circulating IgA and its immune complexes are prone to deposition and may also be 
capable of initiating glomerular injury and subsequent scarring. Failure of the 
mesangium to clear the deoposits adequately may result in the activation of the 
mesanglal cells and the release of inflammatory factors. From there on the risk factors 
for disease progression appear to be non-specific and common to all types of 
Lylomeruloner)hritis (GN). 
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Ibe significant differences between the human IgA immune system compared to 
rodents, particularly in IgAl and its hepatic clearance, restricts the direct application 
to human disease of rodent models of mesangial IgA deposition provoked by liver 
injury, such as administration of carbon tetrahydrochloride, alcohol, or bile duct 
ligation. Consequently in hepatic IgAN, just as in primary IgAN, lessons about the 
prime mechanism of mesangial IgA deposition cannot easily be learnt from such 
models and must largely be inferred from human studies. 
More recently, a model of IgAN has been identified in common marmosets (Callitrix 
jacchus), a non-human new-world primate species (Eitner et al 2004). The analysis of 
the renal pathological findings and the clinical syndrome has shown good homology 
between the marmoset model and humans. These primates may therefore represent a 
novel tool for further studies of the pathogenesis of human IgAN in the future. 
1.5.3 Mechanism of elevated serum IgA levels 
There are a number of aspects of IgA production and the characteristics of IgA 
synthesised in IgAN that have been found to be abnormal. However it is difficult to 
apply these findings to all patients given the diverse patient populations being studied 
as well as the lack of uniformity in the way patients are affected by these changes. 
Hence the literature is dotted with conflicting results which confound our 
understanding of the pathogenesis of IgAN in a clear and consistent manner. 
Serum IgA levels have been found in some studies to be modestly elevated in a 
proportion of patients with primary IgAN, especially those in the poor prognostic 
group (Maeda et al 2003). Some researchers have also suggested that the polymeric 
form of IgA appears to be increased compared to normal and that the ratio of lambda 
to kappa isotypes of the light chains is also increased (Chen et al 1991). As with 
normals, IgAl levels predominate over IgA2 with the IgA2 levels being normal 
(Feehally 1988). 
1.5.3.1 In vitro studies of IgA production: A number of studies have found in vitro 
and in vivo evidence of IgA overproduction in primary IgAN (Toyabe et al 2001; 
Layward et al 1994; Hale et al 1986; Egido et al 1983). However other studies have 
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not corroborated these findings in all patients with IgAN (Linne and Wasserman 
1985; Feehally et al 1986; Cagnoli et al 1985). The increased IgA production 
witnessed in some studies may be explained by an exaggerated antibody response to a 
wide array of antigens (Layward et al 1992). Many reports of dietary, environmental 
and infectious antigens in IgAN exist in the literature but none of these have been 
consistently associated with IgAN and no single pathogen has been established. The 
increased IgA antibodies have been found to be IgA I by some investigators (Layward 
et al 1993; van den Wall Bake et al 1992). 
The findings regarding the circulating polymeric and monomeric forms of IgA in 
IgAN have varied in different studies. A number of studies are quoted as evidence for 
an increased percentage of the polymeric form (Leinikki et al 1987; Layward et al 
1992; Ots et al 1999). Others found no difference between the percentages of 
monomeric and polymeric IgAl produced by the bone marrow of these patients 
compared with normal controls, while demonstrating an overall increase in both forms 
in the quiescent phase of the disease ýVan Den Wall Bake et al 1989b). In an earlier 
study the same group demonstrated no increase in the serum production of polymeric 
IgA or IgA I in IgAN (Van Den Wall Bake et al 1988b). 
With regards to the mechanism of elevated circulating IgA levels, despite the 
disparities in the in vitro studies of IgA production, the consensus opinion is that of 
increased production of IgA by hyperactive circulating plasma cells. This is based on 
the results of a few studies showing cultured peripheral blood mononuclear cells 
(PBMCs) from a proportion of IgAN patients producing more IgA both spontaneously 
and in response to ri-ýitogenic stimulation when compared with normal subjects (Egido 
et al 1982; Schena 1986; Chen et al 1991). These changes were also apparent in a 
number of unaffected relatives of IgAN patients (Waldo 1992). Whilst some studies 
have produced evidence for intrinsic B cell overproduction of IgA in vitro (Egido et al 
1987; Allen et al 1994; Layward et al 1994) other more recent studies of IgA 
production in IgAN demonstrated no significant differences in the IgA subclass 
synthesis when compared with controls (Baskin B et al 1996; De Fijter et al 1998). 
Baskin et al using in situ hybridization showed a three-fold increase in the numbers of 
IgAl- and IgA2-producing plasma cells, but the subclass distribution was similar to 
the controls. Furthermore, using the nested primer polymerase chain reaction (PCR) 
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for amplifying switch (Sp/Sa) breakpoints, they demonstrated that in unstimulated 
PBMC the switch frequency did not differ from that of controls. In another study by 
de Fijter et al (1998) no evidence of IgA producing B-cell hyper-responsiveness was 
seen. If anything, cytokines such as IL-2 and IL-10, commonly known to induce 
increased IgA production in normals, failed to enhance IgA production in the patient 
group. 'I'hey concluded that no selective IgA or IgAl dysregulation of circulating B- 
cells existed and challenged the widely held paradigm that patients with primary 
IgAN have a hyperactive IgA immune system per se. 
When viewed as a whole, the data from peripheral blood cell cultures have yielded 
conflicting results. This may either reflect the clinical state of the patients in a single 
time point or the heterogeneity of the populations under study (Feehally et al 1986). 
The discrepancies in the literature on the other hand may be the result of different 
pathogenic processes at work in different individuals within a given study cohort. 
A number of other studies have focused on clarifying which cell type is responsible 
for the reported overproduction of IgA. Some studies have produced evidence for both 
intrinsic B cell overproduction of IgA in vitro (Egido et al 1987; Allen et al 1994; 
Layward et al 1994) as well as reduced T-suppressor cell while others have shown 
increased IgA specific T-helper cell activity (Egido et al 1983, Sakai et al 1989). One 
study suggested that the B-cell dysfunction described in IgAN is secondary to a 
primary T cell defect. Indeed when T cell specific mitogens where used in these 
patients and their unaffected relatives, the T-cells responded abnormally whereas the 
B-cells reacted normally to stimulation with LPS (Sakai et al 1988). 
In another study the possible propensity towards M cytokine expression by PBMCs 
and circulating T cells was investigated (Ebihara et al 2001). Studies of circulating 
lymphocytes are difficult to interpret due to the lack of certainty regarding the subsets 
of cells under study. The evidence regarding B and T-cell dysfunction in IgAN 
remains limited and indirect and may only have an aetiological role in a sub-set of 
patients. Unless a specific sequence of events that universally leads to the 
development of IgAN is identified, such a concept remains at best speculative. 
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1.5.3.2 Functional studies of IgA immune system: In vivo studies of IgA production 
have primarily focused on IgA response to vaccination. Exaggerated responses of 
polymeric IgAl to exogenous antigens have been reported (Fortune et al 1992, 
Layward et al 1992). Tonsillar (Harper et al 1995) and bone marrow (Harper et al 
1994b and 1995) IgA producing plasma cell numbers were increased. These studies 
were specific immunohistological examinations of plasma cells producing IgA, IgAl 
and polymeric IgA. Conversely IgA positive B cells and production of polymeric IgA 
in the duodenal lamina propria is reduced with reciprocal increased IgA J chain 
positive B cells in the bone marrow (Harper et al 1994a). This may point to a primary 
defect in the mucosal IgA system possibly involving defective polymeric Ig receptor 
mediated transepithelial IgA transport in IgAN. One study amongst others found 
whilst patients with IgAN developed higher IgG levels after immunisation with 
tetanus toxoid, they produced lower specific IgA antibody levels in the serum, despite 
higher IgA production by mitogen stimulated PBMCs (Waldo 1992). Other studies of 
patients' post-mucosal immunisation have shown diminished IgA responses compared 
to controls. 
More recently, researchers have examined the humoral responses to mucosal antigens 
in situ to avoid the use of an artificial antigen challenge. They found an exaggerated 
systemic IgAl response to Helicobacter Pylori in IgAN, supporting the shift of 
mucosal lymphocytes to systemic sites and the subsequent production of mucosal type 
polymeric IgA into the systemic compartment (Barratt et al 1999). 
1.5.3.3 Antigen penetration: IgA immune system over activity has been described as a 
feature of cirrhosis. However, one could speculate that this may be due to a persistent 
antigenaemia resulting from breakdown of the gut barrier to food and bacterial 
antigens. No such evidence regarding increased mucosal antigen penetration in IgAN 
has been found. Most (75%) IgAN patients have normal intestinal absorption studies 
of Cr-EDTA ruling out a generalised defect of the mucosal barrier (Jenkins et al 
1988). However this does not rule out a more specific defect in immune inhibition of 
immune complex uptake, or a primary defect in epithelial IgA transport mechanisms 
(Cunningham-Rundles 1990). 
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1.5.3.4 IgA clearance: The elevated IgA levels reported in some studies of IgAN may 
be in part due to reduced clearance of IgA or its macromolecules by the reticulo- 
endothelial system. This may be due to altered expression or function of IgA receptors 
such as the hepatocyte ASGP-R, Kupffer cell FcaR, or of the circulating monocyte 
FcaRI affecting its clearance from the circulation. The liver is the main organ of 
serum IgA catabolism, via the asialoglycoprotein receptor and Kupffer cells. 
Circulating monocytes and neutrophils express an FcaRI (CD89), which binds to the 
IgA Fc portion before endocytosis and degradation of the molecule and its immune 
complexes QC). Some studies have pointed to deficiencies in these clearance 
mechanisms in IgAN (Roccatello et al 1993). One study reported down regulation of 
CD89 expression (Grossetete et al 1998) whilst others have found that purified 
monomeric IgA from patients with IgAN bind less well to CD89 compared with 
normal controls (van Zandbergen et al 1998). The latter group have also found 
structural alterations in the myeloid CD89, which appears to be consistently larger, 
and with reduced surface sialylation than that found in normal controls. 
1.5.3.5 IgA Glycosylation: A structural change in the IgAl molecule such as abnormal 
0-glycosylation could theoretically render it less efficient as a ligand at all its various 
natural binding sites. In the search for IgAN specific antigens, studies of various food 
antigens led to the observation that IgA binding in IgAN to a number of plant derived 
lectins was different to normal. In 1990 Andre et al published the first study reporting 
altered binding of IgA from these patients to the plant lectin jacalin. This was 
suggestive of abnormal IgAl 0-glycosylation. Further evidence has accumulated 
from lectin binding, chromatography, fluorophore assisted carbohydrate 
electrophoresis (FACE) (Allen et al 1999), and mass spectrometry studies (Hiki Y 
2001), confirming altered glycosylation in these patients. 
Such structural abnormalities of IgA can alter its interactions with various immune 
cell receptors involved in its clearance, contributing both towards its elevated blood 
levels as well as rendering it more prone to deposition. Given the unique 0- 
glycosylation of the IgA I hinge region, it is possible that such a physical abnormality 
could arise from the O-linked glycans. The evidence from these studies supports the 
presence of under-glycosylated species of the IgAl molecule in IgAN. Some studies 
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have suggested that the defect is in the loss of terminal galactose residues. None of 
these studies have been able to describe the stoichiometry of the IgA molecule or 
determine the site for glycan attachment on to the amino acid backbone. The technical 
challenge of producing high quality structural data has been the main obstacle to 
definitively addressing the issue of aberrant glycosylation in IgA nephropathies. 
1.5.4 Origin of mesangial IRA and role of the mucosal immune system in IgAN 
The source of the deposited mesangial IgA has been the subject of much discussion 
and controversy. Several lines of evidence suggest an involvement of the mucosal 
immune system in the pathogenesis of IgAN. Clinically, the acute haernaturic 
episodes are temporally related to acute infections of the mucus membranes and 
intake of dietary antigens such as gluten. Furthermore, the deposited antigens in the 
renal mesangiurn that have been identified so far are either dietary components or 
mucosal pathogens. Impaired mucosal immunity has also been in evidence from 
studies of immune responses to mucosal immunisation 
In addition to reports of elevated polymeric circulating IgA in IgAN, the mesangial 
deposits are also found to be polymeric IgAl (Leinikki 1987, Ots et al 1999). Likewise 
in hepatic IgAN, most studies indicate that the deposits are polymeric IgA I with more 
definite evidence for elevated polymer to monomer ratio in the serum (Newell 1987). 
Whilst the polymeric nature of the deposits and the concurrence of upper respiratory 
tract infections with acute episodes of nephritis point to a mucosal origin for the IgA, 
the subclass (IgAl) supports a systemic origin for the deposited molecule. This 
finding cannot simply be attributed to an over-spill of polymeric IgA from the 
mucosal system into the systemic side as the number of polymeric IgA secreting 
plasma cells in the mucosa are in fact found to be decreased in IgAN compared with 
normal controls (de Fijter JW 1996). The finding that the number of polymeric IgA 
producing plasma cells in the bone marrow is elevated and that systemic antigen 
challenge produces increased titres of circulating polymeric IgA is supportive of the 
hypothesis that mucosal type IgA is being produced by the bone marrow in response 
to both mucosal and systemic antigen challenges (van den Wall Bake AW 1988a, 
Harper SJ 1996). These data whilst indicative of a defect in the mucosal immune 
response, do not clarify the reasons for IgA mesangial deposition and the onset of 
inflammation. 
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1.5.5 Mechanism of del2osition 
Ile role of the normal mesangium is to maintain glomerular homeostasis. In addition 
to the structural and physiological roles of the mesangial cells, they have been 
implicated in controlling the local responses to glomerular injury. We know from 
autopsy studies that the mere presence of IgA deposits is not pathogenic (Waldherr et 
al 1989). IgA deposits are also known to regress post renal transplantation when a 
kidney with IgAN is transplanted inadvertently into a non-IgAN recipient. These 
findings suggest two things. Firstly that mere IgA deposition is not sufficient for the 
development of inflammation and renal injury. Secondly, that the mesangiurn has 
clearing mechanisms to remove deposited IgA. IgA deposition probably occurs when 
the mesangium's capacity to clear the deposits is exceeded. This may be due to a 
number of processes. On the one hand the sheer quantity of IgA may saturate the 
mesangial homeostatic mechanisms. A qualitative change in the character of the IgA 
may alter its interactions with mesangial components thus rendering it resistant to the 
mesangial clearing mechanisms. Finally a defect in the normal clearing processes 
employed by the mesangial cells per se may be a further hypothetical reason for IgA 
deposition. 
It is reasonable to assume based on mounting evidence that increased serum IgA 
levels in themselves ýo not necessarily lead to mesangial deposition. Conditions such 
as IgA myeloma and HIV that have extremely high levels of circulating IgA are not 
consistently associated with IgA nephropathy. This, along with the absence of a 
consistent, specific mesangial or circulating antigen in IgAN makes the non- 
immunological interactions of IgA with mesangial extra-cellular matrix (ECM) 
components a more plausible mechanism for IgA deposition (Westerhuis et al 1999, 
Barratt et al 1999). Altered 0-glycosylation of IgAl due to defective 
galactosyltransferase activity may modify its molecular interactions thus promoting 
its deposition (Allen et al 1995,1997). 
1.5.5.1 IgA Antigens: Increasingly the evidence points to the fact that IgAN is not the 
result of a classical antigen-antibody deposition in the renal mesangium. Much effort 
has been put in the quest to identify such an antigen, yet no endogenous or auto- 
antigens have been found. Both circulating and deposited immune complexes in IgAN 
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have been found to contain food antigens (Russell et al 1986, Feehally et al 1987). 
Viral antigens too have been detected but these observations have been at best 
sporadic and unconfirmed, possibly not disease specific and even artefactual. Auto- 
reactivity to various auto-antigens have been described. These include mesangial 
antigens such as laminin and collagen IV as well as serum fibronectin and rheumatoid 
factors. However, these findings have not been confirmed as being pathogenic or 
disease specific. Evidence that deposited IgA is polyclonal may mean that the antigen 
specificity of IgA in IgAN is either not disease specific or that different antigens have 
variable ability to trigger IgAN in different affected individuals. 
Another explanation for the immune complex formation and deposition in IgAN has 
come from the unusual finding that IgA itself may be the antigen against which the 
body produces antibodies of the IgG and IgA type. These are 'rheumatoid factors' 
which appear to be specifically against the under-glycosylated hinge region of the 
IgA I molecule (Monteiro et al 1988; Tomana et al 1999; Kokubo et al 2000). 
The precise physicochemical characteristics that make IgA pathogenic are unclear. 
The large size of the polymeric IgA-ICs may render them more prone to non-specific 
size dependent mesangial trapping and deposition (Rifai et al 2000). If production of 
polymeric IgA is indeed in excess of the monomer, larger IgA-ICs will predominate. 
These large complexes are also less likely to bind to receptors involved in their 
clearance and therefore become more available for deposition by trapping in the 
glomerular mesangium. The low efficiency of IgA to activate complement also 
promotes the persistence of immune complex lattice formation in the circulation. 
Aberrant IgAl 0-glycosylation may promote mesangial deposition given its increased 
tendency to self-aggregation (Kokubo et al 2000). 
The charge of the IgA molecule has been the subject of investigation as a reason for 
enhanced tendency to deposition in the mesangium. The accepted notion of IgA as a 
more anionic molecule in IgA nephropathy is not a balanced reflection of the 
conflicting findings in the IgA literature. An early study of IgA deposits in the renal 
mesangiurn of patients with IgAN showed that the isoelectric point (pl) of eluted IgA 
was different to the more neutral pI of IgA obtained from normal serum The 
conclusion was that this more anionic form of IgA was a likely reason for increased 
ý -. -, m 1.49 
binding capability to the renal mesangiurn (Monteiro et al 1985). No renal controls 
were used and deposited IgA from the patient group was compared with normal serum 
IgA. The same group then studied serum IgA from patients with PIgAN, HSP, 
alcoholic liver cirrhosis, membranous GN, and systemic lupus erythematosis 
(Monteiro et al 1988). As no abnormal distribution of IgA isoelectric points was 
detected by isoelectric focusing studies, they went on to detect the charge on serum 
IgA using coated plates with cationic proteins. The degree of binding of IgA to these 
plates was taken as a measure of anionic IgA. They found increased anionic IgA in 
56% of PIgAN and 40% of patients with cirrhosis. They concluded that the presence 
of this negatively charged IgA is involved in the aetiology of IgAN. Harada et al 
(1989) also showed an increase in the anionic proportion and reduced cationic 
proportion of serum IgA in PIgAN compared with controls in a small group of 
patients and controls (n=10). 
Later studies however found that when the charge distribution of IgA light chains in 
IgA nephropathy were measured separately, IgA% was found to be more anionic than 
IgAic (Lai et al 1994, Suen et al 1997). The presence of a higher percentage of IgA% in 
the circulation of patients with IgAN would explain the higher anionic/cationic ratio 
observed in total IgA from some patients compared with controls. Conversely, one 
study of the serum IgA using 2-D gel electrophoresis showed no major shift of pI 
values in the alpha heavy chains but the volume of the a-heavy chain bands were 
distributed towards the cationic region in IgAN as compared to normal healthy 
controls (Shuib et al 1998). They interpreted their data in support of the finding that 
IgA I of IgAN patients were undersialylated. 
1.5.5.2 Mesangial components and mesangial cell receptors: In addition to the non- 
specific deposition discussed above, IgA deposition may also occur in situ with 
mesangial cellular and matrix components. Earlier evidence for auto-reactivity of IgA 
to mesangial collagens has been invalidated (Coppo et al 1994). But aberrant IgAl 
glycosylation appears to promote interactions with fibronectin and type IV collagen 
(Kokubo et al 2000). The tendency of IgA to be more anionic or cationic may also 
increase its interactions with mesangial proteins. 
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IgA deposition has not been found to relate to a specific glomerular antigen. It is not 
known to provoke complement activation nor is it associated with a dominant 
mononuclear infiltrate (except for crescentic IgAN) within the glomerulus. It is 
therefore possible that the glomerular injury may be a result of the interactions of the 
IgA molecule with the mesangiurn per se and not to the recruitment of other arms of 
the immune system. This has focused attention on the direct interaction of IgA with 
mesangial cells and matrix. Mesangial cells are known to bind IgA in vitro (Gomez- 
Guerrero et al 1993), which in turn can trigger proliferation, cytokine secretion and 
ECM production. Therefore, it has been postulated that they could express an IgA 
receptor, explaining in part the pathological features of IgAN. 
Mesangial cells have been shown to express an Fc(x-like receptor for IgA which is 
distinct from the CD89, the poly Ig receptor and the hepatic ASGPR (Moura et al 
2001; Novak et al 2002). A number of researchers have studied these putative 
receptors. One group has defined a receptor in cultured human mesangial cells that 
binds IgA in an Fc alpha-dependent fashion (Barratt et al 2000). 'Me receptor 
recognises both secretory and serum IgAl and IgA2 equally but has a higher affinity 
for polymeric versus monomeric IgA. Ile receptor is immunogenically different yet 
shares molecular homologies with the known myeloid CD89 receptors. In a more 
recent study from Glasgow, primary mesangial cells from humans were found to 
express mRNA for a novel Fca/g receptor that was able to bind IgA and IgM but not 
IgG (McDonald et al 2002). Human transferrin receptor (CD71) expression has been 
recently reported on mesangial cells which may act as an IgA receptor (Moura et al 
2001, Hadad et al 2003) . There is also one report on the presence of an ASGPR on 
the human mesangial cell (Gomez-Gueffero C et al 1998). 
In summary, for IgA to deposit in the renal mesangium, the rate of deposition must 
exceed that of mesangial clearance. The physicochernical characteristics of the 
immune complexes, the antigen load, and the interaction between them and the 
mesangium probably govern this process. 'Me mesangial cell is the most likely point 
where IgA and its immune complexes are cleared and catabolised. The evidence 
regarding the role of the interaction between the IgA and mesangial cells and the 
putative IgA receptor in the development of IgAN remains inconclusive. 
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1.5.6 Inflammation and renal damage 
The mechanism of glomerular injury in IgAN is not well understood. The commonest 
histological feature of the disease is that of mesangial cell proliferation and 
extracellular matrix expansion. As the disease progresses the changes are common 
with any other chronic glornerulonephritis, namely glornerulosclerosis and 
tubulointerstitial damage. 
1.5.6.1 Mesangial cell activation: Increasingly the evidence suggests that deposited 
IgA alone, without co-deposition with IgG, IgM or C3, can disrupt the balance within 
the normal mesangium and initiate inflammation. Mesangial IgA is thought to trigger 
inflammatory processes through mesangial cell and local complement activation. It 
may be that the presence of IgA can trigger mesangial damage via a putative Fc alpha- 
receptor. IgA has been shown to induce the production of TGF-P as well as 
extracellular matrix proteins (Lopez-Armada et al 1996). Ilere is also evidence in the 
literature of IgA interactions with the mesangial cells in vitro initiating the secretion 
of a wide range of pro-inflammatory cytokines such as PAF, IL-1, IL-6, TNF-a which 
may then feed back into a pro-inflammatory loop causing the up regulation of the 
mesangial cell IgA receptors (Monteiro et al 2002). 
1.5.6.2 Cellular effectors In addition to its interactions with the mesangial cell, 
deposited IgA could act as a trigger to leucocytes resident within the glomerulus. 
Unlike other types of proliferative glomerulonephritis, IgAN, with the exception of 
crescentic IgAN, is not generally associated with inflammatory infiltration of the 
glomerulus. Bearing in mind that 15% of resident cells in the mesangiurn are 
macrophages, which are known to express Fc alpha-receptors (Vies et al 1993) the 
glomerular injury may be mediated by the expansion of these cells in situ rather than 
through the recruitment of circulatory inflammatory cells. Macrophages may be 
activated in situ via their Fc alpha-receptors. One study has shown that circulating 
polymorphonuclear cells in IgAN not only have increased expression of Fc alpha- 
receptor, but also generate greater amounts of oxygen free radical species when 
activated by, in amongst other factors, aggregated IgA (Kashern et al 1994). It is 
possible that a similar process could occur in the resident or trafficking leukocytes 
within the mesangium contributing to the inflammatory injury. 
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1.5.6.3 Complement activation: Although the activation of complement is not 
necessary for the development of inflammation and renal injury in IgAN, there is 
evidence of some degree of local complement activation. Mesangial IgA complement 
activation is thought to be independent of the systemic complement cascade. 
Mesangial cells and podocytes may produce 0 locally via the mannose-binding 
lectin pathway (Matsuda et al 1998). Mesangial cells are also known to produce 
complement regulatory proteins and it may be that deposited JgA may modulate this 
immune-regulatory function (Abe et al 1998). 
1.5.6.4 Progression: Following IgA deposition and the initiation of inflammation, the 
subsequent course of the disease, be it progressive damage or resolution is not specific 
to IgAN. The development of progressive renal failure is associated with proteinuria 
and hypertension which arise in tandem with vascular and tubulo-interstitial damage. 
These changes are also generic to all forms of glomerular disease. The mechanisms of 
progressive renal failure have been widely studied both in IgAN and other glomerular 
diseases and are not discussed further in this thesis. 
1.6 Hepatic IgAN 
1.6.1 Epidemiolggy 
Hepatic IgAN is the commonest form of secondary IgAN. Other causes of secondary 
IgAN include suppurative lung disease and inflammatory bowel disease. IgAN has 
also sporadically been associated with a host of conditions ranging from connective 
tissue disorders such as rheumatoid arthritis, SLE, and mixed connective tissue 
disease; neoplastic diseases such as IgA myeloma, non-Hodgkin's lymphoma, and 
carcinoma of the bronchus; and infections such as HIV and schistosomiasis. 
Hepatic IgAN most significantly but not exclusively occurs as a complication of 
alcoholic liver disease which in turn is associated with an IgA immune system 
disorder per se (Van de Wiel et al 1987, Hodgson 1985). Information on hepatic IgAN 
is based largely on autopsy and biopsy studies (Sakaguchi et al 1965, Callard. et al 
1975, Nochy D 1976, Berger et al 1977, Sancho et al 1982, Kalsi et al 1983, Bene et 
al 1988, Coppo et al 1985). Pooled autopsy and biopsy data suggest that between 50- 
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100% of patients with alcoholic cirrhosis have glomerular abnormalities on 
microscopy (Newell 1987). Where immunofluorescence (EF) has been available 30- 
90% of specimens stain positive for mesangial IgA deposits (Newell 1987, Axelsen et 
al 1995). These studies have not always taken account of viral infections, bacterial 
sepsis and other co-morbidities, which may be the cause of the observed glomerular 
injury. They have also used a wide range of criteria for biopsy. No systematic study in 
a large population of cirrhotics has been undertaken which would provide incidence 
data. Although it has been suggested that hepatic IgAN is a simple coincidence of two 
common conditions (Bene et al 1988), the majority of the evidence points to the 
existence of a distinct clinicopathological entity (Axelsen et al 1995). 
1.6.2 Clinical Features 
Hepatic IgAN is characterised by haernaturia, proteinuria, elevated serum IgA levels 
and mesangial deposits of IgA (Kutteh et al 1982). It is usually clinically silent with 
mild histological changes on microscopy (Manignand et al 1981). The most common 
urinary abnormality, like primary IgAN, is microscopic haernaturia. A small 
percentage of patients present with nephrotic syndrome and renal impairment 
(Nakamoto et al 1981). This may be more difficult to assess clinically due to hepatic 
hypoalbuminaemia. This same study discovered that 9.6% of cirrhotics had nephritic 
urine and only 1.6% were nephrotic (Nakamoto et al 1981). While the results of one 
study suggests that serum IgA levels (which are consistently raised) correspond with 
both the severity of hepatic disease and glomerular lesions (Kutteh et al 1982), the 
urinary abnormalities were shown to correlate with the degree of mesangial 
proliferation and therefore the severity of the glomerular disease in another paper 
(Nochy et al 1976). 
Increased circulating IgA antibodies against common food and microbial antigens are 
reported in chronic liver disease. Circulating IgA immune complexes are elevated in 
up to 80% of patients with alcoholic cirrhosis and are higher in the presence of 
glomerulonephritis (Coppo et al 1985, Sancho et al 1981). A major proportion of 
these may be cryoglobulins, which are present in up to 40% of cirrhotics. There is no 
correlation, however, between the levels of IgA-ICs and the degree of cirrhosis. 
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The characteristics of IgA in hepatic and primary IgAN are surnmarised in Table 1.1. 
Both serum IgAl and IgA2 levels have been found to be elevated and IgA2 is 
proportionally higher in some studies (Delacroix et al 1983). The different findings in 
the different studies may be a result of variable antibody specificity and 
heterogeneous cohorts of patients. The ratio of IgAl: lgA2 has not been found to be 
linked to the severity of the liver disease (Van de Wiel et al 1987). 
In alcoholic cirrhosis, only between 25-45% of the circulating IgA is monomeric in 
contrast with 90% in normal individuals (Kutteh et al 1982). Once the liver damage 
becomes apparent, secretory IgA levels in the blood also start to rise possibly through 
the interruption of the normal trans-epithelial mucosal transport of polymeric IgA 
(Delacroix et al 1983). This may be a direct toxic effect of alcohol or other toxins. 
Finally, plasma C3 complement levels in these patients are depressed but it is not 
clear if this is due to under-production by the cirrhotic liver or increased consumption 
by immune complexes and cryoglobulins. 
Hepatic IgAN is thought to be a benign condition that very rarely progresses to ESRD 
(Newell 1987). No correlation has been found between the severity of cirrhosis and 
the extent of renal failure. There is no established therapy for the treatment of hepatic 
IgAN and the prognosis depends on the course of the liver disease. There is no solid 
evidence that improvement in hepatic function leads to an amelioration of renal 
disease. However anecdotal evidence of disease regression after abstinence from 
alcohol, post liver transplantation or surgery for portal hypertension is cited in the 
literature (Babbs et al 1990). Limited re-biopsy data suggests that the glomerular 
morphology remains static over a number of years. 
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Properties PIgAN HIgAN Normal Control 
Serum IgA Elevated Greatly elevated Nonnal 
levels 
Serum IgA sub- TlgAI TTIgA2/TlgAl IgAl 
class levels 
Predominant TPolymer TT Polymer Monomeric 
serum IgA form 
Levels of I L- T ? Normal 
chains 
IgA charge Anionic ? Normal 
Serum C3 Normal Low Udecreased Normal 
synthesis) 
Elevated IgA-IC + ++ 
Mesangial IgAl/IgM/IgG/ IgAl/IgM/IgG/C3 
deposits C3 
IgA Deposit Polymeric IgA I Polymeric IgA I 
Type 
Table 1.1 An outline of the characteristics of serum IgA reported in the literature in both 
primary (PlgAN) and hepatic (HIgAN) IgA nephropathies compared with normal 




The light microscopic features of hepatic IgAN are similar to primary IgAN. There is 
variable widening of mesangial matrix, thickening of capillary wall, either segmental 
or more commonly diffuse mesangial hypercellularity, with mesangial electron dense 
deposits. On immunofluorescence, mesangial IgA predominates but is often 
associated with lesser amounts of IgG, IgM or C3. As with primary IgAN, there may 
be minimal light microscopic changes despite the presence of IgA deposits on IF. 
Mesangial interpositioning and splitting of the glomerular basement membrane are 
more common than in primary IgAN. Mesangiocapillary or crescentic rapidly 
progressive glornerulonephritis have also occasionally been described. 
Polymeric IgA I appears to be the dominant form of deposits in the renal mesangium, 
of patients with hepatic IgAN despite the higher levels of circulatory IgA2. Like in 
primary IgAN, studies of the IgA sub-class distribution in hepatic IgAN have been 
contradictory. This may be due to problems arising from lack of reagent specificity of 
the antibodies used in the studies. One early study suggested that IgA2 was the 
dominant deposit in hepatic IgAN (Andre et al 1980). Ilis same study also over- 
estimated the levels of IgA2 deposited in primary IgAN, suggesting a possible 
problem with the methodology. A later study using more robust staining techniques, 
reporting predominantly polymeric IgAl, may therefore be more informative about 
the nature of the mesangial deposits (Lomax-Sinith et al 1983). One recent case report 
of hepatic IgAN secondary to autoirnmune hepatitis found mesangial deposits 
composed of IgA2 (Singri et al 2004). This may be due to a distinct pathological 
process from that of IgAN secondary to alcoholic cirrhosis. 
Hepatic IgAl deposits are a particular feature of alcoholic cirrhosis. They are present 
in only 12% of cases of non-alcoholic liver disease as opposed to 78% in alcoholics 
with cirrhosis, where IgAl is found in a continuous pattern along the hepatic 
sinusoids (Burgess et al 1992). 
1.6.4 Pathogenesis 
The pathogenesis of hepatic IgAN remains obscure and a common pathogenesis with 
primary IgAN cannot be assumed despite the many common features that they share. 
Abnormalities of the IgA immune system, antigen overload, defective liver clearance 
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of IgA and cellular control of IgA production may influence the distribution and 
behaviour of IgA in liver disease. 
1.6.4.1 Increased polymeric IgA production Raised circulating IgA and IgA immune 
complexes may represent an appropriate response of a normal IgA immune system to 
excess antigen exposure and persistent antigenaemia resulting from diminished 
mucosal integrity. There is also some evidence of an exaggerated intrinsic IgA system 
activity. In alcoholic cirrhosis circulating B-cells show increased spontaneous and 
mitogen stimulated production of IgA in vitro possibly due to abnormal T cell 
cytokine patterns or suppressor cell function (Giron et al 1992). Peripheral blood 
mononuclear cells also have an enhanced IL-6 response leading to further IgA 
secretion from B-cells and thus may promote an auto-amplification loop in vivo 
(Deviere et al 1999). 
1.64.2 Decreased clearance Ile binding of IgA to its hepatic receptors may be 
impaired in hepatic IgAN thus reducing its clearance rate. The fractional catabolism 
of IgA and its complexes is reduced in alcoholic cirrhosis (Delacroix et al 1983) and 
all hepatic removal routes for these complexes are impaired (Roccatello et al 1993). 
This reduced clearance may result from alterations in the structure (and therefore 
interaction) of the receptor, the IgA molecule itself or the surface distribution of the 
receptor. In health the ASGP-R is based in the sinusoidal/lateral aspect of the 
hepatocytes. In cirrhosis, loss of hepatic polarity may account for the observation that 
the receptor reverts to the canalicular surface, thus preventing exposure of the receptor 
to circulating IgA and the IgA immune complexes (Burgess et al 1992). There is also 
evidence that the expression of Fc-alpha receptors in cirrhosis is reduced on 
circulating monocytes and that the endocytosis of the immune complexes of IgA is 
defective (Silvain et al 1995). This may in turn contribute to reduced clearance of IgA 
from the circulation. These findings may not be directly applicable to hepatic IgAN 
and such studies are yet to be performed in this group of patients. 
1.64.3 IgA mesangial deposition There have been no direct studies of the mechanism 
of mesangial IgA deposition in hepatic IgAN. High levels of food and bacterial 
antigens circulating in cirrhotic patients may lead to formation of antigen-antibody 
complexes either in situ in the glomerulus or in the circulation. But this presumption 
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has not been confirmed and indeed there are no studies to reliably identify the 
antigens within the mesangial deposits. As in primary IgAN, abnormal glycosylation 
may modify interactions influencing mesangial deposition and glomerular injury. 
These have not been studied in hepatic IgAN. The explanations for variable 
glomerular injury and disease progression in hepatic IgAN are no clearer than in 
primary IgAN. Further studies of the pathogenesis of hepatic IgAN may provide 
valuable insights into IgA pathobiology and the range of processes involved in IgA 
tissue deposition in both primary and secondary IgANs. 
1.7 Summary 
Despite the identification of a whole variety of immune and non-immunological 
processes in idiopathic IgAN, the basic pathogenic mechanisms involved in this 
condition remain obscure. We still do not know exactly why IgA deposits in the renal 
mesangium and why in some patients it produces inflammation and glomerular injury 
whilst remaining an innocuous feature in others. Patients with hepatic IgAN can be 
studied in a comparative manner alongside patients with primary IgAN with the aim 
of elucidating the different mechanisms involved in the development of this 
heterogeneous condition. 
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Chapter 2: IgA Glycosylation 
2.1 Introduction 
Protein glycosylation is a common form of post-translational modification. It plays a 
crucial role in the structure, function, and interactions of glycoproteins. Glycobiology 
is a relatively young science, studying the synthesis, structure and function of the 
sugar residues on glycoproteins and the control mechanisms involved in the 
glycosylation process. As a discipline it has been overshadowed in the past by the 
interest in the biological and pathological role of proteins. However, it has gained 
increasing relevance over the last two decades, as more diseases have been associated 
with abnormalities of protein glycosylation. Glycobiology has become more 
prominent as a discipline in investigating the pathogenesis of IgA nephropathy over 
the last 15 years. The absence of a consistent antigen as a trigger for IgA deposition 
prompted the search for a physicochemical property in the IgA molecule itself which 
would render it more liable to deposition. In this chapter the background to my IgA 
glycosylation work will be reviewed. 
2.2 Protein Glycosylation 
Glycoproteins are formed when specific amino acid residues on the protein backbone 
are linked covalently to carbohydrate chains. The presence of these chains creates 
significant heterogeneity in the structure of the glycoproteins. Ilis is due to the 
multiple possible combinations of monosaccharides and their diverse linkage to 
various amino acid sequences. Furthermore, each glycosylation site on a protein may 
have variable occupancy with different glycans giving rise to a multitude of 
glycoforms of a single glycoprotein (Lis and Sharon 1993). 
2.2.1 Glycans present in glycoproteins 
Two different types of monosaccharides occur in mammalian glycoproteins. Those 
constituted from a 6-carbon ring are Glucose (Glc), Mannose (Man), Galactose (Gal), 
Xylose (Xyl), Fucose (Fuc), N-acetyl glucosamine (GIcNAc), and N-acetyl 
galactosamine (GaINAc). Mese monosaccharides predominantly form the core sugars 
in the glycan chains of glycoproteins. Various forms of a 9-carbon sialic acid residue 
are also found in glycoproteins of which N-acetyl neuraminic acid (NeuNAc) and N- 
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glycolyl neuraminic acid (NeuGlc) are the commonest (Figure 2.1). These glycans 
are different to other monosaccharides found in mammalian glycoproteins in a 
number of respects. The commonest type of sialic acid found in man is N-acetyl 
neuraminic acid (NeuNAc) with an acetyl group at the 5-carbon position. These 
sugars usually take on the terminal position of the N- and O-glycans and as such play 
an important role biologically, being highly negatively charged, reactive species at the 
outer surface of the glycan core. The labile nature of sialic acids means that they are 
readily lost during the life span of a protein. This is particularly true as a protein ages 
and under experimental conditions, and differences in sialylation may simply reflect 
the degradation of the glycoprotein both in vivo and in vitro (Varki 1992). This can 
confound investigations of protein sialylation and has led to investigators focusing on 
the core glycans rather than on the sialic acids. 
2.2.2 Glycan linkage to protein back bone 
Glycans are linked covalently to the protein backbone in two different ways, via an N- 
link to asparagine residues or through an O-link to serine or threonine (Montreuil et al. 
1995). 
2.2.2.1 N-Unks N-linked glycosylation is common in both secreted and membrane 
bound proteins and is a feature of immunoglobulins. Ile N-linked sugars are 
connected to the protein chain via GIcNAc in a al-N linkage with an asparagine 
residue as a co-translational event in the endoplasn-& reticulum (Opdenakker et al 
1993). N-linked oligosaccharides have a common inner core structure of 5 sugars 
which is conserved in all N-glycopeptides. The remaining sugars exist in a number of 
branched chain varieties (Figures 2.2a-c). The high mannose type is formed of 
mannose and GlcNAc residues alone. The complex type contains the latter residues as 
well as galactose, fucose and sialic acid. The hybrid type is a mixture of the latter two 
types (Montreui11984). 
2.2.2.2 0-linked glycans O-linked glycoproteins have a range of 1-20 sugars which 
are found clustered in heavily glycosylated domains. These are found in high 
concentration predominantly in membrane bound proteins. 0-glycans are rarely found 
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Figure 2.1 The structure of some of the mono saccharides present in mammalian 
glycoproteins is demonstrated: A. Galactose (C6HI206), B. Mannose, C. Glucose, D. 
Fucose, E. Sialic Acid, F. GaINAc, G. GlcNAc. 
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Man(xl, 2- Manal, 6 
Manctl, 2- Manctl, 3 
> 
Manal, 6 
Manal, 2- Manal, 2 - Manal, 3 
Manpl, 4-GIcNAcpl, 4-GIcNAcplN 
Figure 2.2a showing high mannose type side chains of N-linked glycans 
NeuNAca2,6-Galol, 4-GIcNAcpl, 6 
Manal, 6 
NeuNAccx2,6-Galpl, 4-GIcNAcpl, 4 
NeuNAc(x2,6-Galol, 4-GIcNAcpl, 2 
NeuNAcc(2,6-Galpl, 4-GIcNAcpl, 4 
Manal, 3 
NeuNAca2,3-Gal5l, 4-GIcNAcDI, 2 
Manol, 4-GIcNAcpl, 4-G]cNAcpl, N 








Manpl, 4-GIcNAcpl, 4-GIcNAcpl, N 
Figure 2.2c showing hybrid type side chains of N-linked glycans 
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gonadotrophins, erythropoetin, plasminogen, fetuin, and a number of cytokines such 
as IL-2 and IL-6 (Hortin and Trimpc 1990). 
O-linked glycosylation typically occurs on repeating sequences of amino acids which 
are rich in serine, threonine, and proline as a post-translational modification in the 
Golgi apparatus. The glycans are added sequentially by glycosyltransferases to the 
serine and threonine residues. The tertiary structure of the complete protein does not 
allow glycosyltransferases to access all potential glycosylation sites. The presence of 
this repeating sequence of amino acids tends to form an extended structure with many 
0 turns rather than conforming to a helix formation. Furthermore, clusters of O-linked 
glycans on such peptides create a rigid structure, allowing the creation of long mucin 
domains (Hounsell and Davies 1993, Lis and Sharon 1993). 
There are three types of O-linked glycans (Montreuil 1984). The mucin type sugars 
are based upon a 1,3 GaINAc connection to a serine or threonine residue. Further 
substitution with simple monosaccharides such as galactose or neuraminic acid can 
occur in a single chain. This is the type found in immunoglobulins and in the IgAl 
hinge region (figure 2.3). Ile proteoglycan type is based on a xylose residue attached 
via a 1,3 serine residue creating a long single chain of repeating disaccharides. The 
collagen type is made up of a galactose in a 1,5 linkage with hydroxy-proline or 
hydroxy-lysine. 
2.2.3 Protein glycosylation enzyMes 
2.2.3.1 Glycosyltransferases Diverse and numerous but poorly characterised. 
glycosyltransferases, (GTase) and glycosidases, are responsible for protein 
glycosylation (Kleene and Berger 1993; Narimatsu 1994). Most of the glycosylation 
reactions that generate the great diversity of oligosaccharide structures of eukaryotic 
cells occur in the Golgi apparatus (Kleene and Berger 1993). Glycosylation pathways 
may also occur in the cytosol and the endoplasmic reticulum (Montreuil et al 1996). 
More recently further information regarding the functional organization of Golgi- 
resident glycosyltransferases as well as X-ray crystal structure determination of 
glycosyltransferases has become available, shedding light on the molecular basis for 
donor and acceptor substrate specificities as well as GTase catalytic function (Breton 
et al 2001). 
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1. I Ser/Thr 1- 0 -> I GaINA 
2.1 SerfThr 1- 0 -> I GaIN -#1,3 
3.1 Ser/Thr 1-0->1 GaIN 
a2,6 
I 
4. SerfT r0 ->I Ga #1,3 
a2,3 
5. Ser/Thr -0 ->I Ga fli, 3 
a2,6 a2,3 
II 
Figure2.3 The various permutations of the IgAl hinge glycopeptide 0- 
glycosylation. Each serine or threonine residue in the amino acid backbone 
can potentially be substituted with a GaINAc residue via an al O-link. This 
can either be a terminal GaINAc as in example 1, or it may be further 
substituted with a terminal galactose residue via a PI, 3 link as in example 2. 
The terminal GaINAc may also be directly substituted by a neuraminic acid 
residue via an (x2,6 link as shown in permutations 3 and 5. Galactose residues 
may also have a terminal sialic acid residue linked to them via (X2,3 links as 
shown in examples 4 and 5. 
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Functionally, glycosyltransferases are one of the most diverse group of enzymes. The 
genes for these enzymes are highly conserved but show little homology across the 
different species. Every type of biopolymer is modified by GTases, with varied 
effects. Bearing in mind the structural and functional diversity of these products 
combined with the distant phylogenetic relationships of the GTases, it is 
understandable that sequence homologies between glycosyltransferases are low. 
Interestingly, the majority of glycosyltransferases belong to only two structural super- 
families, creating a narrow repertoire for glycosyl transfer (Hu and Walker 2002). 
Glycosyltransferases are monomeric transmembrane proteins with tightly folded 
carboxy-terminal domains where the catalytic function resides. The classification and 
nomenclature of glycosyltransferases, is according to their monosaccharide substrate. 
For example 0-1,3galactosyltransferase and a-2,6sialyltransferase transfer galactose 
and sialic acid to their acceptors respectively Qoziasse 1992). They catalyse the 
transfer of the sugar residue from a nucleotide donor such as UDP to an acceptor 
protein in a specified linkage. No enzyme is capable of transferring more than its 
specified type of sugar and therefore the assembly of the carbohydrate chain occurs 
sequentially as the product passes along a string of transferases with various 
specificities. The glycosyltransferases also exhibit acceptor molecule specificity 
whether this is a protein or a core oligosaccharide already added to the peptide 
backbone. The protein template appears to be responsible for dictating the type of 
glycosyltransferase used and therefore what the composition of the oligosaccharide 
chains will be. This oligosaccharide acceptor specificity ensures the correct sequence 
of sugar residues is added (Breton and Imberty 1999). Recent experimental data has 
demonstrated the importance of these enzymes in donor and acceptor substrate 
binding and in catalysis. Fold-recognition studies are providing the first models of the 
catalytic domains of some of these enzymes (Breton and Imberty 1999). 
O-glycan synthesis is by far simpler than the pathways involved in N-oligosaccharide 
production. It begins in the cis Golgi apparatus with the transfer of the first sugar 
residue GaINAc from a nucleotide sugar by a specific polypeptide O-GaINAc 
transferase. The chain then grows by the addition of further Gal, Fuc, or GlcNAc 
residues in the medial Golgi. Sialylation occurs in the trans Golgi (Brockhausen 
1995). 
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N-oligosaccharides biosynthesis starts in the endoplasn-iic reticulurn ER with a large 
precursor oligosaccharide that contains 14 sugar residues. This precursor is linked to 
dolichol pyrophosphate, which acts as a carrier for the oligosaccharide which is then 
transferred to an Asn residue on the growing polypeptide chain (Verbert 1995). It is at 
this point that all the glucose and mannose residues are removed by specific 
glycosidases, producing an oligosaccharide with 10 residues instead of 14. Ile 
maturation of the N-oligosaccharides takes place in the Golgi complex via a 
coordinated and sequential set of enzymatic reactions, which remove and add specific 
sugar residues. The enzymes involved (glycosidases and glycosyltransferases) are 
located in the cis, medial, and trans Golgi (Schachter 1995). The reaction product of 
one enzyme is the substrate for the next. The high-mannose and hybrid 
oligosaccharides appear as intermediates along the processing pathway. The complex 
type is the mature form of N-linked oligosaccharides. 
2.2.3.2 Regulation of glycosylation Factors regulating glycosyltransferase expression 
are not well understood. They are often highly tissue and cell specific and may occur 
at precise stages of differentiation. The control levels appear to be at the transcription 
level given that protein levels correlate with mRNA expression (Kleene R and Berger 
1993). Cytokines and bacterial products may be involved in the regulation of their 
function. It has been postulated that increased IL-6 secretion triggered by infection 
may lead B-cell differentiation into plasma cells with increased sialyltransferase 
activity at the expense of galactosyl transferase function. Likewise genetically 
induced changes in GTase activity may affect glycosylation of IgA (Shur 1994). 
2.2.4 Micro-heterogeneity of glycans 
The mixture of glycosylated variants is known as its glycoforms, where the same 
peptide sequence exists with more than one oligosaccharide at the same glycosylation 
site. In fact a single glycan may occur on the same glycosylation site but in different 
combinations with other glycans and via different linkages. A single glycopeptide 
may have a different structure in part due to the folding of the peptide moiety and its 
exposure to and recognition by glycosyltransferases as a potential oligosaccharide 
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acceptor. The prevalence of glycoforms also depend on the cell type in which it is 
found as well as its enzymatic machinery, its stage of development and the nutritional 
or pathological state. 
2.3 IgA Glycosylation 
2.3.11gAl 
Both subclasses of IgA, like all immunoglobulins, are glycosylated. Both IgAl and 
the two allotypes of IgA2, have N-linked glycosylation sites. IgAl is heavily 
glycosylated with around 6-7% of the molecule made up of carbohydrates. There exist 
two N-linked sites on human IgAl (Asn 263 and Asn 459) that carry complex type 
residues. N-glycans of normal human IgAl are heavily galactosylated and sialylated 
with a large degree of heterogeneity as well as carrying a number of mannose, N- 
acetylglucosamine and fucose residues (Field et al 1994). 
In addition to these N-linked glycans, IgAl is also 0-glycosylated in the hinge region 
connecting the CHI and CH2 domains (Kerr 1990) as shown in Figure 2.4. Although 
the sequence of IgA2 differs only by 20 amino acids compared with IgAl, the highly 
unusual structure of the hinge region makes it unique in its glycan and protein 
composition. Humans are the only species with such an unusual hinge region 
structure. The presence of O-linked GaINAc, Gal and NeuNAc residues is a rare 
phenomenon in circulating serum glycoproteins and is the feature which also 
distinguishes IgAl from IgA2 (Field et al 1989). This feature is responsible for the 
IgAl molecule's susceptibility to bacterial proteases. There is much variety in the 
glycoforms present in IgAl due to the multitude of glycosylation sites and glycan 
number and position variations. The presence of many closely packed O-linked sugars 
makes the structure of the IgAl hinge region distinctive. 
Much of the early information about IgAl structure and glycosylation came from 
studies of myeloma IgA (Baenzinger and Komfeld 1974). 'Mese showed that the 
hinge glycopeptide is composed of a 21 amino acid sequence with repeating serine, 
proline and threonine residues and that the sites of 0-glycosylation were located on 5 




Figure 2.4 Molecular model of human IgA I showing the constant and variable light 
and heavy chains, the hinge region, tail piece and the N- and O-linked glycosylation 
sites with their glycan chains shown in yellow. Re-produced courtesy of Professor 
Raymond Dwek. 
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on desialylated pools of glycans (Field et al 1989). Latterly, the intact glycan structure 
of the sialylated forms has been studied. Theoretically O-linked GaINAc substitutions 
may occupy up to 9 sites per alpha chain. The pattern of signal depression and 
silencing in the amino acid sequencing cycles in one study suggested that there were 5 
serine or threonine residues that were potential glycosylation sites. The Th? 28, Ser230, 
and Ser232 were found to be fully occupied whereas Thr225 and Ibr236 appeared to be 
partially occupied (Mattu et al 1998) (Figure 2.5). 
The glycan chains of the IgAl hinge peptide are of the mucin type. There are five 
possible combinations of glycans on the hinge glycopeptide which have been shown 
in Figure 2.3. These consist of GaINAc residues attaching via an 0 linkage to the 
serine or threonine amino acids in the backbone. This may be a terminal GaINAc or 
alternatively, it may be further occupied by a galactose residues via a P1,3 link. The 
GaINAc may also be occupied by a sialic acid residue via an (x2,6 link. The sialic acid 
may also be added indirectly via a galactose residue through an (x2,3 link. Finally 
some GaINAc residues may be substituted with both sialic acid and galactose, which 
in turn may or may not be substituted by further sialic acid residues. The glycosylated 
moieties thus create considerable micro-heterogeneity in the structure of the IgAl 
HGP. The literature suggests that the glycosylation site or occupancy is variable with 
a Gal-GaINAc disaccharide with mono- or desialylated forms being the most 
prevalent. One study did not find any variants with a terminal GaINAc residue in the 
O-glycans in normal serum IgAl (Mattu et al 1998). 
Studies of secretory IgA show further glycosylation possibilities where the core 
GaINAc has been substituted with GlcNAc which in turn may be heavily 
galactosylated and sialylated with larger glycans compared with serum IgAl. The 
differences in size, heterogeneity, and O-glycan site occupancy may be a reflection of 
tissue specific glycosylation. Recently, a molecular model of secretory IgAl with all 
its glycans has been constructed, in which the Fab anns, form aT shape and the SC is 
wrapped around the heavy chains (Royle et al. 2003). The O-glycan regions on the 
heavy (H) chains and the SC N-glycans have been shown in this work to contain 
adhesin-binding glycan epitopes including galactose-linked PI, 4 and PI, 3 to GlcNAc, 
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Figure 2.5 Schematic diagramme of the serum IgA I molecule indicating the hinge region and 
the 33 mer (208-240) hinge glycopeptide situated between the constant heavy chains I and 2 
(CHI and CH2) isolated after trypsin digestion. The amino acids in blue indicate the hinge 
glycopeptide core. The black arrows demarcate the fully occupied positions, and the grey 
arrows the partially occupied 0-glycosylation sites in normal serum IgAl. Further glycans 
(? ) may be located at any of the remaining serine (S) or threonine (T) residues. The various 0- 
glycan permutations are indicated. 
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and a2,3 and a2,6-linked sialic acids. These epitopes are thought to provide secretory 
IgA with further bacterial binding sites. While the Fab region mediates adaptive 
immunity, these glycan epitopes will enable it to participate in innate immune 
reactions. Furthermore the N-glycans on the heavy chains of both secretory IgAl and 
IgA2 have been found to have terminal GIcNAc and mannose residues that are 
normally masked by SC, but that can be unmasked and recognized by mannose- 
binding lectin. 
2.3.2 IgA2 
IgA2 has a higher carbohydrate content than IgAl adding up to around 8-10% of its 
total mass. This is due to the two allotypes of IgA2, A2m(l) and A2m(2), having 4 
and 5 N-glycosylation sites substituted with GIcNAc, mannose and fucose 
respectively (Tomana et al 1972). There are no O-linked glycosylation sites in either 
IgA2 allotype and they have a much shorter hinge region compared with IgAl. IgA2 
was previously thought to have arisen from the deletion of the hinge region in IgAl. 
However, there is now solid evidence that IgAl is phylogenetically the newer 
molecule of the two and IgAl was formed as a result of the insertion of a 13-long 
amino acid sequence into the hinge area of IgA2 (Peppard and Russell 1999). 
2.4 Functional Role of IgA glycans 
Carbohydrate moieties can influence the structure and therefore the interactions and 
functions of immunoglobulins in a number of ways. Ibe three dimensional 
conformation of glycoproteins allows them to be recognised by receptors and thus 
mediate biologically important activities. These include cell trafficking, cell adhesion 
and determining the biological half-life through altering their clearance mechanisms 
(Drickamer and Taylor 1993). 
There are marked differences between the different IgA types in the human. Ibis 
suggests that these differences may play a fundamental role in the biological functions 
of the IgA molecules. The glycans can be relatively bulky in size thus dictating the 
stability of the tertiary and quaternary structure of the molecule (Wright and 
Morrisson 1993). For example the presence of O-linked sugars on the repeating 
protein sequence will encourage a typical folding pattern conferring certain stability to 
the structure and permitting the creation of long mucin type domains. The chemical 
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properties of carbohydrate residues can also affect the whole of the structure. For 
example sialic acid is highly negatively charged and therefore quite labile and 
reactive. By enveloping the glycoprotein it can influence its interactions with other 
molecules and receptors (Lis and Sharon 1993). 
Glycosylation also affects the assembly, transporting and surface expression and 
secretion of the glycoprotein. Carbohydrates also have many post-secretory effects on 
the molecule. They could prolong the half-life of the molecule by protecting it from 
proteolysis, increasing its solubility and decreasing immunogenicity (Montreuil et al 
1982; Lis and Sharon 1993). IgAl is normally very susceptible to degradation by 
bacterial proteases. This is not the case in IgA2 as the main focus of the attack is that 
of the hinge region which is absent in IgA2 (Keff 1990). The heavier hinge region of 
secretory IgAl may be more protected due to its bulk thus conferring an added 
conformational advantage to the molecule in the hostile mucosal environment (Wold 
et al 1994). One study has suggested that this appears to be particularly useful in the 
gastric mucosa where the extra glycosylation of the secretory IgA compared with 
serum IgA has been shown to inhibit the adherence of Helicobacter pylori to the 
gastric mucosal surface (Boren et al 1993). 
The clearance of IgA may also be mediated by their glycans for example by binding 
to ASGP-R directly (Moldoveanu et al 1990). The hepatic ASGP-R binds the 
desialylated terminal Gal and GaINAc with a higher affinity for IgA I rather than IgA2 
where the O-linked sugars of its hinge region act as the ligand (Stockert et al 1982). 
One explanation for altered clearance of IgA has come from studying the properties of 
IgA circulating immune complexes (CIC) (Tomana et al 1999). They tend to be prone 
to self-aggregation and therefore significantly larger than normal. 'Ibis could inhibit 
the normal catabolic pathways involved in their removal. The antibodies to the 
exposed glycoprotein core can also obscure the natural binding sites for the ASGP-R 
and prevent uptake and catabolism, leaving high levels of CIC for deposition in 
tissues such as the renal mesangium. Such large immune-complexes are also unable to 
cross the sinusoidal fenestrae in the space of Disse where the glycoproteins come into 
contact with the ASGP-R (Phillips et al 1986). The net electric charge of these CICs 
may also influence their distribution and deposition. 
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IgA is also cleared via the Fc(xR1 (CD89) on monocytes and other arms of the 
reticulo-endothelial system (Silvain et al 1995). The glycan epitopes on IgA can 
therefore theoretically have an effect on the Fc-mediated clearance of the molecule. 
In addition, the ligand for the leukocyte Fc alpha-receptor lies within the CH2 domain 
of the IgA molecule in close proximity to the N-linked Asn 263 residues as well as the 
hinge glycopeptide region (Mazengera and Kerr 1990). The sugars are involved in the 
interaction between the ligand and its receptors as demonstrated by studies involving 
glycosylation site-directed mutagenesis and inhibition experiments with 
monosaccharides (Burton and Woof 1992, Keidan et al 1995). Human activated CD4 
and CD8 T cells also express receptors that recognise O-linked sugars on the hinge 
regions of the IgA I but not IgA2 (Rudd et al 1994). 
IgA cannot fix complement by the classical pathway due to the lack of aCIq binding 
site. It can however activate the alternative pathway under certain circumstances (Kerr 
1990). N-glycosylation of IgA has been shown to be pivotal in the binding of C3 and 
therefore activation of the alternative complement pathway (Zhang and Lachmann 
1994). The authors used IgA2 in this study to avoid the confounding effects of the 
IgAl 0-glycans and therefore little is known about the role of IgAl 0-glycosylation 
in complement interactions. 
2.5 Glycobiology of pathological conditions 
2.5.1 Introduction 
N- and 0-oligosaccharide variants on glycoproteins (glycoforms) can lead to 
alterations in protein activity or function that may manifest themselves as overt 
disease. The number of diseases cited in the literature with abnormalities of protein 
glycosylation is an ever-increasing list. The proteins affected may be cell surface or 
free glycoproteins. These alterations range from physiological responses due to an 
acute condition to characteristic pathogenic aberration of the protein glycosylation 
pattern. In this section a summary of those diseases that are known to be the result of 
an inherited or acquired glycoprotein oligosaccharide structural alteration follows. 
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2.5.2 Congenital diseases 
Alterations of 0- and N-linked glycans in glycoproteins have been found in an ever- 
increasing number of congenital diseases. These conditions have been summarised in 
Table 2.1. 
2.5.3 Acguired diseases 
2.5.3.1 Rheumatoid arthritis (RhA), juvenile RhA, SLE, Sjogren's: Rheumatoid 
diseases are amongst the best know conditions where aberrant protein glycosylation 
exists. The abnormality occurs on the IgG molecule in particular the N-linked glycans 
at Asn 297 of the gamma heavy chain. Normally this moiety has the capacity to carry 
up to 3 galactose residues. Immune complexes from patients with rheumatoid arthritis 
are particularly rich in asialo-agalactosyl IgG (Bond et al 1996). The proportion of 
patients with under-glycosylated IgG is consistently higher than matched controls 
(Rademacher et al 1988). Similar changes have been found in SLE and Sjogren's 
syndrome (Axford and Hay 1991). The defect appears to be in the activity of the 
galactosyltransferase in both B and T cells, which is inversely proportional to the 
levels of the agalactosyl phenotype (Axford and Alavi 1995). This does not appear to 
be due to a gene locus abnormality, as B cell GTase activity can be stimulated with 
EBV (Axford and Alavi 1995). No inhibitors of the enzyme are known in these 
patients. The percentage of the abnormally glycosylated IgG correlates with poor 
prognosis and disease activity. 71be changes of IgG galactosylation with pregnancy 
(decreased levels of abnormal glycoforms are associated with remission and with 
increasing levels in post-partum relapse) also suggest a pathogenic role for abnormal 
glycosylation in RhA. Defectively galactosylated IgG are prone to self-aggregation 
and formation of complement fixing IgG complexes. They are also incapable of 
ligating B-cell Fc receptors causing disruption of the normal feedback suppression of 
B cells, which in turn leads to the expansion of auto-reactive B cell clones and auto- 
immunity. 
2.5.3.2 Th polyagglutinability syndrome (TnPS): In this rare haematological disease, 
red blood cells are lysed by normal ABO compatible serum. This is due to defective 
glycosylation of erythrocyte membrane proteins, glycophorins A and B, creating a 
neo-antigen to which individuals will have natural autoantibodies. These proteins are 
heavily glycosylated with an N-linked site and 14 O-linked residues. In TnPS, the 
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Disease Clinical Features Biochemistry References 
Leroy AR, mental Lack of Golgi GlcNAc Leroy et al 1970 
Disease retardation, death in phosphotransferase 
(lysosomal I" decade 
storage 
disease) 
Congenital Ia/II: neurological la/lb: Jaeken et al. 
disorders of dysfunction phosphomannomutase 1994 and 1997 
glycosylation 1b: hepatic, defect; II: GlcNAcase 
(CDG) Ia/Ib intestinal disease deficiency 
and II 
Leukocyte Severe mental Absence of neutrophil sialyl Becker et al 
adhesion retardation Lewis x 1999 
deficiency ? Secondary to fucose 
type II deficiency 
HEMPAS AR; anaemia, Absence of poly N- Fukuda 1999 
cirrhosis acetyllactosamine 
Wiskott- X-linked, eczema, Lymphocyte O-linked glycan Higgins et al 
Aldrich thrombocytopoenia, defect 2" to altered GIcNAc 1991 
Syndrome immunodeficiency and sialyl trasferase activity 
Multiple Muscular dystrophy Glycosylation defects of a Martin et al 
forms of dystroglycan 2003 
muscular 
dystrophy 
Walker- Neuronal migration Defective 0-mannosylation Martin-Rendon 
Warburg disorder causing et al. 2003 
syndrome brain abnormalities 
Fukuyama Muscular dystrophy Genes mutations encoding Martin-Rendon 
congenital glycosyltransferases et al 2003 
dystrophy 
-- 
Table 2.1 Congenital disorders associated with the presence of abnormal 0- or Winked 
glycosylation. AR: autosomal. recessive, G1cNAc: N-acetylglucosamine, GIcNAcase: N- 
acetylglucosamine transferase, HEMPAS (Hereditary erythroblastic multinuclearity 
associated with nositive acidified -.; enjm). 
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defect is either due to asialylation (F antigen named after Thomsen-Friedenrich) or 
due to agalactosylation (Tn antigen) the latter being due to loss of 01,3 
galactosyltransferase activity (Cartron et al 1978). This in turn is because of gene 
repression rather than mutation (Thurnher et al 1993). Figure 2.6 shows the structures 
of the different antigens found in different conditions. 
Z5.3.3 Other conditions associated with altered glycosylation: Other conditions in 
which altered glycosylation have been observed include: inflammatory bowel disease, 
in particular Crohn's disease; infectious conditions such as periodontal disease, TB 
and leprosy; systemic vasculitides such as ANCA positive vasculitis (Holland et al 
2002); and paroxysmal nocturnal haemoglobinuria. Furthermore, in conditions such 
as cystic fibrosis (CF), altered glycosylation of the secretory component of mucosal 
IgA has been found with evidence of undersialylation and overfucosylation (Marshall 
et al 2004). In addition, the CF glycophenotype is expressed on membrane 
glycoconjugates, of CF airway epithelial cells as increased fucosyl residues in al, 3 
and al, 4 linkage to N-acetyl glucosamine, decreased fucosyl residues in al, 2 linkage 
to galactose and decreased sialic acid. One study has found evidence supporting the 
hypothesis that wild type CF transmembrane conductance regulator acts in the Golgi. 
its mutation in CF causes changes in the compartmentalization of terminal 
glycosyltransferases, thus creating the CF glycophenotype (Stoykova et al 2003). 
Finally, increasingly the role of altered glycosylation of tumour antigens has become 
the subject of research. Many turnours are known to express a high level of tumour 
associated carbohydrate antigens which are associated with a more aggressive course 
and poor patient survival. Examples of this are the presence of Tn and Sialyl-Tn in 
colorectal, lung, and breast cancer (Hakomori 2001). Other glycoforms suppress 
tumour metastases, yet the biochemical mechanisms behind this are mostly unknown. 
In the case of breast cancer, a recent study suggested that a particular type of 0- 
glycosylation was responsible for the inertness of tumor-associated MUCI 
glycoforms expressed on the breast cancer cells to effective dendritic cell processing. 
ibis was mediated by the O-glycans masking the cleavage site on the peptide which is 
















Figure 2.6 Scheme of different antigens arising from the variable glycosylation of the 
senne/threonine (Ser/Thr) residues in O-linked glycopeptides. The red square represents 
the GaINAc residue which is O-linked to the protein back bone (shown in a black curved 
line). The green circle and yellow star represent galactose and sialic residues respectively. 
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2.6 Glycosylation of IgAl in IgAN 
2.6.1 Investigative tools in IgAN 
A number of tools have been used in the study of the IgA I glycosylation. Whilst each 
of these has added to the body of information about the structure of the molecule, 
each of them has their unique limitations. These have ranged from studies where the 
whole IgAl molecule has been analysed using ELISA-type lectin-binding studies, to 
various chromatographic techniques of assessing the free glycans of the hinge peptide, 
and finally a mass spectrometric analysis of the hinge region glycopeptide. 
It is important to note at this stage though, that the majority of these studies have used 
different methods to isolate and purify IgAl. This may affect the results of the 
glycosylation studies per se. Techniques such as gel filtration and ion exchange 
chromatography separate molecules by size alone. Given that many other proteins of 
similar size appear in the serum and that the isoelectric point (pl) of serum IgA is also 
variable, these two methods are unsuitable for purification of IgAl. Out of the 
immunological affinity techniques, chromatography using Sepharose columns damage 
the O-glycans in particular the labile sialic acids and ELISA-type techniques 
immobilise the IgA onto plates and therefore elution is not possible. 
Jacalin affinity chromatography (JAC) has been used in many studies where the 
specific affinity of jacalin for the Galol, 3-GaINAc has been utilised to isolate IgAl. 
As this binding is not specific to IgA, other O-linked glycans in the serum may 
contaminate the IgAl preparation. Clesterase inhibitor (ClInh) is one such molecule 
which may be separated out by precipitating high molecular weight (HMW) proteins 
and discarding the low molecular weight (LMW) components containing CI Inh. The 
other common contaminant may be IgG from its immune complexes with IgAl. 
However the main criticism of this method of IgAl purification may be that the very 
0-glycans analysed are those used for purification and therefore there is a risk of 
losing any potential non-jacalin binding IgAl glycoforms. Having said this, in studies 
where JAC and IgAl immobilisation on immunoplates have been performed in 
parallel, good correlation has been found between the results (Allen 1999). From a 
practical point of view, this method is the only effective approach to purifying IgAl 




Lectins are plant and animal derived proteins with specific affinity for carbohydrate 
ligands. The existence of erythrocyte-agglutinating proteins has been recognised since 
the turn of the 19th century. By the 1960s it had also become apparent that such 
proteins also agglutinate other types of cell in a sugar-specific manner. Although 
shown to occur widely in plants, and to some extent also in invertebrates, very few 
lectins had been isolated till the early 1970s. This changed with the recognition of 
lectins as extremely useful tools for the investigation of carbohydrates on cell 
surfaces, in particular of the changes that the latter undergo in malignancy, as well as 
their use in the isolation and characterization of glycoproteins. In recent years 
numerous lectins have been identified from plants, microorganisms, and animals, and 
the structures of hundreds of them has been elucidated. Concurrently, it has been 
shown, that lectins function as recognition molecules in cell-molecule and cell-cell 
interactions in a variety of biological systems (Sharon and Lis 2004). 
Lectins are polyvalent proteins with multiple sugar binding sites and their binding can 
be inhibited by the appropriate oligosaccharide. In nature their function is variable but 
they are in general involved in recognition and binding processes. In scientific work, 
lectins are used as tools to identify glycan moieties and lectin binding is a simple 
method of screening for glycosylation changes in glycoproteins. They can be used in 
an ELISA-type set up. A variety of lectins with variable specificities are available 
which recognise different 0-glycan moieties. Table 2.2 summarises the most 
commonly used lectins for analysis of 0-glycans in IgAN. Some of the lectins used in 
the assessment of IgA I 0-glycans are discussed below. 
As will be discussed later, a number of lectins are available that have strong and 
specific affinity for O-linked glycans, the most commonly commercially available one 
being jacalin bound to agarose. Jacalin recognises the Gal 01,3 GaINAc link. Its 
binding is not affected by sialylation and it also has some affinity for agalactosylated 
moieties (Roque-Barreira and Campos-Neto 1985). Therefore it is assumed that it is 
capable of binding all glycoforms of IgAl. The most commonly used lectins in IgAl 
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Lectin Binding Specificity 
Artocarpus integrifolia Galpl, 3GaINAc and GaINAc Not affected by NeuNAc 
(Jacalin) 
Amaranthus caudatus Galpl, 3GaINAc Partially inhibited by 
(AC) NeuNAc 
Arachis hypogaea (Peanut Strong affinity for asialylated Highly inhibited by 
agglutinin, PNA) Galpl, 3GalNAc NeuNAc (low binding to 
native IgA I) 
Vicia villosa GalNAc Inhibited by 
(W) Gal/NeuNAc 
Helix aspersa Affinity for GaINAc Inhibited by 
(HAA) Gal/partially inhibited by 
NeuNAc 
Helix pornatia GaINAc Inhibited by 
(HPA) Gal/NeuNAc 
Caragana arborescens GaINAc Inhibited by 
(CAA) GaVNeuNAc 
Bauhinia pupurea Galpl, 3GaINAc Inhibited by NeuNAc 
(BPA) 
Table 2.2 Summary of a number of lectins used in the assessment of O-glycan carbohydrate 
structure. This table shows the preferential glycans the lectins bind to as well as the 
specificity for the oligosaccharides by which they are inhibited. 
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glycobiology are Vicia villosa (VV), Helix aspersa (HAA), and peanut agglutinin 
(PNA). VV and HAA both preferentially bind to 0-glycans with GaINAc alone (T 
antigen) and are used as an indirect measure of the presence or lack of galactose 
(Osawa and Tsuji 1987). PNA however binds preferentially to the Gal-01,3-GaINAc 
and is highly inhibited by the presence of sialic acids (Osawa and Tsuji 1987). 
Studying samples of IgA I using a variety of lectins such as the examples cited above 
give an indirect picture of the glycan content of the glycopeptide. 
2.6.3 Lectin bindiniz studies 
2.6.3.1 Findings of lectin binding studies in IgAN Although many studies have 
reported aberrant glycosylation of IgAl in IgAN, the precise structural characteristics 
of this molecule have not been elucidated. The main strategies adopted, their strengths 
and shortcomings are discussed below. Andre et al first noted aberrations in IgAl 
glycosylation in IgAN in 1990. He observed that IgA from patients with IgAN had 
reduced reactivity with the lectin jacalin which is highly specific for the P-1,3 
galactose linked to GaINAc on the 0-linked glycan chain. Although other groups 
independently confirmed these findings, others showed the reverse, where evidence of 
altered glycosylation was found as increased binding to jacalin (Tomino et al 1995; 
Hiki et al 1996). Other groups subsequently reported increased binding of IgAl from 
sera of these patients to other lectins that recognise terminal GaINAc (Allen et al 
1995; Baharaki et al 1996; Tomana et al 1997). These studies all suggested alterations 
in patients with IgAN using indirect evidence for degree of lectin binding of the intact 
or desialylated IgAl. Whilst some explained their findings as evidence of under- 
galactosylation, others interpreted their results as over or undersialylation or a 
combination of both. 
2.6.3.2 Limitations of lectin binding studies in IgAN The main problem with these 
studies has been the use of a speculative and indirect technique which is subject to 
variation in the result depending on the source and specificity of the lectin used 
(Kobayashi et al 1988). Even when the same lectin has been used, as in the initial 
Andre paper (1990) as well as studies by Hiki et al (1996), and Tomana et al (1997 
and 1999), conflicting results have been found about the differences in IgAl jacalin 
binding. In one study that examined the interactions between IgAl and different 
lectins with seemingly similar reactivity to glycan moieties of IgAl, contradictory 
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results were obtained (Allen et al 1995). One study even drew the wrong conclusion 
of increased sialylation from its finding of increased binding of IgAl to PNA which 
on the contrary is known to be inhibited by the presence of sialic acid on the Gal P1,3- 
GaINAc (Baharaki et al 1996). 
The other technical issue that may result in different findings has been the use of a 
variety of techniques in the isolation of IgA as well as the assessment of the binding. 
Whilst some groups have used anti-IgA antibodies to immobilise and purify the IgAl 
molecule, others have used JAC which in itself may introduce a bias in terms of the 
characteristics of the purified IgA. Jacalin is supposed to be highly specific for the Gal 
01,3-GaINAc residue and is not thought to be inhibited by the presence or absence of 
either galactose or sialic acid residues (Roque-Barreira and Campos-Neto 1985, 
Gregory et al 1987). However, there is no assurance from the literature that severely 
altered glycans are still bound by jacalin and it may be that the most abnormal and 
potentially pathological glycoforms are lost as a result of the JAC purification process 
employed by some of these studies. 
Finally the other main limitation of these studies is that they were conducted on 
diverse groups of patients from vastly different racial backgrounds ranging from the 
original French series, to the Japanese, and American groups. The differences 
highlighted by the different groups could simply be a reflection of the genetic 
differences between the groups of patients and controls under study. 
2.6.4 Reverse phase HPLC and gas liguid chromatography 
More indirect evidence of abnormal glycosylation has come came from studies using 
various biochemical techniques such as gas-liquid chromatography and HPLC 
following chemical release of intact IgAl 0-glycans in their native form by 
hydrazinolysis (Patel et al 1993). Analysis of free 0-glycans can be brought about 
using a number of techniques. Again, none of these can give precise information 
about O-glycan site occupancy but they do impart some knowledge of the structure 
and relative frequencies of the sugar residues. IgA 0-glycans may be released 
chemically or enzymatically. The former is achieved by hydrazinolysis at 60 degrees 
Celsius to guarantee the release of intact 0-glycans as opposed to any N-glycans. 
Enzymatic release of sialylated glycoforms is achieved only after treatment with 
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neuraminiclase to remove sialic acid residues. Asialylated glycoforms may be released 
by 0-glycanase or GaINAcases. 
The total carbohydrate content of IgAl 0-glycans has been assessed in this way 
(Mestecky et al 1993). This study showed a decrease in the total galactose content 
found in serum IgA I from patients with IgAN compared with normal controls. Hiki et 
al (1996) later demonstrated decreased ratio of higher to lower galactosylated forms 
of the IgAl HGP in IgAN using rpHPLC to analyse the 0-glycans released from IgAl 
by hydrazinolysis. They showed a significant increase in the percentage of species 
containing asialylGalpl, 3GaINAc with a parallel decrease in the mono-sialyl species 
in IgAN. None of these studies however were able to produce a detailed report of the 
glycoforms or their stoichiometry. The studies using lectin binding and 
chromatographic techniques in analysing the IgAl 0-glycosylation have been 
summarised in Table 2.3. 
2.6.5 Fluorophore assisted carbohydrate electrophoresis (FACE) 
FACE is performed by labelling free 0-glycans with a fluorophore which are then run 
on a polyacrylamide gel. The densities of the bands obtained under UV light 
correspond to the relative quantities of glycans present in the sample (Klock and Starr 
1998). A paper by Allen et al (1999) using this method following the enzymatic and 
chemical release of IgAl 0-glycans has shown increased frequency of single GaINAc 
units in IgAN. This also corresponded well to binding with the GaINAc specific lectin 
Vicia Villosa. 
2.6.6 Mass SpectrometEy: 
Mass spectrometry was successfully adopted for glycoprotein structure over a quarter 
of a century ago (Morris et al 1978). These early studies led, to the discovery of 
multiple oligosaccharides O-linked through an-ýino acid residues to the protein 
backbone. The methodology at the time involved the production of volatile 
derivatives using permethylation, which survives until the present day for some 
analyses. Glycopeptide analysis however is now best done using one of the more 
advanced soft ionisation techniques such as matrix assisted laser desorption ionisation 
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METHOD IgAN FINDING COMMENT REFERENCES 
Jacalin binding Binding tojacalin; Calculated binding Andre et al 1990 
First evidence of using relative index 
reduced galactose of the anti-IgA Ab 
content dose-resPonse curve 
against IgA. 
Jacal in coated T Binding to jacalin 7 Due to different Tomino et al 1995 
ELISA microplates suggesting T Gal jacalin specificity or 
with IgA I from n=22 content of IgAl from genetic differences 
IgANs, n=14 renal patients with IgAN 
and n=20 normal 
controls 
ELISA based lectin 1. T W/HA binding ACIPNA findings Allen et al 1995 
binding, jacalin suggesting presence not consistent with 
affinity of increased terminal WMA binding 
chromatography GaINAc in IgAN 
purification 2. No change in 
N=20 IgAN AC/PNA binding 
N=20 Normal specific for fully 
Controls galactosylated 
Gal 01,3 GaINAc 
1. IF with Jacalin/ 1. Same reactivity in 1. Different jacalin Hiki et al 1996 
IgAl and IgA2 mAb serum and mesangial sourcelspecificity? 
in renal tissue IgA to anti-IgA I and 2. Racial differences? 
2. Serum IgA I (D- FITC-jacalin 3. Assay used: D- 
galactose inhibition 2. T Binding in 33% galactose inhibition 
assay) in 58 IgAN of IgAN patients vs. assay limiting 
patients, 41 renal and normals (3.8%) and findings to IgA I 
52 healthy controls other GNs (9.8%) reactive to jacalin 
Sandwich ELISA TSialylation/4, No renal controls, Baharaki et al 1996 
lectin binding in 47 galactosylation desialylated IgA I 
patients and controls 
JAC, Gas-phase Undersialylation of Effect of Hiki et al 1996 
hydrazinolysis, IgAl hydrazinolysis on 
HPLC analysis 
1. Carbohydrate 1. THAA/CAA 1.4- Galactose Tomana et al 1997 
content analysis: binding of intact content in IgAN 
Gas-liquid IgA 1: 10 patients, 10 2. Based on 
chromatography controls; TBPA/HPA neuraminidase 
2. ELISA based binding of treated IgA I 
lectin binding desialylated IgA 1 3. Anti-IgAl Ab 
3. Lectin binding from 10 IgAN vs. 10 purification avoids 
both on intact and normal and 9 renal IgAl loss 
de-sialylated IgA controls 
Eluted glomerular TLectin binding to Indirect evidence of Allen et al 2001 
IgAl from W, HAA of eluted altered deposited 
nephrectomies, IgAl compared with IgAl glycosylation; 
Lectin binding I serum IgA 11 Only 3 samples I 
Table 2.3 A summary of the investigations of IgAl 0-linked glycans in IgAN using a 
variety of techniques such as lectin-binding, chromatography, and inhibition assays. 
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(MALDI) (Dell and Morris 2001). Such studies are coupled with gas chromatography 
and other biochemical methods such as trypsin and exoglycosidase digestion to 
inform us of the detailed stoichiometry of glycoproteins. 
2.6.6.1 MALDI-MS This is the most sensitive of the ionisation technologies. 71be 
sample is normally embedded in a LMW UV-absorbing matrix. A pulsed laser beam 
is then fired at the sample to effect ionisation. The matrix absorbs the laser energy and 
transfers the pulse to the sample in such a way that produces a singly charged 
molecular ion. This process does not produce very many fragments and it is therefore 
useful for screening molecular ions with high sensitivity (Dell and Morris 200 1). 
2.662 Studies of IgAl glycosylation using mass spectrometry Table 2.4 summarises, 
the findings of different studies using mass spectrometry for the analysis of the glycan 
structure of IgAl. Only one group of investigators has successfully employed this 
technique for the analysis of O-glycans. As their technique has become more accurate, 
they have shown consistently that a proportion of serum IgAl glycoforms from 
patients with IgAN show some degree of under galactosylation or under sialylation of 
the hinge peptide (Hiki et al 1998, Iwase et al 1998, Odani et al 2000, Hiki et al 
2001). One paper has shown evidence of increased presence of TF antigen with small 
amounts of Tn and sialyl Tn antigens in IgAN (lwase et al 2002). More importantly, 
Hiki et al in their paper published in 2001 also showed that the deposited IgAl eluted 
from biopsy specimens from the kidneys of patients with IgAN, showed reduced 
levels of galactose and sialic acid. One recent paper has also shown that cultured 13- 
cells from tonsils of patients with IgAN, when cultured, produce undersialylated and 
undergalactosylated IgAl (Horie et al 2003). In short, over the last 8 years, 
tremendous effort has been put into analysing the structure of the IgAl hinge region 
and its O-glycans and so far mass spectrometry has produced the best results. The 
spectra obtained however are not clear enough to give a definitive view of the 
structure, stoichiometry and the spatial relationship of the glycans with the protein 
backbone and with each other. At best this technique has offered comparisons of 
ratios of different glycoforms with each other and a definitive quantitative and 
qualitative comparison of the glycosylation of IgAl hinge structure from normal and 
diseased serum is still out of reach. 
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METHOD FINDINGS IN IGAN COMMENT REFERENCE 
MALDI ToF MS No clear peaks obtained Evidence for Iwase et al 1996 
Sequential de- from intact IgA I but multiple 
glycosylation multiple glycoforms glycoforms in 
were identified post de- normal IgA I 
sialylation 
JAC, MALDI Suggestive of defect in Only Hiki et al 1998 
N=13 IgAN Gal and/or GaINAc Galpl, 3GaINAc 
N= II other GN residues analysed due to 
N=8 normal poor spectra 
controls 
MALDI, endo- Determined further Study of normal Iwase et al 1998 
peptidase glycoforms of IgAl serum IgA I 
treatment HGP 
Electrospray Decreased GaINAc, Gal Pooled sera used Odani et al 2000 
Ionised liquid MS and NeuNAc IgAN n=4, renal 
controls n=10, 
normals n=5 
Eluted glomerular Decreased sialylation First direct Hiki et al 2001 
IgA I from 291 and galactosylation information about 
biopsy samples deposited IgA I 




IgA glycosidase Increased numbers of Iwase et al 2002 
treatment to TF antigens 
assess sugar side 
chain ratios 
MALDI on IgA I Increased percentage of IgAN n=7 Horie et al 2003 
from cultured asialo/agalacto-type of Chronic tonsillitis 
tonsillar B-cells IgAl in 57% of IgAN n=5 
patients (p<0.04) 
Table 2A A summary of IgAl O-glycan analyses using mass spectrometry and the results 
obtained in IgAN 'and normal serum. These data have suggested the presence of under- 
galactosylated and undersialylated species both in the serum and in mesangial deposits of 
patients with IgAN but have failed to produce spectra that yield detailed data on the 
glycoform structure. 
87 
2.6.6.3 Problems with MS in the analysis of IgAl Whilst mass spectrometry has been 
successful in the quantitative analysis of relative frequencies of N- and 0- glycoforms 
of glycopeptides, there have been a number of difficulties encountered in studying the 
glycosylation pattern of IgAl hinge peptide. This part of the IgAl molecule is a short 
sequence of amino acids with a high density of O-glycans. It would therefore make 
MALDI an attractive method for identifying the 0-glycan structure. Unfortunately, 
the glycopeptides obtained from digested IgAl in their native glycosylation state 
contain a wide array of glycoforms. This means the spectra obtained show wide, 
poorly differentiated peaks. 71is has been the main stumbling block for definitive 
analyses of IgAl glycosylation using this technique. Hiki et al (2001) have partially 
overcome this problem by enzymatically removing sialic acid residues from the 
molecule, as these sugars are bulky and notoriously difficult for analysing on MALDI 
mass spectrometers. This has allowed some insight into the number of configuration 
of the core sugars of the hinge peptide but not that of the intact molecule. 
2.6.6.4 Summary of MS findings At present the consensus opinion on the role of 
glycosylation in the pathogenesis of IgAN is that a fraction of the IgAl molecules in 
the blood of these patients is under glycosylated, exposing the underlying hinge 
region to immune-complex formation with naturally occurring antibodies. These 
immune-complexes may then interact with components within the renal mesangiurn 
where they are deposited and set off an inflammatory reaction. IgA circulating 
immune complexes have been found to contain under-galactosylated IgA I (Tomana et 
al 1997). A recent paper by Allen et al showed IgAl eluted from nephrectomy 
specimens of 3 IgAN patients had reduced jacalin binding and increased binding to 
lectins specific for GaINAc lending indirect support to the notion that deposited IgAl 
in the renal mesangium is under glycosylated (Allen et al 2001). Hiki Y et al 2001 
also analysed IgAl extracted from pooled renal biopsy samples and found mass 
spectroscopic evidence of under-galactosylation in deposited IgAl. The bulk of 
evidence lends partial support to the hypothesis that serum and deposited IgAl is 
under-glycosylated in IgAN although many of the findings have been contradictory or 
confounded by technical difficulties. 
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2.6.7 Summga: 
The first suggestion that IgA glycosylation may be abnormal and contribute to the 
pathogenesis of IgAN was made nearly 15 years ago (Andre et al 1990). Since then 
there has been much research interest and progress towards the identification the 
structure and role of these glycans in IgAN. Despite the attraction of the theory and 
some convincing experimental data, no definite role for the aberrant glycosylation of 
IgAl in the pathogenesis of IgAN has been found. This is predominantly due to the 
uncertainty regarding what normal glycosylation pattern in IgAl is as well as the 
technical difficulties in assessing protein glycosylation listed above. In the search for 
IgAl glycosylation abnormalities, the results of different studies, based on a whole 
host of techniques has produced widely varied results. These contradictory findings 
may on the one hand be a reflection of the racially and genetically diverse populations 
under study, or they simply reflect the absence of a unified approach to the elucidation 
of the structure of these glycans. There is much more to be learnt about the exact 
nature of the IgAl hinge region and its glycans of both normal and diseased serum 
and their interactions with the receptors and effector cells, which may have a pivotal 
role in the pathogenesis of IgAN. This highlights a clear need for a definitive 
technique to unravel the glycosylation pattern of the IgAl molecule in normal serum 
and in those with diseases such as IgAN. 
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Chapter 3: Methods and Materials 
3.1 Patient recruitment 
3.1.1 Subiects 
Patients and normal subjects were recruited according to the guidelines of the local 
Ethics Committee. No patients were recruited under 18 years and over 75 years of 
age. Other exclusions included the diagnosis of HIV and diabetes as well as patients 
of Afro-Caribbean extraction. The majority of patients were recruited from the King"s 
College Hospital renal and liver units and controls were from members of staff at the 
hospital and the laboratories at King's College and Guy's Hospitals. Dr Alice Smith 
of Leicester University donated a number of sera from patients with known primary 
IgAN, myeloma, myeloma and Henoch-Schdnlein Purpura (HSP), and normal 
controls. 
Patient groups: 
A. Patients with histological diagnosis of primary IgAN 
B. Patients with histological diagnosis of hepatic IgAN 
C. Patients with HSP secondary to IgA myeloma 
Control groups: 
D. Patients with histological diagnosis of Non-19A associated renal disease (e. g. 
membranous nephropathy, mesangioproliferative GN, minimal change nephropathy, 
and focal and segmental glomerulosclerosis (FSGS)) as controls for group A 
E. Subjects with hepatic cirrhosis with either biopsy proven or clinical absence of 
evidence of glomerular disease serving as controls for group B 
F. Patients with IgA myeloma, with no renal involvement as controls for group C 
G. Normal healthy controls for both groups A and B and C 
Patients were matched for age but not gender. Subjects under the care of the liver unit 
with no previous histological diagnosis were screened for evidence of renal 
involvement. Those with evidence of nephritis, i. e. presence of haernaturia, greater 
than 1+ proteinuria, and/or creatinine above the normal range were referred to a renal 
clinic and enrolled in the appropriate group according to diagnosis. All subjects were 
recruited with full informed consent. Normal controls and patients with hepatic 
cirrhosis with no evidence of renal disease were not biopsied. Normal renal function 
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was inferred from the presence of a normal serum creatinine, blood pressure, and 
urinalysis. 
3.1.2 Samples 
Urine and blood samples were obtained to identify potential patients for recruitment 
for the study as well as samples for the investigations. Venous blood was obtained 
from all subjects for laboratory tests of renal function and immunological assessment, 
namely serum creatinine, urea, and immunoglobulin levels. Blood samples taken for 
experimental purposes were collected in heparinised tubes. Peripheral blood 
mononuclear cell and monocyte preparations were separated from blood by density 
gradient centrifugation as described below. Serum was separated by centrifuging a 
clotted sample at 2383Xg for 10 minutes. The serum was then frozen immediately in 
Iml aliquots at minus 20"C for future analysis. Urine samples were examined by 
dipstik urinalysis. Renal biopsy samples were used to classify subjects according to 
histological diagnoses. 
3.2 Serum Separation 
25ml of venous blood were collected into heparinised tubes and placed on ice to 
maintain at 4*C. 'Me samples were centrifuged at 94 1 Xg for 10 minutes at 4*C in a 
refrigerated RT-6000 centrifuge. The plasma was removed and a pinch of protamine 
sulphate (Sigma P2162) and 2 drops of thrombin (Sigma, T9549) were added. This 
was then left to clot for 2 hours after which the tubes were spun at 2383Xg and the 
supernatant serum was frozen in Iml aliquots at -200C. 
3.3 PBMC Culture 
3.3.1 Matcrials-and Solutions 
Lymphoprep Solution (Robbins Scientific Catalogue No. 221397) 
50 ml Leucosep tubes (Greiner No 227290) 
96 Microwell flat bottom culture plates (Nagle Nunc Int., Rochester, USA 160377) 
RPMI plus glutarnine culture medium 1640 (Gibco BRL, Paisely, UK) 
RPMI+ 
Foetal Calf Serum (Sigma, Poole, Dorset, UK, F 3371) 
Pokeweed mitogen (PWM) (Sigma L9379) 
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Trypan Blue (Sigma T6146) 
Hepes Buffer I molar (Sigma H0887) 
Sodium pyruvate solution IOOmM (Sigma S8636) 
L-Glutamine/Penicillin/Streptomycin 200mM (Sigma G6784) 
3.3.2 Procedure 
The cell preparation was performed under sterile conditions in a good primary cell 
culture laboratory. All the work was carried out at 4"C on ice or in the refrigerated 
RT-6000 centrifuge. After removing the serum, cells from the collected whole blood 
were re-suspended in RPMl up to their original volume and mixed gently. PBMCs 
were then separated by density-gradient centrifugation which isolates cells based on 
their size and density (Graziani-Bowering GM et al 1997). A Leucosep tube was filled 
with l6mls of Lymphoprep solution and spun at 280Xg for I minute until the fluid 
settled below the Leucosep disc. 15mls of the reconstituted cells in RPMl were 
layered onto each Leucosep tube and centrifuged at 94 1 Xg for 20 minutes at 4"C with 
brakes off. The PBMC layer was aspirated and washed twice with 25 ml of RPMI and 
then centrifuged at 280Xg for 10 minutes each time with brakes on. The pellet of cells 
was then re-suspended in I ml of RPMI' and counted in a Neubar haemocytometer by 
taking 20gl of the cell preparation and adding 180W of Tryphan Blue to make a 1: 10 
dilution. 
The cells were then suspended at I million per ml in RPMI+ in 96-well flat-bottom 
plates to be cultured for 7 days. To prepare the RPMI+ solution, 65ml of Gibco RPMI 
with glutarnine was removed from a 500ml bottle containing the solution. 50MI (10%) 
of thawed Sigma F-3371 Foetal Calf Serum was then added to RPML A further 5ml 
(1%) of Hepes buffer, Pyruvate and defrosted mixture of 
Penicillin/Streptomycin/Glutamine solutions each was added to the RPMIIFCS 
mixture. This was mixed well and filtered. The wells were filled with 100 microlitres 
of RPMI+ or PWM/ RPMI+ and 100 microlitres of cells were added to each to make 
up the appropriate dilution per well, i. e. 106 cells per millilitre or 105 cells per well. 
Blank cells were used as negative controls in two central columns. Stimulated cultures 
had PWM in RPMI+ at 0.125gg/ml concentration. The supernatant was removed and 
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stored at -20 degrees Celsius for later analysis after seven-day incubation at 37" C 
and with 5% C02- 
3.4 Leukocyte CD89 Expression by flow cytometry: 
3.4.1 Materials and solutions 
Antibodies (Ab): 
-Fc block or anti-CD16/32 Ab (Pharmingen Cat. No. 01241A) for preventing non- 
specific binding 
-a-CD89 Ab Phycoerythrin (PE) conjugated (Becton Dickinson, Oxford, UK Cat No. 
33535X) for binding to Fccc receptor on leucocytes 
-a-CD14 Ab (FrrC-conjugated) (Dako, Ely, UK Cat No. F084401) for identifying 
monocyte population 
-FITC-conjugated IgGlic (Dako X092701) an irrelevant mouse antibody used as a 
negative control 
-(x-CD45 Ab RPE-conjugated (Dako R708701) as positive control as universally 
present on all leucocytes 
Solutions: 
-Phosphate buffer albumin prepared from 500ml phosphate buffered saline (PBS) (5 
Phosphate Buffered Saline (Sigma P5368) tablets added to 500 mls de-ionised water) 
to which 0.5g Bovine Serum Albumin (Sigma F3371) plus 0.25 g Sodium Azide 
(Sigma S2002) were added. 
-FACS&LYSE (Becton Dickinson Cat. No. 349202) solution: 20mls of a 1: 10 
dilution in distilled water. 
Cell line: 
U937 immortalised monocyte cell line donated by Dr Alice Allen of Leicester 
University. The original cells had been obtained from ATCC (CRL 1593). 
3.4.2 Methods 
5 ml of whole venous blood was collected into an EDTA vacutainer and maintained at 
4"C. A 50: 50 solution of PBA (0.5 ml) and whole blood (0.5 ml) was prepared and 
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mixed well. 5gl of Fc block (cc CD16/32 Pharmingen Cat. No. 01241A) was added to 
the tube to make stock solution. This was to avoid non-specific binding by saturating 
all non-specific binding sites. 
Flow (Falcon) tubes were labeled prior to addition of 100[11 of the stock solution as 
follows: Fc block only, a-CD89, a-CD14, mouse IgG I r, and a-CD45. The contents 
of each tube were stained with their respective antibodies at 5gl per tube. These were 
agitated and incubated at 4 degrees Celsius for 20 minutes. 2mls of FACS & LYSE 
solution was added to each tube and left at room temperature for 10 minutes to lyse 
the red blood cells. The tubes were then centrifuged at 941Xg for 5 minutes and the 
supernatant was discarded. The cells were washed once more in PBA and finally re- 
suspend in Iml of PBA. 
U937 cells were used as positive controls. They were cultured in Cellstar 75cm2 tissue 
culture flasks with membrane filter packs and incubated in a fully humidified air 
atmosphere containing 5% C02 at 370C, maintained in standard culture medium. 107 
U937 cells were used for each experiment after a minimum of three passages. They 
were treated as above with the exception of the FACS & LYSE step, where they were 
mixed with PBA solution instead. 100 pI of cells was placed into 2 separate tubes. 
1OW of Fc block was added to both tubes as well as 5gl of a CD89 antibody to one, 
using the second sample as an unstained control. 
All tubes were then read on the Coulter Epics Flow Cytometer on the following 
settings. The U937 readings were taken from their respective protocol, where the 
settings were gated on the cell line. Acquisition was set to read up to 20,000 events. 
For the leucocytes the device was set for counting a minimum of 2000 monocytes. 
The protocol was set to gate monocytes, neutrophils and lymphocytes. 71be measure of 
median luminescence was used for analyses. 
3.5 Serum IgAl Purification using Jacalin-Agarose Chromatography: 
3.5.1 Materials and solutions 
-Ammoniurn sulphate solution: 28g of ammonium sulphate (Sigma A4915) in 50mls 
of PBS (I tablet in 50ml Ultra High Quality Water (UHQW)) 
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-TRIS HCI 0.175M pH 7.5: 21.2g of TRIS base (Sigma T6791) was dissolved in 
Ilitre of UHQW and stirred with a magnetic stirrer. When dissolved pH was adjusted 
to 7.5 with HCI. Stored at 4 degrees. 
-0. IM melibiose (Sigma M5500): 4.1 g in 120ml of TRIS HCI 
-0.8M galactose (Sigma G0625) in TRIS HCI: 8.64g in 60ml of TRIS HCI 
-Jacalin Storage Solution: 2.383g of HEPES in I litre of UHQW pH 7.5 (IOmM); plus 
8.766g of NaCl (0.15M); 0.0147g CaCl (O. ImM); 3.61g galactose (20mM); 7.22g 
lactose (20mM); 0.8mg Na Azide (0.08%). 
-Jacalin Agarose (Vector Laboratories LI 153; Batch L0229 used throughout all 
experiments) 
-Snakeskin pleated dialysis tubing (Pierce Cat No 68 100) 
3.5.2 Method 
IgAl was purified based on a modified jacalin affinity chromatography method 
(Iwase H et al 1996). This technique is highly sensitive for recognising Galpl, 3- 
GaINAc and therefore appropriate for purifying IgAl from serum. Frozen serum 
containing the equivalent of 4mg of IgA was thawed at room temperature. Equal 
volumes (50: 50) of saturated ammonium sulphate solution and serum was pipetted 
into Starstedt tubes. The mixture was agitated for 20 minutes before centrifuging at 
2078OXg for 10 minutes in the microfuge. The supernatant containing low molecular 
weight proteins was discarded and the pellet containing high molecular weight 
proteins was reconstituted in TRIS HCI up to the original volume of serum. (Tbe 
LMW proteins contain molecules such as CI esterase inhibitors, which also contain 
O-linked glycans, and therefore would confound results of glycosylation results of the 
study). The HMW protein pellet was dissolved using the vortex and then agitated for 
30 minutes. 
12 j acalin agarose columns were prepared by pipetting I ml of well-mixed j acalin into 
a filter column (3ml spe filtration column). These were placed on a vacuum manifold 
on which a buffer exchange was performed by washing the column with at least 5 
column volumes of TRIS HCL Ile sample containing the IgA-TRIS solution was 
added to each column and allowed to drain to waste. This was then washed through 
with 10 column volumes of TRIS HCI and 5mls of 0.8M glucose in TRIS to release 
non-specifically bound protein, before eluting with 10mls of OAM melibiose[IRIS 
95 
HCL (Tbis volume for elution was selected based on an experiment where 0.5ml 
fractions of eluted IgAl was collected in separate tubes and the protein content 
assessed on a UV 280 spectrophotometer and found to be maximal in the first 6mls of 
flow through). 
The flow through containing the eluted IgAl was collected in separate Snakeskin 
pleated dialysis tubing molecular weight cut-off of 10,000 Dalton. The columns were 
regenerated after each use by washing with TRIS HCI and preserving in jacalin 
storage solution at 4* C. The solution containing the IgAl was dialysed at 4" C in 
distilled water for 2 days, changing the water three times a day. The sample was 
Iyophilised overnight and reconstituted in 100 microlitres of distilled water and stored 
at -20*C. 
An ELISA performed on purified IgAl confirmed the presence of IgAl and showed 
that this method produced a yield of 60%. 
3.6 Isolation of IgAl from breast milk 
Breast milk was expressed into sterile containers at various times during lactation 
period. It was stored at -20"C immediately and saved for future use. IgA separation 
was performed using a method described by Kerr et al 1997. After de-frosting, 8ml of 
milk was mixed with an equal volume of isotonic saline. The solution was centrifuged 
at 10,000g for I hour at 4"C. The clarified milk was separated from the pellet of cell 
debris and the surface layer of fat. The pH was then lowered with HC1 to 4 to 
precipitate out the casein. This was then centrifuged again at 30,000g for 30 minutes 
at 40C. The supernatant was removed and neutralised to pH 7.0 with 2M TRIS HC1 
solution after which it was re-centrifuged as before and the supernatant was used to 
purify IgA I by j acalin affinity chromatography as described above in section 3.5. 
3.7 Isolation of IgAl hinge glycopeptide 
3.7.1 Materials and solutions 
-8M Urea buffer: 0.35M TRIS; 4mM EDTA pH 8.6: 24g urea dissolved in 25ml water 
on heater stirrer plus 2.2g TRIS and 0.075g di-sodium EDTA. pH was adjusted with 
HCI and made up to 50ml when cooled. Stored at 4'C. 
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-DTr/urea solution: 2 mg of dithiothreitol (Sigma D5545) per MI. of urea solution 
-2M formic Acid: 250gl of formic acid (Sigma F0507) in 3 ml of UHQW 
-0.5M AMBIC: 0.8g NE4HC03 in 20ml UHQW 
-Methanol 'AnalaR' 
-5% Acetic Acid (glacial) 'AnalaR' 
-50150 solution of methanol and 5% acetic acid 
-Trypsin (Sigma T-1426) 
-Strata C18 columns (6ml) 
3.7.2 Reduction/alkylation 
The reduction alkylation steps were based on a modification of the method by Iwase 
H et al 1996. Purified IgAl was subjected sequentially to disulphide-reduction by 
dithiothreitol, alkylation with 4-vinylpyridine and trypsin digestion. Purified IgAl 
was dissolved in Iml of ultra high quality water (UHQW). A 30gl aliquot was 
removed and frozen at -20"C for future measurement of ratio of polymeric versus 
monomeric IgAl by size exclusion chromatography. A further IOORI was saved for 
IgAl ELISA. 50ml of 8M urea/0.35M TRIS/4mM EDTA buffer pH 8.6 was made 
and 500gI of it was added per I mg of IgA I. The protein was reduced by adding 5.4gl 
of DTr/lJrea solution per I mg of IgAl in glass containers and incubated at 37"C for 
4 hours. After cooling to room temperature, 6.4gl of 4-vinyl pyridine was added to 
each sample for recarboxymethylation and incubated for 90 minutes at room 
temperature. The reaction was stopped with 200gI of 2M formic acid per sample. The 
reduced and pyridylethylated IgAl was dialysed against UHQW in a lOkDa 
Snakeskin dialysis membrane for 72 hours at 4*C and Iyophilised in preparation for 
trypsin digestion. 
3.7.3 jUsin digestion 
This was carried out by dissolving samples in 60OW of 0.5M ammonium bicarbonate 
to which 40gg of trypsin and 0.05% Na Azide were added (i. e. 100: 1 IgA to trypsin 
ratio). After an overnight incubation at 37"C a further 20gg (50: 1) of trypsin was 
added. The tryptic digest was then Iyophilised to remove the AMBIC. 
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3.7.4 Hinge Glycopgptide isolation 
The Iyophilised tryptic digest samples were dissolved in 2ml 0.175M TRIS buffer 
pH7.5. The hinge glycopeptide was eluted with 10ml O. IM Melibiose in TRIS HCI on 
a jacalin column. The samples were desalted on 6ml Strata C18 columns 
(Phenomenex, Ca USA), which had been primed first with 6ml methanol and then 
with 12ml 5% acetic acid. After applying the samples to the columns and allowing the 
effluent to run to waste, the columns were washed with at least 3 column volumes of 
5% acetic acid on a vacuum manifold. The desalted HGP was eluted into glass 
containers in 6ml of 50: 50 methanol/5 %acetic acid solution and Iyophilised. 
This entire process produced a pool of 33mer hinge glycopeptides with an unusual 
trypsin cleavage on the C-terminal side of serine 240 which has been attributed to the 
presence, in the reduced and alkylated. protein, of two adjacent pyridylethylated 
cysteines (residues 241 and 242) with the amino acid sequence of the isolated tryptic 
fragment being (208)HYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPS(240) (residue 
numbers are those of intact IgA I). 
3.7.5 Purification of HGP by IpHPLC 
The presence of purified IgA HGP was confirmed by rpHPLC. The glycopeptides 
containing O-linked glycans were separated from all the remaining peptides by the 
same JAC method as before. The run-off from the column containing the 
miscellaneous peptides was discarded and the eluted O-linked HGP was collected as 
shown in flgure 3.1. 
The purified HGP was reconstituted in 200gl of UHQW and applied to a PLRP-S300 
rpHPLC column (l50x4.6mmx8jtm). Elution was performed using a linear gradient 
for 25 minutes from 8-48% acetonitrile in 0.1% trifluoroacetic acid with a flow rate of 
Iml/min. Detection was made by monitoring the UV absorption at 214 nanometers. 
Under these chromatographic conditions, the HGP peak was observed at 
approximately 9 minutes (figure 3.1). The material eluted at peak position was 
















0 5.60 10.60 15.60 20.60 min 
PLRP-S300 (Olim) 150x4.6 mm 1 milmin 4-60Y. AcN in 0.1% TFA over 20 min 
Figure 3.1 Reverse phase HPLC trace of eluted IgAl hinge glycopeptide (HGP) and 
tryptic digest in run-off. Green trace is the discarded flow through containing a mixture 
of N-peptides obtained from the tryptic digest of IgAl. The red trace contains the peak 
observed at 9 minutes, representing the 0-glycosylated IgA I HGP, which was collected 
for further processing. 
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3.8 Hinge glycopeptide de-glycosylation 
3.8.1 Materials and solutions 
-Neuraminidase (Sigma N2133) in 5mM citrate/0. I% w/v sodium azide 
-0 1-3 galactosidase (New England Biolabs P0726S) 
-a-N-acetyl galactosaminidase (NEB Cat. No. P0734S) in 5mm phosphate buffer pH 
7.5 and 0.1% sodium azide 
3.8.2 De-sialylation step 
Intact HGP was dissolved at pH 4.5 in 5mM citrate/0.1% w/v sodium azide + 
neuraminidase I unit to cleave any 2,3,2,6, or 2,8 linkages and incubated for 24hours 
at 370C. An aliquot was removed and stored at -20'C until required, and then desalted 
using a C18 ZiPtiP @ (Millipore) prior to MALDI analysis. 
3.8.3 De-galactosylation 
An aliquot from the above de-sialylated sample was removed and added to 10 units of 
01-3 galactosidase (New England Biolabs) and incubated at 37*C for 24 hours. A 
further aliquot was removed and stored and treated as above prior to MALDI analysis. 
3.8.4 De-N-acetyl gal actosamylation 
After de-galactosylation the sample was mixed in 5rnM phosphate buffer pH 7.5, 
0.1% sodium azide and 40 (NEB) units of a-N-acetyl galactosaminidase (NEB). This 
enzyme catalyses the hydrolysis of terminal cc-GaINAc linkages in oligosaccharides. 
The solution was incubated again as above and analysed by mass spectrometry. 
3.9 Matrix assisted laser desorption and ionisation time of flight mass 
spectrometric (MALDI-ToF-MS) analysis of IgAl HGP 
3.9.1 Materials and solutions 
2mg/ml THAP matrix in acetonitrile and ammonium acetate solution: prepared by 
dissolving 2mg of 2,4,6-3 hydroxyacetophenon hydrate (Sigma T6460-2) in a solution 
of 250 Id acetonitrile and 7501d of 20mM ammonium acetate. 
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3.9.2 MALDI analyses 
Lyophilised intact HGP samples were dissolved in 20gl of UHQW and a glycopeptide 
pool at a total concentration of 50-100pmol/gl (0.5[tl) was applied to the MALDI 
target plates. Whilst still in liquid form, 0.5gl matrix was added and the mixture 
instantly vacuum dried in less than one minute. The first samples were analysed by 
matrix assisted linear desorption time of flight mass spectrometry on the Voyager DE- 
mass spectrometer (PerSeptive Biosystems) and later on a Kratos Axima CFR mass 
spectrometer (Kratos Analytical, Ltd, Manchester UK) operating in positive linear 
mode. Accelerated and grid voltage of 25, OOOV and 94% were used respectively. 200 
shots were applied per analysed sample. The calibration of the mass/charge ratio was 
performed using bovine insulin (5737). The precise composition of the 0-glycans in 
the hinge region of IgAl was analysed by comparing the obtained peaks with a table 
of calculated masses of the hinge region peptide plus all possible combinations of 0- 
glycans to identify the constituents of each peak. The percentage peak area per 
glycoform, as a percentage of the whole spectrum peak area was used to compare the 
preponderance of one glycoform against the others within and between each group. 
Furthermore, the de-glycosylated samples were used for further verification of the 
HGP structure. 
3.9.3 Java programme for handling and analysis of mass swStra 
The data were handled in two different ways. Initially manual manipulation of the 
relative abundance of the glycoforms was attempted. This was a laborious task and 
prone to inaccuracies and so a Java programme was specifically devised by Mr 
Howard Smith of Leicester University for automating the handling of the spectral 
analyses. This programme automatically produces a list of the identified individual 
glycoforms from the m/z values fed into it. It also highlights m/z values that remain 
unassigned and matches them to a peak which may be a sodiated or potassiated form 
of a potential glycoform. Any further unidentifiable and unassigned peaks are then 
marked as U. For example the m/z of 4385 was one such peak that was encountered 
repeatedly in the spectra but the programme was unable to match it to any of the 
glycans listed in Table 4.1 (presented in chapter 4), or to any other unusual 
oligosaccharide side chain permutations. The programme calculates the peak area for 
each individual glycoform as a percentage of the total area for each spectrum 
101 
produced. A mean percentage of peak area was then calculated for the patients and 
controls in each group. The programme also facilitates the ranking of the species in 
terms of their relative abundance. Finally, a value for the percentage sialylation and 
galactosylation of the GaINAc residues for each species is calculated. 
3.10 Serum and supernatant Immunoglobulin detection 
3.10.1 Materials and Solutions 
Antibodies 
-Rabbit anti-human IgA Ab (Dako A0262) 
-Rabbit anti-human IgG Ab (Dako A0423) 
-Rabbit anti-human IgM Ab (Dako A425) 
-Mouse anti-human IgA monoclonal Ab (Oxoid M26012) 
-Mouse anti-human IgA I monoclonal Ab (Sigma 17262) 
-Mouse anti-human IgA2 monoclonal Ab (Becton Dickinson 345110) 
-Mouse anti-human IgG monoclonal Ab (Sigma 16260) 
-Mouse anti-human IgM monoclonal Ab (Sigma 16385) 
-Rabbit anti-mouse IgG alkaline phosphatase conjugate (Sigma A1902) 
Solutions 
-Tween 20 (Sigma P1379) 
-WHO (World Health Organisation) standard reference serum 
-p-nitrophenol phosphate substrate (1 mg/ml) (Sigma N 189 1) 
-Diethanolamine buffer pH 9.8 (Sigma D8885) 
-3M Sodium hydroxide 
3.10.2 Detection of total serum IgA and its sub-classes 
A sandwich ELISA technique was used to measure total IgA, IgAl and IgA2 
concentrations. Microtitre plates were coated with I 00ul of a 1: 1000 dilution of rabbit 
anti-human IgA in PBS azide by incubation at 37 0C for 2 h. The plates were washed 
three times with PBS/Tween 20 solution and subsequent non-specific binding was 
blocked by incubation at 37 *C for 2h with 200ul of PBS containing 0.5% bovine 
serum albumin (BSA) and 0.05% Tween20 MO). 
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Doubling dilutions of serum samples were made from 1: 4000 to 1: 128000 for IgA, 1: 
1000 to 1: 16000 for IgAl and IgA2. Reference WHO serum with known 
concentration (2.4mg/ml) of IgA immunoglobulin was used as standard sera. Standard 
curves were constructed from 10 serial dilutions, in duplicate, beginning at 1: 2000 
and later adjusted to mg/ml. The plates were washed three times with PBSMO and 
serum IgA bound during overnight incubation at 4'C was then detected by incubation 
at 2h at 37* C with 100ul of mouse monoclonal anti-IgA (diluted 1: 1000), IgAl 
(1: 500), or IgA2 (1: 500). The plates were washed thrice, after which 100ul of rabbit 
anti-mouse IgG alkaline phosphatase conjugate 1: 1000 was added and plates 
incubated for Ih at 37' C. Phosphatase activity was assessed at room temperature with 
100ul p-nitrophenol phosphate substrate (1mg/ml) dissolved in diethanolamine buffer 
(pH 9.8). The reaction were allowed to proceed unit sufficient yellow colour had 
developed (10 -15 min) and were then stopped by the addition of 50ul of 3M sodium 
hydroxide prior to reading of the plates in a Dynatech automated ELISA reader at 
405nm. 
The results were expressed as IgA, IgAl or JgA2 mg/ml calculated from the standard 
curve obtained from the WHO reference serum expressing IgA antibody 
concentration as 2.4mg/ml. The value for each dilution of serum falling in the 
standard curve was taken and the value for the sample calculated as the mean of the 
six separate dilutions. 
3.10.3 TgG detection in serum 
Microtitre plates were coated with 100ul of a 1: 520 dilution of rabbit anti-human IgG 
in PBS azide by incubation at 37 'C for 2 h. Serum sample dilutions were 1: 8000 - 
1: 256000. Reference WHO serum with known concentration (12mg/ml) of IgG 
immunoglobulin was used as standard sera. Standard curves were constructed from 10 
serial dilutions, in duplicate, beginning at 1: 8000 and later adjusted to mg/ml. The 
remainder of the procedure was as for IgA detection. 
3.10.4 IgA detection in supgrnatant 
Microtitre plates were coated with 100ul of a 1: 600 dilution of rabbit anti-human IgA 
(Dakopatts) in PBS azide by incubation at 37 0C for 2 h. Serum sample dilutions were 
1: 4-1: 128. Reference WHO serum with known concentration of IgA immunoglobulin 
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was used as standard sera. Standard curves were constructed from 10 serial dilutions, 
in duplicate, beginning at 1: 2000 and later adjusted to mg/ml. The remainder of the 
procedure was as for serum IgA detection. 
3.10.5 IjzG detection in supernatant 
Microtitre plates were coated with 100ul of a 1: 500 dilution of rabbit anti-human IgG 
in PBS azide by incubation at 37'C for 2 h. Serum sample dilutions were 1: 4-1: 128. 
Reference WHO serum with known concentration of IgG was utilised. 
Immunoglobulin detection was used as per standard sera. Standard curves were 
constructed from 10 serial dilutions, in duplicate, beginning at 1: 4000 and later 
adjusted to mg/ml. Rest of the procedure was per serum IgG detection. 
3.10.6 IgM detection in supgmatant 
Microtitre plates were coated with 100ul of a 1: 500 dilution of rabbit anti-human IgM 
in PBS azide by incubation at 37 *C for 2 h. Serum sample dilutions were 1: 4-1: 128. 
Reference WHO serum with known concentration of IgM was utilised. 
Immunoglobulin detection was used as per standard sera. Standard curves were 
constructed from 10 serial dilutions, in duplicate, beginning at 1: 4000 and later 
adjusted to mg/ml. Rest of the procedure was as described above. 
3.10.7 Statistical analyses 
The results are expressed as mean ± SEM per group. An unpaired Student's t-test was 
used to compare the means for each group. All data analyses were undertaken using 
the Prism statistics package. 
3.11 ELISA-type Lectin binding assays 
These experiments were performed by Dr Alice Smith in the renal laboratories at the 
University of Leicester on samples collected by Dr Smith from patients at Leicester 
General Hospital: 13 with primary IgAN, 7 normal controls, 4 patients with IgA 
myeloma, and 2 with HSP secondary to IgA myeloma. Serum samples were collected 
and stored as above. The samples were tested using a method described by Allen et al 
(1995) against a panel of the following lectins: Vivia Villosa (W), Peanut agglutinin 
(PNA), and Helix Aspersa (HAA). Briefly IgAl was immobilised either indirectly 
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onto immunoplates using anti-IgAl antibodies or directly by using purified IgAl from 
jacalin affinity chromatography. A biotinylated lectin which binds to specific IgAl 0- 
glycans was then applied followed by the application of a peroxidase-conjugated 
avidin which binds the biotin in the previous layer. The colour reaction development 
was through the action of peroxidase on a chromogenic substrate. The absorbances 
detected by an automated plate reader were proportional to the amount of lectin 
bound. The results were adjusted for the IgAl captured on the wells. 
3.12 Measurements of polymeric to monomeric serum IgA ratio by size exclusion 
chromatography 
Size exclusion chromatography was used to determine the different molecular forms 
of IgA in the sera of our patient and control groups. HPLC analyses were conducted 
using a Gilson HPLC equipped with 2 Gilson 306 pumps, one 302 pump, I model 118 
UV detector at 214 nm, a Gilson model 715 PC-based control and data collection 
system, and a Gilson model 234 autosampler (Anachem, Luton, UK). The column 
used was a Tosoh TSK3000 SW column (Anachem, Luton, UK) with column 
dimensions of 30 cm long x 7.8mm in diameter. The column was calibrated using 
two mixes of calibrants containing proteins with molecular weights ranging from 66- 
669 kDa as per figures 3.2 and 3.3.50pl of each sample was injected into the column 
at a flow rate of 0.5ml/min. The chromatograms were normalised using 
chromatograms, of identical standards. The peaks obtained were then assigned a 
molecular form of IgA depending on the molecular weight, the integration having 
been based on the MW fractions derived from the standard proteins (Figure 3.4). The 
ratio of the polymeric to monomeric IgA was calculated and compared between the 
groups. Results were shown as +/-SEM and analysed by Mann-Whitney U test. P 
value of <0.05 were taken as statistically significant differences. 
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Figure 3.2 The superimposed traces of proteins used to calibrate the size exclusion 
column for the analysis of the IgA polymers. Two mixes of calibrants were run. Mix A 
(blue trace) produced 3 peaks 1,2, and 3 corresponding to Apo ferritin (MW 443 kDa), 
Alcohol dehydrogenase (MW 150kDa), and Carbonic Anhydrase (MW 29kDa) 
respectively. Mix B (green trace) came up as a further 3 peaks, with peak 4 representing 
thyroglobulin (MW 669 kDa), peak 5 was P-amylase (MW 200kDa), and peak 6 which 
was bovine serum albumin with a molecular weight of 66kDa. 
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Figure 3.3 The calibration of the TSK 3000 size exclusion column with a good 
correlation between retention time (tR) and the molecular weight (MW) of the 


















Figure 3.4 Sample chromatograms showing a normalised peak with different 
molecular weight fractions coming off the size exclusion column at different times. 
The higher molecular weight species have the shorter retention times and vice versa. 
In this chromatogram the peaks have been normalised to the azide peak which was 
found in all the samples. Peak A contains species with a molecular weight of greater 
than 680 kDa, B has molecules with a molecular weight of between 450-680 kDa, C 




Chapter 4: IgAl hinge glycopeptide 0-glycosylation 
4.1 Current knowledge of IgAl 0-glycosylation 
Despite the increasing interest in the role of IgAl 0-glycosylation in IgAN, there is 
relatively little information on the precise structure and stoichiometry of the molecule. 
As described in chapter 2, this limited knowledge has either been inferred indirectly 
from lectin binding studies or is based on HPLC sugar analyses of enzymatically 
manipulated IgAl. More recently mass spectrometry has been used to analyse the 
glycosylation of IgAl in IgAN (Odani et al 2000) but the results have not had the 
discriminatory power to allow meaningful comparisons between patients with IgAN 
and normal controls. This is in part due to the inherent technical obstacles to the 
precise analysis of a heavily glycosylated molecule as well as the occurrence of a 
multitude of glycoforms in the serum of each individual subject making statistical 
analyses of the results very complicated (See chapter 2.6.5). Furthermore, whilst there 
is increasing information available on the structure of normal IgAl, the exact nature 
of the glycans and their positions on the protein back bone have not been fully 
characterised in what is considered to be normal glycosylation, giving no basis for 
comparison between so called normal and aberrant patterns. In this chapter we present 
the spectra obtained from our patients and their controls using a modification of mass 
spectrometry techniques applied in the study of IgAl glycosylation. This chapter 
contains a descriptive presentation of our results outlining the evolution of the spectra, 
as our technique developed. A detailed statistical analysis of the different glycoforms, 
we found in the different groups will follow in chapter 5. 
4.2 Identification of IgAl by mass spectrometry 
The entire tryptic digest of IgAl was analysed by mass spectrometry using bovine 
serum albumin (BSA) as its control. The spectra obtained were of poor quality and a 
clear peak was not seen initially. A peptide mass fingerprinting tool (MS-Fit) from the 
University of California at San Francisco that produces a best fit list from matching 
mass spectrometry data to a protein sequence in an existing database was used. This 
database can suggest the identity of the user's protein. When used on the tryptic digest 
of IgA I, it matched the findings with a number of proteins including human Ig alpha- 
I heavy chain constant region. It also correctly identified the BSA. 
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43 Initial identification of IgA hinge glycopeptide spectra 
Mass spectra for the hinge glycopeptide were obtained from samples purified as 
described in chapter 3. The initial samples were analysed on the PE Biosystems 
Voyager System. These spectra which fell consistently within the expected wide 
4200-6500 mass/charge range were identifiable as the hinge glycopeptide previously 
obtained by other studies (1wase et al 1998). As with data from other studies in the 
literature, the baseline in many of the spectra was elevated and noisy (Figure 4.1). 
in order to verify that this was indeed the hinge glycopeptide, the masses from the 
different peaks in any given spectrum were subtracted from each other and a pattern 
emerged where the differences in mass between peaks corresponded to the difference 
in the mass of a single oligosaccharide. For example in the spectrum in figure 4.2, the 
difference in mass between the peaks assigned 6017 and 5814 is 203 which 
corresponds to a mass difference of one GaINAc residue. Mass differences of 291 and 
162 represent the presence or absence of a single sialic acid and galactose residue 
respectively. Furthermore the masses obtained were within 0.5-1% of the calculated 
glycopeptide mass. 
Further experiments using de-glycosylating enzymes definitively confirmed that the 
spectra produced were those of the various glycoforms of the IgAl hinge region. 
Figures 43,4.4, and 4.5 present the progressive loss of glycans from a single sample, 
which has undergone sequential de-sialylation, de-galactosylation, and de-N- 
acetylgalactosamylation. These spectra show that the glycopeptide is progressively 
simplified through loss of its outer oligosaccharide coat until the denuded peptide 
backbone is left representing a single discrete peak at 3478 (calculated mass 3478), 
which corresponds to the previously calculated mass of the 33mer amino acid chain 
obtained by the reduction/pyridylation/tryptic digestion of IgAl (Hiki et al 1997). 
Table 4.1 shows the calculated values for each potential glycoform of IgA I HGP. 
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Figure 4.1 An example of the quality of mass spectra obtained by other 
investigators of IgAl hinge 0-glycosylation using MALDI MS. Figures 
reproduced courtesy of Dr Y Hiki. 
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Figure 4.2 Mass spectrum of the normal serum IgAl HGP. The different peaks 
represent the glycoforms with variable degrees of glycosylation. For example the 
observed peak at 6471 (calculated mass 6468) represents a glycoform containing 
5 GaINAc, 5 Gal, and 4 NeuNAc residues. The next observed peak (6307) is a 
glycoform comprising 5GalNAc, 4 Gal, and 4 NeuNAc residues with the m/z 
difference of 161 being due to the extra Gal on the former glycoform. 
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Figure 4.3 Mass spectrum of de-sialylated IgAl hinge glycopeptide. The 
spectrum has become simplified due to the removal of all the sialic acid 
residues, leaving a number of discrete peaks (with additional sodiated and 
potassiated and incompletely de-sialylated species). In this example the 
observed peaks 5302 (calculated m/z 5304), 5140 (calculated m/z 5140), 5018 
(calculated m/z 5021), 4978 (calculated m/z 4978), 4937 (calculated m/z 4937), 
4775 (calculated m/z 4775), and 4572 (calculated m/z 4573) correspond to the 
asialyl-species 550,540,620,530,440,430, and 330 respectively. 
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Figure 4.4 Mass spectra from the de-sialylated and de-galactosylated hinge 
glycopeptide with a number of distinct peaks reflecting the presence of the asialo-, 
agalacto- forms of the hinge glycopeptide. Peak 4087 (calculated m/z 4085) 
corresponds to the 300 glycoform while peaks 4290 (calculated m/z 4289) and 
4493 (calculated m/z 4492) correspond to the 400 and 500 glycoforms respectively. 
The small peak assigned to 4696 (calculated m/z 4695) corresponds to the 600 
species. The remaining observed peaks correspond to sodiated, postassiated, or 
incompletely de-glycosylated species. 
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Figure 4.5 Mass spectrum of the totally de-glycosylated normal IgAl hinge 
glycopeptide showing the single peak with a mass of 3478, which represents the 33 
amino acid chain present in the tryptic digest of the reduced/pyridylated IgAl to 
which the O-linked glycans are normally attached. The smaller peaks labelled are 
single, double, and treble sodiated species identified by the mass spectrometer of 







Glycoform (x+y+z) Calculated Mass Glycoform (x+y+z) 
3478 000 5304 550 
3681 100 5310 621 
3843 110 5349 640 
3882 200 5358 432 
4044 210 5398 522 
4085 300 5432 541 
4134 111 5466 333 
4208 220 5476 631 
4247 310 5507 650 
4289 400 5520 442 
4337 211 5561 532 
4410 320 5595 551 
4492 500 5600 622 
4499 221 5635 641 
4540 311 5649 433 
4551 410 5668 660 
4573 330 5723 542 
4613 420 5767 632 
4654 510 5798 651 
4695 600 5811 443 
4702 321 5852 533 
4743 411 5886 552 
4775 430 5926 642 
4790 222 5959 661 
4816 520 6014 543 
4859 610 6058 633 
4864 331 6089 652 
4905 421 6102 444 
4937 440 6177 553 
4945 511 6217 643 
4978 530 6250 662 
4993 322 6307 544 
5021 620 6380 653 
5066 431 6468 554 
5107 521 6508 644 
5140 540 6541 663 
5150 611 6671 654 
5155 332 6759 555 
5185 630 6832 664 
5196 422 6962 655 
15228 1 441 7123 665 
15270 1 531 17414 666 
Table 4.1 Table of theoretical IgAl hinge glycopeptide calculated masses and their 
corresponding glycoforms. x=number of N-Acetyl galactosamine (GaINAc) residues, 
y=galactose (Gal) residues and z=the number of N-acetyl neuraminic acid (NANA) residues 
in each glycoform, the difference between the different glycoforms being due to the varying 
number of oligosaccharides. The masses of NANA, GaINAc, and Gal are 291,203 and 162 
respectively. 
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4.4 Normal spectra 
Having established that the spectra obtained so far were those of the IgAl HGP 
glycoforms, the technique was applied to the IgAl purified from the sera of the 
different patient and control groups. This included work on myeloma, HSP/myeloma 
sera as well as paired sera and breast milk from two lactating normal controls. There 
were 24 normal serum samples processed for IgA I HGP analysis. A sample spectrum 
is shown in Figure 4-6. 
In order to determine signal reproducibility, 10 analyses were performed on a single 
spot of a HGP pool that had been dried together with matrix onto a MALDI target 
plate. Each of the profiles obtained was then normalised with respect to the largest 
peak present in the spectrum and the peak area of individual glycoforms calculated as 
a percentage variation around its mean value. The spectra and values for percentage 
peak area were identical in the 10 different readings. 
Similarly 10 analyses were performed on 10 different spots of a single sample of a 
HGP pool and the results similarly analysed (Figure 4.7). The spectra obtained from 
the pools, exhibited high reproducibility with a mean coefficient of variance (C of V) 
of 10% (range 5-15%) (based on the percentage peak area of each peak as a function 
of the total peak area of the spectrum). This enabled us to confidently use the data for 
the relative quantification of the different glycan species present in different patient 
and control groups. Furthermore, one serum sample which was split into 4 and 
processed in parallel as 4 individual samples from start to finish, were analysed 
individually to assess reproducibility throughout the preparation and analysis of the 
HGP. This also demonstrated good reproducibility between the spectra obtained 
(Figure 4.8). 'Me mean percentage peak areas and the co-efficient of variance were 
calculated for each sample and the major peaks were found to have a mean C of V of 
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Figure 4.6 A mass spectrum showing the peaks obtained from serum IgA I hinge 
glycopeptide from a normal subject. 
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Figure 4.7 Superimposed spectra from a single IgAl HGP sample spotted 10 times 
onto a MALDI target plate for analysis. The spectra demonstrate that the peaks are 
identical despite being split and analysed separately. The percentage peak area as a 
percentage of the total peak area for each spectrum was also comparable. 
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Figure 4.8 IgA I HGP superimposed spectra from single sample of normal serum 
processed 4 times separately. 
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4.5 Pathological spectra 
Serum samples from patients and their patient controls were also analysed using 
MALDI ToF-MS. There were 32 samples from patients with primary IgAN, II 
samples from patients with non-IgA glornerulonephritis, 7 with hepatic IgAN, 9 with 
cirrhosis of the liver with no evidence of glomerular disease, 2 samples from patients 
with HSP secondary to myeloma and 4 patients with myeloma and no associated renal 
glomerular lesions (Table 4.2). Whilst every effort was made to match the groups for 
level of renal function, there inevitably are differences between the groups. Examples 
of these spectra have been compared in figures 4.9-4.15. 
PIgAN HIgAN GN Cirrhosis 
Number 32 7 11 9 
Age 43±2.5 51±2 51±4.7 55.8±3 
Creatinine 127±12 197±45 98±8 148±33 
yGT 24±3 114±42 32±7 288±82 
% TBP 67 50 39 40 
Albumin 42±1 34±3 38±2 37±2 
Uprotein (g/d) 0.9±0.3 1.6±0.8 1.3±0.6 0.2±0.01 
Table 4.2 This table summarises the clinical parameters measured in the main patient groups. 
Results are the mean values for each group ± SEM. There were no statistically significant 
differences in the age of the patients in the different groups. Statistical analyses were done 
between PlgAN and HIgAN, PlgAN and GN, and HIgAN and cirrhosis. Blood pressure, 
urinary protein excretion and serum creatinine levels were also comparable between the 
groups with no statistically significant differences found. Patients with PlgAN had statistically 
higher albumin levels compared with both HIgAN and patients with GN (p values < 0.007 and 
0.03 respectively). yGT levels were not statistically different between the study and control 
groups. Abbreviations: PlgAN: patients with primary IgAN, GN: patients with renal 
glomerular disease other than IgAN, HIgAN: hepatic IgAN, % TBP. Percentage of patients 
with hypertension in each group, Uprotein, urinary protein excretion per day 
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Figure 4.9 Superimposed sample of IgAl HGP spectrum from a normal subject 
(green) and patient with primary IgAN (red). This example demonstrates the 
difference between more complex glycoforms with higher mass/charge (nVz) values 
and those with relatively reduced glycan content. A shift towards the lower m/z is 
evident in the patient with IgAN as compared to the normal individual in this 
example. 
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Figure 4.10 IgA I HGP spectra from a patient with primary IgAN (red) and hepatic 
IgAN (blue) superimposed to demonstrate differences in glycoform prevalence. In 
this example the patient with HIgAN appears to have a striking shift in the 
glycoforms with a lower mass/charge compared to the patient with primary IgAN. 
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Figure 4.11 Superimposed spectra from IgA I HGP sera from a patient with primary 
glomerulonephritis of non-IgA type (blue) versus one from a patient with primary 
IgAN (shown in red). The spectrum from the patient with PIgAN has a greater 
preponderance of the lower mass/charge glycoforms compared with its control. 
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Figure 4.12 Superimposed spectra of a patient with hepatic IgAN (blue trace) and 
another with cirrhosis (orange trace) showing no difference in spectra between the 
two patients. This suggests that the glycoforms present in these examples have very 
similar glycan content to each other. 
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Figure 4.13 Overlaid IgAl hinge glycopeptide spectra from two patients with 
Henoch-Schbnlein Purpura secondary to IgAl myeloma. The spectra have a 
different range of glycoforms as would be expected from two different monoclonal 
expansions of the B cells producing IgA I protein. 
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Figure 4.14 Superimposed IgAl HGP spectra from three patients with myeloma 
with no nephropathy. The 3 spectra are completely different in their composition, 
reflecting the distinct monoclonal production of myeloma proteins. 
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Figure 4.15 Spectra from IgA I hinge glycopeptide of normal serum (navy trace) 
compared with that of a patient with Henoch-Sch6nlein Purpura secondary to IgA I 
myeloma (green trace). The patient in this example with nephropathy demonstrates a 
shift towards the lower mass/charge and suggesting the presence of predominantly 
under glycosylated glycoforms as compared with the normal control. 
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4.6 Spectra obtained from mucosal IgAl HGP 
The IgAl from paired sera and breast milk of two healthy lactating women was 
compared by MALDI MS (Figure 4.16). We had expected to find striking differences 
in the glycosylation of the mucosal and systemic IgAl HGP. A cursory inspection of 
the spectra did not reveal any major differences in the glycoforms observed. We were 
unable to analyse the differences in the percentage peak areas representing the 
different glycoforms due to small sample numbers (n=2). 
Figure 4.16 Spectra comparing the traces obtained from paired samples of normal 
serum and breast milk IgA I HGP. The green trace represents the glycoforms of the 
IgA I HGP of the normal serum, overlaid with the spectrum from breast milk IgA I 
HGP in red. 
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4.7 Summary 
The figures presented in this chapter are a culmination of the technique used to purify 
and analyse the IgAl hinge peptide and its glycans by MALDI-ToF mass 
spectrometry. These spectra demonstrate the unrivalled quality achieved in this study. 
The spectra are baseline resolved and the peaks form discrete entities allowing 
accurate analyses of the carbohydrates in the HGP as well as comparisons between the 
different patient and control groups. Having presented the IgAl HGP spectra in this 
chapter, the statistical analysis of the peaks will be carried out in the following 
chapter. 
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Chapter 5: Analyses of the IgAl hinge glycopeptide spectra and their 
significance 
5.1. Introduction 
71be complexity and variety of the glycoforms obtained by MALDI mass spectrometry 
present a daunting array of results requiring meaningful statistical analyses. Previous 
studies of IgAl glycosylation by mass spectrometry have relied on comparing peak 
areas to a nominal peak, allowing at best a descriptive presentation of the findings. 
Also the poor baseline resolution of the spectra obtained by other groups has made 
comparisons between patient and control groups unreliable. Having obtained very 
high quality IgAl HGP spectra, it is now possible to tackle the statistical analysis of 
the results. 
Using the Java programme output, as described in chapter 3, it became possible to 
process the spectra in a variety of ways, namely differences in total glycan number for 
the three different oligosaccharides, found in the HGP, percentage glycosylation of the 
GaINAc residue, rank order of the different glycoforms and identification of 
differences in terms of glycoform. omissions or additions in each patient or control 
group. This data is presented in this chapter. 
5.2 Glycan content 
The incidence of different numbers of GaINAc, galactose, and sialic acid residues in 
the patient and control groups were analysed by calculating the mean value for the 
percentage peak area of all the spectra in each group for each glycoform. The mean 
percentage peak area for all species containing different numbers of oligosaccharides 
found in each patient and control group was calculated. The mean percentage peak 
area for each group was then compared using the Mann Whitney U test and 
Bonferroni correction. Table 5.1 summarises the findings of the glycan analyses 
performed by presenting the mean number of sugar residues per IgA molecule. 
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MEAN NANA MEAN GAL MEAN GALNAC 
NUMBER NUMBER NUMBER 
Normal 2.42 3.6 4.52 
PIgAN 1.94ý 3.4 4.43T 
GN 1.99 3.4 4.34T 
HIgAN 1.35T 3.7 4.3 1T 
Cirrhosis 1.55t 3.6 4.33 
Myeloma 2.1 4. Ot 4.32t 
HSP/myeloma 2.1 3.9 4.26 
Breast Milk 2.1 3.9 4.29 
Table 5.1 Mean number of sugar residues per patient and control groups. f denotes 
the presence of a statistically significant difference (p<0.05) with respect to normal 
when applying the Mann Whitney U test and the Bonferroni correction to the results. 
The numbers represent the average glycan residues per IgA molecule in the different 
groups. NANA=Sialic Acid, Gal=Galactose, GALNAC=N-acetYlgalactosamine 
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5.2.1 GaINAc 
The literature suggests that there are 9 potential sites for GaINAc residues via which 
they can attach to the polypeptide backbone of the IgAl HGP. Three of these are 
presumed to be fully occupied and the other 2 partially occupied (figure 2.5) (Mattu 
et al 1998). We identified a 6th GaINAc substitution present in all our patient and 
control groups (except for patients with HSP secondary to myeloma). Our findings 
suggest that this hexa-substitution is a universal phenomenon. 
Previous studies of IgA glycosylation in IgAN have found no difference in the 
GaINAc content of patients with primary IgAN and healthy controls. Our detailed 
comparisons between the prevalence of the number of GaINAc residues in each group 
have highlighted a number of differences. Figure 5.1 summarises these findings in a 
bar chart. Each patient and control group is represented by a bar measuring the mean 
percentage peak area of each glycan. The mean number of GaINAc residues found in 
each groups is shown in table 5.1. Whilst the mean GaINAc number for normal 
controls was 4.52, by comparison patients with PIgAN, other GNs, HIgAN, and 
myeloma had significant reduction in their mean GaINAc content. 
Figure 5.2 shows a scatter graph of the mean percentage peak area of the 3 GaINAc 
species in the different subjects. Species containing only 3 GaINAc residues constitute 
a small proportion of the glycoforms present in normal individuals (Figure 5.1). 'Me 
mean value for this group was 1.9% ± 2.3 (standard deviation of the mean). By 
comparison, patients with primary and hepatic IgAN had elevated means of 3.7% ± 
4.0 and 7.1% ± 6.5 respectively. This achieved statistical significance with p<0.04 for 
PlgAN and p<0.02 in H19AN using the MWU. The mean values for the myeloma 
group and the results from mucosal IgA (samples of breast milk from normal 
controls) were similar to normals. Even though the mean for patients with HSP 
secondary to myeloma was strikingly lower than any of the other groups, the small 
number of patients (n=2) does not allow any meaningful statistical comparisons to be 























Figure 5.1 Bar chart showing a comparison between the GaINAc numbers in the 
different patient groups. 
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Figure 5.2 Scatter graph showing the difference in percentage peak area of 
glycoforms with 3 GaINAc in the study groups. Both patients with primary 
and hepatic IgAN had a greater number of glycofon-ns with this species 
present. 
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Normal PlgAN GN HIgAN CirrhosisMyeloma HSPM BM 
4 GaINAc substitutions were more common than 3 GaINAc in all the groups and in 
breast milk with a mean value of 43.4% ±5.3 in normal controls. Like the 3 GaINAc 
species, there were statistically significant differences between patients with HIgAN 
(but not PIgAN) and myeloma as compared with the normal controls. The mean 
percentage peak area for HlgAN and myeloma were calculated as 52.3 ±9.9 and 63.2 
±20.2 with p values <0.0066 and <0.0065 respectively as compared with normal 
controls (figure 5-3). The two samples from patients with HSP secondary to myeloma 
were also found to have higher proportion of 4 GaINAc substitutions but again, 
because only two samples were processed, no valid statistical comparisons where 
possible. 
The 5 GaINAc substitutions were found to be different in patients with HIgAN, 
myeloma and HSP/myeloma compared with normal controls. The mean values for the 
percentage peak areas were lower than normal controls which is to be expected given 
that a greater proportion of the patients had 4 GaINAc substitutions (Figure 5.4). 
Finally glycoforms containing 6 GaINAc residues were found to comprise a mean of 
4 percent ±3.4 of the total peak area in normal controls whereas patients with PIgAN, 
other GN, and HIgAN had lesser values at 2.0 ±1.6 (p<0.01 1), 0.8 ±0.97 (p<0.0006), 
and 0.9 ±1.3 (p<0.0066) respectively (rigure 5.5). Patients with myeloma showed a 
trend towards lesser 6 GaINAc substitutions that did not achieve statistical 
significance and no 6 GaINAc containing glycoforms were identified in the 2 patients 
with HSP myeloma. In contrast to systemic IgAl, mucosal IgAl from breast milk had 
a lower proportion of IgAl glycoforms containing 6 GaINAc residues, the statistical 
significance of this does remain doubtful due to the small number of samples (n=2). 
Having compared the different patient and control groups, the Bonferroni statistical 
correction was applied to the obtained p values in order to modify the significance of 
the results by taking into account the multiple comparisons between the different 
subject groups. Following this manipulation there was no statistically significant 
difference between the mean percentage peak areas for 3 GaINAc residues. Only the 
following results remained significantly different. Both patients with myeloma and 
HigAN had p values of less than 0.033 when compared with normal controls for the 
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Figure 53 Scatter graph showing the difference in percentage peak area of 
glycoforms with 4 GaINAc in the study groups. Both patients with hepatic IgAN 
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Figure 5.4 Scatter graph showing the difference in percentage peak area of 
glycoforms with 5 GaINAc in the study groups. Both patients with hepatic 
IgAN and myeloma with no renal disease had a lower percentage of 
glycoforms with this species present. This is a reflection of the increased 





Figure 5.5 Scatter graph showing the difference in percentage peak area of 
glycoforms with 6 GaINAc in the study groups. Patients with primary and 
hepatic IgAN as well as those with non-IgA GN had lower percentage of 
these glycoforms. This is a reflection of the higher percentage of the 
glycoforms containing 3 and 4 GaINAc residues. 
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Normal PlgAN GN HIgAN Cirrhosis Myeloma HSPM BM 
percentage peak area for 6 GaINAc residues in patients with PIgAN, HIgAN, and 
other GN also remained significantly different from normal controls with p values of 
less than 0.05,0.033, and 0.003 respectively. It is interesting to note that the lowest 
number of GaINAc residues was found to occur in patients with non-IgA 
glomerulonephritis. A summary of these results is presented in Table 5.2. 
This is the first report of a diminished number of GaINAc substitutions of the IgAl 
HGP in patients with IgA nephropathies, myeloma, and other glomerulonephritides. 
Interestingly cirrhosis per se does not appear to be associated with changes in the 
number of GaINAc substitutions but renal diseases of different aetiology do. 
5.2.2 Galactose 
Previous reports using lectin binding and gas chromatographic studies have indicated 
the presence of reduced galactosylation in primary IgAN. There has been limited and 
conflicting evidence from mass spectrometry regarding the number of galactose 
residues present in the various glycoforms of the IgAl hinge glycopeptide in IgAN 
For a summary of these studies see Tables 23 and 2.4 in chapter 2. Our experiments 
did not highlight any significant change in the galactose content of the hinge 
glycopeptide of IgAl from our IgAN patients. Table 5.3 and Figure 5.6 summarise 
our findings which are discussed in detail below. 
Having examined the galactose content of the different groups by MALDI, we found 
that all the groups had peaks corresponding to at least one galactose residue being 
present and there were no glycoforms containing zero. galactose residues (figure 5.6). 
The mean galactose residue per IgAl molecule in normal controls was 3.6 Crable 
5.1). The mode for galactosylation was the presence of 4 galactose residues in all 
groups. We found no statistically significant difference between the patients and 
controls in the proportion of glycoforms with I or 2 galactose residues. However, we 
did find that a greater proportion of PIgAN patients showed evidence of under- 
galactosylation with an increase in the mean percentage peak area of species 
containing only 3 Gal and a proportional reduction in the number of 4 Gal residues 
both of which attained a slight statistical significance (flgures 5.7 and 5.8). The mean 
percentage peak area for 3 Gal and 4 Gal in normal controls was 31.0 ± 9.4 and 62.5 
±1 1.6 respectively. 
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GaINAc 3 4 5 6 Content 
Normal 1.9 43.4 49.8 4.1 
IgAN 3.7 44.7 48.5 2.0 
(p<0.04) (P<0.01 I)T 
GN 4.1 45.3 47.3 0.8 
(p<0.0006)t 
HIgAN 7.1 52.3 37 0.9 
(p<0.02) (p<0.0066)t (p<0.008)t (p<0.007)* 
Cirrhosis 2.8 44.1 50.4 2.7 
Myeloma 2.2 63.2 33.1 1.5 Specific 
(p<0.0065)t (p<0.02) 
Table 5.2 Summary of the significant results of the GaINAc composition of 
the IgA I HGP compared with normal controls. The values are the mean 
percentage peak area for each group with p values of less than 0.05 deemed 
significant by the Mann Whitney U test. t denotes statistical significance 
after applying the Bonferroni correction. 
IAI 
Gal 0 1 2 3 4 5 Gal content 
Normal 0 0.01 3.8 31.0 62.4 1.8 
PIgAN 0 0.6 6.4 37.8 53.3 0.8 
(p<0.0 13) (p<0.02) 
GN 0 0.5 6 33.9 55.6 1.5 
HIgAN 0 0.4 1.7 36.2 56.1 2.9 *--+ 
Cirrhosis 0 0.2 3.1 30.2 61.9 3.9 
(p<0.02) 
Myeloma 0007.2 82.3 9.8 
(p<0.003)T (p<0.01)t (p<0.01) 
Table 5.3 Summary of the significant results of the Galactose composition of 
the IgA I HGP. The values are the mean percentage peak area for number of 
galactose residues for each group. p values of less than 0.05 were deemed 
significant by the MWU test when compared with normal controls. Thet 
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Figure 5.6 Number of galactose residues in patient and control groups. There were no 
glycoforms containing no galactose residues in any of the groups. No differences were 
observed in those containing I galactose residues. 
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Figure 5.7 Graph showing the mean percentage peak area of glycoforms 
containing 3 Galactose residues in the different patient and control groups. 
Patients with PlgAN showed a statistically significant increase in the 
proportion of glycoforms containing 3 Gal substitution when compared with 
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Figure 5.8 Graph demonstrating the presence of a lower percentage of 4 Gal 
species in patients with PIgAN as compared with normal. The reverse is seen in 
patients with myeloma were the proportion of 4 Gal substitutions are increased. 
This is a reflection of the decreased percentage of the 3 Gal substitutions in this 
group. 
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In PlgAN they were 37.8 ±12.1 (p<0.013) for 3 Gal and 53.3 +/-19.1 (p<0.021) for 4 
Gal respectively. The reverse was true in patients with myeloma where the percentage 
of species containing 4 and 5 Gal was significantly increased whereas there were 
fewer species containing 3 Gal (figures 5.7,5.8, and 5.9). Patients with cirrhosis also 
had a slightly higher proportion of species containing 5 galactose residues (p<0.022) 
compared with normal controls suggesting some degree of over-galactosylation. The 
trend in IgAl obtained from breast milk is towards higher number of galactose 
substitutions. 
In summary, as far as the number of galactose residues found on the hinge peptide is 
concerned, only the patients with myeloma showed a consistent trend towards over 
galactosylation and the differences found in the results in PIgAN and cirrhosis were 
not significant with the application of the Bonfeffoni correction. 
When the data was analysed using the Java programme, the percentage 
galactosylation of each sample was calculated automatically. Ibis represents the total 
number of galactose residues per GaINAc in each individual sample. A mean value 
was then calculated for each group and compared with one another. We found that 
total galactosylation was not different between the groups except in patients with 
myeloma and HIgAN where there was a statistically significant increase in 
galactosylation with p values of less than 0.003 and 0.01 respectively. The p values 
after applying the Bonferroni correction remained significant at 0.015 and 0.05 
respectively. This data is summarised in figure 5.10. Our results therefore do not 
support the previous findings inferred from lectin binding and chromatographic 
studies where significant changes in the galactose content of patients with IgA 
nephropathy have been reported. 
5.2.3 Sialic Acid 
The most salient changes in glycosylation were found in the studies considering the 
abundance of sialic acid. Glycoforms, were found with between nought to 4 NeuNAc 
residues and the mode in the normal individuals appeared to be glycoforms, containing 
2 or 3 sialic acids (figure 5.11). The mean value calculated for normal controls was 











Figure 5.9 Scatter graph showing 5 Gal substitutions in the patient and control 
groups. Both patients with myeloma and cirrhosis with no renal disease had higher 
proportion of the 5 Gal species. 
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Figure 5.10 Percentage IgA I galactosylation of GaINAc residues showing 
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Figure 5.11 Number of sialic acid residues in the different study groups 
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without renal disease had significantly reduced sialic acid numbers at 1.94,1.35, and 
1.55 respectively (Table 5.1). 
In normal controls the 0 NeuNAc species comprise only 2.6% of the total peak area 
and by comparison they are significantly elevated only in patients with HIgAN (mean 
percentage peak area of 15.7 ±14.2, p<0.016) figure 5.12. However the proportion of 
glycoforms with I NeuNAc was significantly elevated in all patients with renal and 
liver disease irrespective of the presence or type of renal disease, the most significant 
rise being in patients with PIgAN followed by those with cirrhosis and HIgAN with p 
values of less than 0.0001,0.0002, and 0.0005 respectively. Patients with other GN 
showed a significant trend towards increased species with I NeuNAc (p<0.035), but 
this was less marked than the changes found in PIgAN. Figure 5.13 shows the 
differences between the groups. The patients with myeloma showed no significant 
differences with the normal controls in this respect. 
We found no apparent difference in the number of species with 2 NeuNAc residues 
but the percentage of species containing 3 or 4 NeuNAc was significantly reduced in 
patients with PIgAN, cirrhosis, HIgAN, and other GN (figures 5.14 and 5.15). When 
analysing the 3 NeuNAc residues the following p values were obtained: 0.0002, 
0.034,0.0003, and 0.0005 in PIgAN, other GN, HIgAN, and cirrhosis as compared 
with normal controls respectively. There was no significant change found in patients 
with myeloma. Likewise, in the analysis of the 4 NeuNAc residues the results were 
significant on a Mann-Whitney U test with p values of < 0.001,0.03,0.001, and 
0.0001 in the PIgAN, GN, HIgAN, and cirrhotic group respectively as compared with 
normal controls. After the application of the Bonferroni, the differences between the 
GN group and normal controls were no longer significant. 
When the data were analysed by the Java programme for percentage sialylation of the 
GaINAc residues, the changes found above were reflected in the analyses (Figure 
5.16). Patients with PIgAN and HIgAN were significantly under-sialylated as 
compared with normal controls (p<0.0042 and 0.001 respectively). This was also true 
of patients with cirrhosis (p<0.002) but not those with GN (p< 0.165). These changes 
were maintained when the results were subjected to the Bonferroni test. The 






Figure 5.12 Scatter graph comparing the percentage peak area of glycoforms 
containing zero sialic acid residues. Even though both patients with HIgAN and 
cirrhosis appeared to have elevated levels of 0 NeuNAc, only in patients with 
hepatic IgAN did this achieve statistical significance as compared with normal. 
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Figure 5.13 Scatter graph showing the differences between the groups in 
percentage peak area of glycoforms with I sialic acid residue. The levels 
were statistically elevated in patients with PIgAN, other GN, HIgAN, and 
cirrhosis. 
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Figure 5.14 Percentage of species with 3 sialic acid residues in the IgAl 
HGP. There were significant changes in patients with PIgAN, other non-IgA 
GN, HIgAN, and cirrhosis, where the mean percentage peak area was 
reduced compared with normal controls. No statistically significant 
difference was apparent in the patients with myeloma or in the composition 
of breast mi Ik IgA I- 
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Figure 5.15 Percentage of species with 4 sialic acid residues in the IgAl 
HGP. There were significant changes in patients with PIgAN, other non-IgA 
GN, HIgAN, and cirrhosis, where the mean percentage peak area was 
reduced compared with normal controls. No statistically significant 
difference was apparent in the patients with myeloma or in the composition 
of breast milk IgA I- 
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Figure 5.16 Percentage sialylation of the IgAl hinge glycopeptide in the 
patient and control groups. Patients with PIgAN, GN, HIgAN, and cirrhosis all 
showed evidence of under-sialylation. 
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NANA 0 1 2 3 4 NANA 
content 
Normal 2.6 13 34.7 36.6 12.3 
PIgAN 3.9 28.2 38.4 23.8 4.6 
(P<0.0001)t (p<0.0002)t (p<0.0001)t 
GN 4.6 23.2 37.4 25.6 6.5 
(p<0.03) (p<0.0345) (p<0.03) 
HIgAN 15.7 40.9 29.8 9.1 1.8 
(p<0.016) (p<0.0005)t (p<0.0003)t (P<0.001)t 
Cirrhosis 14.1 35.7 32.2 15.1 2.3 
(p<0.0002)t (p<0.0005)t (p<0.0001)t 
Myeloma 16.6 20.5 21.1 22.5 19.1 
Table 5.4 Summary of the significant results of the sialic acid composition of the IgAl 
HGP. The values are the mean percentage peak area for each group with p values of less 
than 0.05 deemed significant by the MWU test with respect to normal controls. The 
denotes statistical significance after applying the Bonferroni correction. 
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In summary, in our MALDI analyses undersialylation appears to be a prominent 
feature of the IgA I structure in patients with PIgAN, HIgAN, and cirrhosis. 
5.3 Glycan ranking in order of abundance 
The various glycoforms identified by mass spectrometry were tabulated in rank order 
as seen in tables 5.5 and 5.6. 
5.3.1 Rank order 
'Me ranking of the glycoforms shed further light on the composition of the various 
IgAl species in the different subject groups. In normal individuals the commonest 
glycoforms appear to be the more abundantly glycosylated species such as 443 and 
543. The least abundant or absent species were those with lower numbers of sialic 
acid residues. In the top ten glycoforms, although the ranking varied to a minor degree 
between patients with PlgAN and normal, similar changes were found in patients with 
non-IgA GNs- The ranking between the PIgAN group and its renal control were 
virtually identical in the major species. However the most significant changes were 
found in the least abundant species which will be discussed further below. 
There were obvious differences in terms of the ranking of species between the normal 
controls and patients with liver disease. Unlike in the normal individual, both HIgAN 
and cirrhosis patients had higher ranking glycoforms with only one, two or even no 
sialic acid residues. In patients with myeloma with and without renal disease, the 
striking finding was the simplification of the spectra with fewer glycoforms, being 
present. In the myeloma group the highest ranking glycoforms were those containing 
4 GaINAc and 4 Gal substitutions with varying degrees of sialylation. In contrast 
those with myeloma leading to HSP showed a pattern with a whole variety of 
glycoforms not too dissimilar to the normal. 
5.3.2 Additions 
In each of the patient groups we were able to identify a number of glycoforms that 
were specific to that group. These are shown in Table 5.7. The glycoforms, in order 
of abundance, that were specific to the PlgAN group and not the normal and renal 
(GN) control groups were: 420,630,320,611,321,400. These were only present in 
less than one percent of the total peak area for each group. 71be 331,411, and 511 
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Rank PIGAN GN HIGAN cN HSPM m BM 
441 541 443 4 4 
2 442 542 442 542 543 443 143 4,1:, - 
3 443 4 43 431 442 542 441 442 5 -4 11 
4 543 543 54 1 441 442 444 441 4,4, i 
5 532 532 54, ) 4 4,33 532 541 440 
6 541 432 432 543 444 1 441 
7 443 531 432 440 
8 431 431 531 431 533 ý3 5,1,, 3 
9 441 441 540 532 544 532 550 531 
10 531 531 440 _:, ýq 541 533 540 431 
433 - , ýj 4,1 '2 51) 540 433 - -- 6-5-2 - 332- 
12 433 430 440 431 551 553 433 
13 4,14 533 - 332 530 441 433 54 -1 1,1, 
14 F-) 44 544 543 430 531 -132 552 444 
15 521 332 530 551 620 431 551 
16 332 521 331 433 5,14 5ý1'ý 
17 421 333 550 332 531 552 
18 540 520 330 533 553 
19 422 540 4,44 540 
20 333 530 552 
21 530 
Table 5.5 Presentation of giycoforms in rank order which consist of greater than one percent 
of the mean total peak area for each group. The top ten glycoforms (separated with the 
horizontal red line) from normal controls have been highlighted in blue in the normal subjects 
as well as the other patient and control groups for ease of comparison between the groups. It 
is clear that the highest-ranking glycoforms in the normal subjects, with a few exceptions, 
also represent the most abundant forms in the other groups. 
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PIGAN GN HIGAN CN HSPM m BM 
522 421 444 544 332 550 332 632 
631 522 551 631 333 430 333 531 
430 422 433 421 632 332 532 540 
632 552 544 331 552 320 432 550 
322 430 333 632 621 321 531 553 
440 322 552 550 633 322 433 440 
551 440 322 521 551 330 642 422 
552 551 533 420 553 331 554 331 
511 331 511 333 422 333 511 521 
331 553 631 520 530 400 533 522 
621 632 630 422 522 411 431 320 
620 511 420 553 521 420 631 321 
411 633 521 630 540 421 632 322 
520 620 553 620 421 422 641 330 
633 411 641 621 631 510 530 333 
420 554 321 321 322 511 331 400 
630 631 421 641 520 520 320 411 
510 642 520 633 550 521 321 420 
320 652 620 510 642 522 322 421 
611 320 422 642 643 530 330 430 
553 321 522 650 554 554 400 510 
550 330 554 610 440 610 411 511 
321 400 510 522 430 611 420 520 
400 420 610 330 510 620 421 530 
330 510 320 320 652 621 422 554 
554 550 400 322 644 630 430 610 
610 610 411 400 320 631 510 611 
641 611 611 411 321 632 520 620 
642 621 621 511 330 633 521 621 
643 630 632 554 331 641 522 630 
644 641 633 611 400 642 610 633 
650 644 642 643 411 643 611 641 
652 650 643 644 420 644 620 642 
652 644 652 511 650 621 643 
650 610 652 630 644 
652 611 633 650 




Table 5.6 The glycoforms shown in red are presented in rank order representing those 
glycans identified with a mean percentage of total peak area of less than one percent. The 
glycoforms in green are those absent in each group and are not in rank order. 
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PIgAN PIgAN/GN HIgAN/Cirrhosis; Cirrhosis 
420 331 331 420 
630 411 330 630 




Table 5.7 List of glycoforms present specifically in the respective patient groups. 
160 
glycoforms were found only in patients with PIgAN, HIgAN, and cirrhosis and not in 
any of the other groups. In patients with HIgAN, only two glycoforms were found 
additionally which were not present in the normal controls and these were 331 and 
330. In addition to these two glycoforms, patients with cirrhosis also had the 
following species in their spectra: 420,630,321,641,650, and 6 10. 
IgAl HGP purified from breast milk appears to have very similar glycoforms present 
as compared with the systemic IgA in normal controls, with the addition of the two 
species 552 and 551. There were no additional glycoforms identified in patients with 
myeloma. 
5.3.3 Omissions 
In patients with PIgAN there were 5 main glycoforms absent from the spectra as 
compared with the normal. These were species 554,652,642,643, and 644, the last 3 
of which were also not found in patients with other GN. In those with HIgAN, a 
number of species were missing when compared with normal controls, namely 
glycoforms 621,632,633,643,644, and 652. The cirrhotics have also lost the latter 3 
glycoforms as well as 322 and 554. Patients with myeloma and HSP myeloma did not 
contain any 6 GaINAc species and only one species with 3 GaINAc in the latter 
group. There were many species absent from the relatively simple spectra of these 
patients which also holds true of the IgAl from breast milk. These glycoforms are 
shown in Table 5.8. 
5.4 Correlating glycosylation with lectin binding 
Much of the glycosylation work on IgAl has been done using lectin binding 
techniques as reviewed in chapter 2. In this study we have demonstrated very good 
correlation between the lectin binding studies on some of our samples which were 
subsequently analysed by mass spectrometry. Dr Alice Smith of Leicester University 
performed lectin binding studies on a number of samples. These same samples then 
underwent analysis by mass spectrometry in our laboratory. There were 13 patients 
with PIgAN, 7 normal controls, 4 myeloma patients, and 2 patients with HSP 
secondary to IgA myeloma. The assays were performed using the three different 
lectins Vicia villosa (VV), Helix aspersa (HAA), and Peanut agglutinin (PNA) as 
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PIgAN GN HIgAN Cirrhosis 
554 642 621 322 
652 643 632 554 
642 644 633 643 
643 643 644 
644 644 652 
652 
Table 5.8 List of glycoforms absent in the respective patient groups compared to 
those found in the normal controls. 
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described in the methods and materials chapter. In brief, the assays were performed on 
serum and not purified IgAl with the IgA being captured on anti-IgA-coated plates 
before applying the lectins. Duplicate plates were developed with anti-IgAl antibody 
to ensure the wells were saturated with IgAl and that the differences in lectin binding 
were not due to different amounts of IgAl on the plates. 
Table 5.9 and Figure 5.17 contain the results of these studies which show that 
patients with PIgAN had statistically increased (p<0.0004) binding to both HAA and 
VV with no difference in binding to PNA compared with normals. Patients with 
myeloma on the other hand showed reduced binding to the VV lectin (p<0.01) and 
increased binding to PNA (p<0.04) and no change in the binding pattern to HAA as 
compared with normal. Both HAA and VV are known to have the strongest affinity 
for GaINAc amongst lectins. Therefore the higher binding to IgAl from patients with 
PIgAN is a result of lower glycosylation. PNA has the strongest affinity for 
asialylated P-1,3 Gal linked to GaINAc and to a lesser extent to unsubstituted 
GaINAc. It is extremely inhibited by the presence of sialic acid and therefore binds 
weakly to native IgAl. The increased binding to myeloma IgA suggests 
undersialylation of the IgAl in these patients with no significant changes in patients 
with primary IgAN being observed, suggesting there are still sufficient number of 
sialic acid residues present in this group to inhibit the binding to PNA. 
We then went on to assess the correlation between binding to these lectins with 
percentage sialylation and galactosylation by the Spearman r test using 95% 
confidence intervals to assess statistical significance. Figure 5.18 shows the 
correlation between the lectin binding with VV, HAA, and PNA with galactosylation. 
The results showed significant correlation between the percentage galactosylation and 
the binding to all 3 lectins. Both HAA and VV showed a significant negative 
correlation with percentage galactosylation of the purified IgAl HGP with r values 
equal to -0.64 (p<0.0004) and -0.57 (p<0.002) respectively. This is consistent with 
the finding that the presence of galactose blocks the access of these lectins to the 
GaINAc residues and lowers their binding, hence the negative correlation. HA and 
VV also showed negative correlation with sialylation with r values of -0.47 (p<0.037) 
and -0.53 (p<0.016) respectively. This negative correlation is because sialic acid will 
similarly block access to the GaINAc, especially so because of its larger size and the 
163 
Subjects HA w PNA 
PIgAN 2.02 1.65 0.32 
PIgAN 1.75 1.41 0.25 
PIgAN 1.71 1.52 0.28 
PIgAN 2.48 2.23 0.24 
PIgAN 1.79 1.91 0.39 
PIgAN 1.; 5 1.59 0.44 
PIgAN 2.45 2.30 0.23 
PIgAN 1.95 1.57 0.22 
PIgAN 1.57 1.47 0.31 
PIgAN 1.73 1.42 0.14 
PIgAN 1.72 1.58 0.18 
PIgAN 2.12 1.76 0.13 
PIgAN 1.56 1.48 0.26 
Normal 1.17 1.16 0.26 
Normal 1.38 1.19 0.18 
Normal 1.38 1.20 0.18 
Normal 1.04 0.86 0.21 
Normal 1.29 1.23 0.27 
Normal 1.36, 1.18 0.25 
Normal 1.33 1.21 0.17 
Myeloma 1.53 0.99 0.46 
Myeloma 0.72 0.21 0.76 
Myeloma 0.84 0.69 0.22 
Myeloma 0.60 0.64 0.67 
HSPM 2.04 1.53 0.50 
HSPM 0.53 1.94_ 0.30 
Table 5.9 Results from the lectin binding studies, showing the degree of binding of IgA from 
serum to the lectins Helix aspersa, Vicia villosa, and Peanut agglutinin in patients with 
primary IgAN, normal controls, myeloma and HSP myeloma. The data shown are the 
absorbance values for the ELISA-based lectin binding studies. 
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Figure 5.17 Figures showing the differences in lectin binding between normal controls 
and patients with PIgAN, and myeloma. When analysed by the Mann Whitney U test, 
IgA from PIgAN shows significantly increased binding to HAA and VV and no 
difference in binding to PNA. Myeloma patients have increased binding to PNA and 
reduced binding to VV with no significant change in HAA binding. 
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Figure 5.18 Two graphs demonstrating the correlation between percentage 
galactosylation and sialylation with lectin binding. The top graph shows the negative 
correlation between VV and HA and number of galactose residues and a positive 
correlation with PNA. The lower graph shows that only VV and HAA binding correlate 
with the percentage sialylation and that there is no correlation with PNA. 
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strong negative charge that it carries. Therefore the more sialylated the hinge region, 
the more strongly will lectin binding will be inhibited. The results of the correlation 
between PNA binding and sialylation was not significant but there was a positive 
correlation with percentage galactosylation with an r value of 0.5 (p<0.005). PNA has 
the strongest affinity for the un-sialylated, galactosylated GaINAc residues with little 
binding to GaINAc alone. The positive correlation with percentage galactosylation 
therefore is in line with its preference for galactosylated glycans. It may be that the 
PNA is not showing significant correlation with degree of sialylation, because all the 
samples examined are heavily sialylated and it is therefore only detecting the 
galactosylation level with increasing binding capacity as the number of galactoses 
increase. 
5.5 Correlation between IgAl 0-glycosylation and clinical features 
In order to assess the role of IgAl 0-glycosylation in the pathogenesis and the 
progression of renal failure in patients with IgAN, we compared the degree of 
sialylation and galactosylation with the serum creatinine in the patient and controls 
enrolled in the study. We found no correlation between either the number of sialic 
acid or galactose substitution and the level of serum creatinine (Figure 5.19 and 
5.20). Although there are no satisfactory markers for degree of liver failure, we 
employed yGT levels in patients with liver disease as a marker for severity of 
cirrhosis. We found no correlations between the serum yGT levels and the percentage 
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Figure 5.19 This figure demonstrates that there is no 
correlation between the percentage galactosylation of the 
IgAl HGP and serum creatinine in patients with primary 
IgAN. 
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Figure 5.20 This figure shows the absence of correlation 
between degree of sialylation and the serum creatinine in 
patients with primary IgAN. 
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Figure 5.21 Graph showing the relationship between serum -yGT levels of patients 
with HIgAN and cirrhosis and the percentage galactosylation of the IgAl HGP. 
There was no statistically significant correlation between the two parameters on a 










Figure 5.22 Graph showing the relationship between serum yGT levels of patients 
with HlgAN and cirrhosis and the percentage sialylation of the IgAl HGP. There 
was no statistically significant correlation between the two parameters on a 
Spearman R test. 
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5.6 Summary 
We have identified novel glycosylation features in normal IgAl hinge glycopeptide. 
Our findings include hitherto unreported glycoforms, in particular the 6 th GaINAc 
substitution as well as other less common species which have previously escaped 
detection due to less sensitive techniques to those that we have employed. In total we 
found 41 different glycoforms of the IgAl hinge region in the normal population 
studied. The most abundant glycoforms appear to consist of species with a mean 
GaINAc, Gal, and sialic acids content of 4.5,3.6, and 2.4 respectively. Ilese results 
highlight the vast variety and micro-heterogeneity present both within the serum of 
each individual and in the collective sera of the group as a whole. When comparing 
the overall sialylation and galactosylation of the IgAl hinge peptide in normal serum 
with that extracted from breast milk (mucosal IgAl), we found no significant 
differences between the two. 
We found a number of significant changes in the glycosylation pattern of patients 
with primary IgAN. The spectra pointed towards global under-glycosylation in 
patients with PIgAN with a greater preponderance of species with lower GaINAc 
substitutions, minor reduction in galactosylation and significantly lower degrees of 
sialylation. These patients had a mean GaINAc number of 4.4 as their norm (which is 
slightly lower than found in normal IgAl) due to a slightly higher number of 
glycoforms containing 3 GaINAc. The mode for the number of galactose residues was 
like the normal also 3 or 4 but again with an increase in the 2 Gal species. We also 
found that the greatest difference between these patients and their controls were in the 
least abundant glycoforms present. The most common glycoforms were common to 
the normal and GN group but the order of abundance was different in both these 
patient groups as compared with normal controls. Unlike normal IgAl, the majority of 
species in the PIgAN group contained I or 2 sialic acids. Interestingly, these changes 
were not found to be exclusive to IgA nephropathy and patients with other types of 
GN were found to a lesser degree to be under-sialylated, but with no change in the 
pattern of galactosylation or number of GaINAc residues. 
Patients with hepatic IgAN were found to be deficient in GaINAc residues, greatly 
under-sialylated and have slightly increased galactosylation which was statistically 
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significant depending on the statistical test used. Likewise patients with cirrhosis and 
no glomerular disease were grossly under-sialylated but were no different to normal 
where number of GaINAc residues was concerned. They appeared to have slightly 
increased galactose levels compared with normals. 
We found no significant differences in the glycosylation of IgAl in patients with HSP 
secondary to myeloma but this was perhaps due to the very small number of samples 
available for analysis. The myeloma IgA I 0-glycosylation demonstrated a number of 
features which distinguished it from the normal. Firstly, there was a tendency towards 
increased 3 GaINAc residues and an absence of 6 GaINAc found. Secondly more 
species with high galactose content (4 and 5) were observed and in the calculation of 
the overall percentage galactosylation, this was found to be significantly increased. 
Finally we saw no consistent changes in sialylation in this group of patients. There 
was a wide scatter around the mean and the small numbers made any meaningful 
comparison with the other groups invalid. 
An important technical point reflected in our data is that our analyses using mass 
spectrometry on purified IgAl correlate well with results of lectin binding studies 
performed on serum. This suggests that our NIS findings on purified IgAl are 
representative of the whole array of glycoforms present in the serum and that no 
major glycoforms have been lost in the processing of the samples using jacalin 
affinity chromatography. 
5.7 Conclusions 
We have found great variety in the normal glycoforms, of the IgA I hinge glycopeptide 
using MALDI mass spectrometry. Our results confirm the previous findings of other 
groups that the O-glycosylation changes in PlgAN are real. We have not only found 
evidence of under-sialylation, but also slight reduction in galactosylation and changes 
in the GaINAc content of the HGP in primary IgAN. However, the finding of similar 
changes in patients with other GNs suggests that under-glycosylation is not specific to 
PlgAN and therefore probably not necessarily a sole factor in its pathogenesis. We 
also found the main differences between the patient and control groups in the least 
abundant glycoforms. This may mean that such unusual glycoforms are the 
pathogenic species involved in the deposition of IgAl and triggering of an 
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inflammatory process. Further studies of these 'micro-glycoforms' are required to 
assess their pathogenicity. 
IgA I 0-glycosylation of patients with HIgAN and cirrhosis had not previously been 
studied by mass spectrometry. We found that these patients had a marked degree of 
under-sialylation. This could be explained by the poor hepatocyte function in this 
patient group. Failure of the ASGPR to clear serum IgA can result in high levels of 
circulating de-sialylated IgAl in these patients. Given that this finding was common 
to both patients with and without nephropathy, it is unlikely that under-sialylation of 
IgAl per se leads to the development of renal disease. Also the mechanism of 
decreased GaINAc: substitutions and increased overall galactosylation in HIgAN 
cannot be explained and contradicts the finding in the PIgAN literature where under- 
galactosylation has been proposed as the key pathogenic factor in IgAl deposition. 
The absence of these changes in patients with cirrhosis without renal disease suggests 
they are not a simple consequence of the 'cirrhotic milieu'. 
Finally, the changes found in patients with myelorna are difficult to explain but are 
probably a reflection of the properties of the specific clonal expansion for each 
individual. None the less, the increased galactosylation appears to be a real 
phenomenon and further studies in this area may shed light on the post-translational 
modification mechanisms controlling IgAl HGP glycosylation. 
In conclusion, our study has clearly demonstrated the presence of a variety of 
glycosylation changes in the different patient and control groups. No obvious pattern 
or candidate glycoform has been identified as one that leads to the development of 
IgAN. The presence of a vast variety of glycoforms in different conditions poses more 
questions about the significance of glycosylation patterns in different disease 
processes rather than providing a key to the aetiology of IgAN. 
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Chapter 6: Fca-Receptor I (CD89) mediated IgA clearance 
6.1 Introduction 
Monocyte and neutrophil FcaRl (CD89) expression was measured in these studies as 
per protocols discussed in the methodology chapter (3). The aim of these studies was 
to observe any differences in the expression of the CD89 receptor on circulating 
monocytes and neutrophils in our patient and control groups. Previous reports in this 
area have been contradictory some showing increased (Kashem et al 1994; Kashem et 
al 1996) and others showing decreased receptor expression in IgA nephropathy 
(Grossetette et al 1998). These findings have been used by some to explain the 
elevated IgA levels in patients with IgAN and liver disease (Silvain et al 1995). Using 
cells obtained from the patients and controls described in chapter one, we examined 
the expression of this receptor on circulating white blood cells. 
6.2 Flow cytometry 
Polymorph mononuclear cells were obtained as described in chapter 3 and stained 
with the relevant positive and negative control antibodies at 4*C to avoid modulation 
in the receptor expression. FACS analysis results were obtained as forward and side 
scattered profiles. The median channel fluorescence (MCF) was used as the measure 
of cell fluorescence intensity because this parameter has been shown to most 
accurately reflect the average fluorescence of cells in a cytometric sample. In all cases 
the data presented have been corrected for non-specific binding by subtraction of 
auto-fluorescence and background staining. Fluorescence intensity was analysed with 
log amplifier output and light scatter data acquired in the linear mode. Forward scatter 
(FSc) and side scatter (SSc) were measured and data stored in list mode. Figure 6.1 
shows the forward and side scatter characteristics of whole blood. U937 cells, which 
are an immortalised monocytic cell line were also used as a positive control for the 
presence of CD89 activity. Cells were taken from the 3 rd passage onwards. The 
forward and side scatter profiles for these cells are demonstrated in Figure 6.2. 
Furthermore, the shift in the cells is demonstrated in Figure 6.3 where the U937 cells 
are counterstained with anti-CD89 antibodies. The cells were all stained with 




IA 37? K-% rn k ý - IL 
S 
CD . 
't -f * ýAio,; - a. *-*.. G2 
D 
,-1. . W. IL 
C2, 
FSC44 
Fig 6.1 Forward scatter and side scatter characteristics of white blood cells after 
separation from whole blood. Gates were established around the separate populations 
of neutrophils (G I), monocytes (G2) and lymphocytes (G3). These gates were used for 
live gating during data acquisition. Dead cells and cell debris can be seen occupying the 








Figure 6.2 U937 cells scatter characteristics. Acquisition gates were drawn 
around homogeneous cell populations and data live-gated for all experiments. 






Figure 6.3 Shows the shift in the Fc-block stained U937 cells before (top 
figure) and after (bottom figure) staining with anti-CD89 antibody. This 
demonstrates that all the cells express CD89 on their surface and may be used as 
a positive control for the peripheral blood mononuclear cells under study. 
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Figure 6.4 Shows the shift in the population of monocytes stained with Fc 
block only in the top figure. The shift shown in the cells in the lower trace is 
after double staining with anti-CD14 antibody, which is specific to 




6.4 shows a population of monocytes which are positive for CD14 when stained by 
the relevant antibody. Finally Figure 6.5 is an example of monocytes showing a 
positive shift when stained with anti-CD89 antibodies. 
63 Measurement of granulocyte size and granularity 
Forward scatter is a measure of mean cell size by flow cytometry. Although a wide 
range of granulocyte size was found in all groups, there was no difference between 
their mean values in this respect. Side scatter is a reflection of cellular complexity. 
This is determined by cell granularity and as such reveals information about the state 
of activation of the cell. Cells with reduced granularity have been activated and 
undergone de-granulation. Figures 6.6 and 6.7 show the results of the mean side and 
forward scatter for the granulocytes populations studied by flow cytometry 
respectively. Amongst the different study groups, we only found evidence of 
neutrophil de-granulation and activation in patients with cirrhosis, where cell 
granularity was reduced significantly (p<0.0042). The obtained data are summarised 
in Table 6.1. 
6.4 Monocyte CD89 expression 
Monocytes, were found, as expected, to comprise 5% of the PBMCs in the samples. 
Figure 6.4 shows the representative profiles of monocytes counter-stained with CD14 
in a normal individual. Monocytes from patients with primary and hepatic IgAN were 
compared with their respective controls. No statistical differences were found between 
any of the patient or control groups. Figure 6.8 shows a scatter graph of CD89 
expression, expressed as log median fluorescence for each subject group. No 
significant difference was apparent in the mean value for each group. 
6.5 Neutrophil CD89 expression 
The same analyses were performed to assess the CD89 expression on neutrophils. 
Again we did not find any significant differences between normal controls and the 
patient groups and their respective controls. Figure 6.9 illustrates these results. 
6.6 Percentage CD89 positive monocytes 
In order to assess the contribution of monocyte numbers to the above results, we 









Figure 6.5 Shows an example of the shift in the population of monocytes stained with 
Fc block alone in the top figure. The shift shown in the cells in the lower trace is after 
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Subject groups 
Figure 6.6 Graph comparing the mean side scatter in the granulocytes studied by flow 
cytometry in normal controls, PIgAN, GN, HlgAN, and Cirrhosis. These results 
demonstrate that there are no differences between the different groups in granularity of 
the cells except for cirrhotic patients (p<0.0042). This suggests that the neutrophils 
from patients with cirrhosis are probably activated. The horizontal bar is the mean value 
for the group. 
Normal PIgAN GN HIgAN Cirrhosis 
No. 23 15 9 6 8 
Mean 672 661 646 660 605 
SD 62 64 64 28 24 
SE 13 17 21 11 8.6 
p N/A 0.68 0.28 0.73 0.0042* 
value 
MWU N/A 158 77 62 28 
Table 6.1 Table surnmarising the statistical analyses of the side scatter data. The Mann- 














Figure 6.7 Mean granulocytes forward scatter in the different patient groups are 
shown in this graph. There was no difference between the groups indicating the 
absence of any significant difference in size between granulocytes in the different 
patients and their controls. 
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Figure 6.8. Comparison of monocyte CD89 expression between normal 
controls (n=19), patients with primary IgAN (n=14), other primary 
glomerulonephritides (other GN, n=8), hepatic IgAN (n=7), and cirrhosis (n=6) 
No significant difference was found in Fc(xR] expression (ordinate) between 
the different subject groups. The horizontal bars indicate the mean for each 
group. 
183 





Figure 6.9 CD89 surface expression on neutrophils compared in normal 
controls, patients with primary IgAN, patients with other GN, hepatic IgAN, 
and cirrhosis. As with monocyte CD89 expression, no difference was found to 
be statistically significant between the groups. 
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Normal Control IgAN Other GN Hepatic IgAN Cirrhosis 
Subjects 
monocytes when stained with the CD89 antibody. We illustrated no differences 
between any of the groups as seen in Figure 6.10. This suggests that the CD89 
expression is uniform within the monocyte population. 
6.7 Percentage CD89 positive neutrophil 
Numbers of neutrophil positive for CD89 were assessed by the same methods 
discussed above. 'Me percentage of these cells was fairly consistent between the 
different groups, although there was a wide scatter about the mean in patients with 
cirrhosis compared with the other subjects. Figure 6.11 demonstrates these findings. 
6.8 Discussion 
Early studies of primary IgAN reported an over-expression of CD89 in both 
peripheral monocytes and neutrophils (Kashern et al 1996 and 1994). However, later 
studies indicated a reduction in CD89 expression on these cells in IgAN (Grossetete 
1998). 'Mere is also one report of defective endocytosis of FcccRI-IgA by PMN and 
monocytes in patients with IgAN (Monteiro et al 1995). A separate study found 
monomeric IgA isolated from patients with IgAN bound less well to the CD89 
receptor compared with normal healthy controls, presenting a further route for 
disruption of systemic IgA clearance in IgAN (van Zandenberg et al 1998). 
Alterations in the post-translational modification of FcccRI (CD89) have also been 
reported in IgAN. Myeloid FcaRI from these patients were found not only to be 
consistently larger (60 to 85 kDa) than those of controls (55 to 75 kDa) but also to 
have decreased binding to a sialic acid-specific lectin indicating impaired sialylation 
of surface Fc(xRl molecules (Grossetete et al 1998). This could potentially influence 
the receptor-ligand interaction and may help explain the reduced binding of 
monomeric IgA seen in IgAN. 
Silvain et al (1995) have found reduced CD89 levels on monocytes in patients with 
alcoholic cirrhosis with a significant correlation between serum 19A levels and 
monocyte CD89 expression. Whilst there has been some evidence for defective 
monocyte function in patients with hepatic IgAN in the literature (Roccatello 1985), 
there are no studies of Fc alpha expression in hepatic IgAN. In this study we have 
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Figure 6.10 Percentage of CD89 positive monocytes in samples taken from 
patients with primary IgAN, hepatic IgAN, other glomerulonephritides, 
cirrhosis, and normal controls; All different groups showed a wide spectrum 
of CD89 positivity about the mean. There was no significant difference 
found between the groups. The mean (horizontal bar) however does show a 
trend towards reduced numbers of cells with CD89 expression in both PIgAN 
and cirrhosis. 
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Figure 6.11 Percentage of CD89 positive neutrophils compared in normal 
controls, patients with primary IgAN, patients with other GN, hepatic 
IgAN, and cirrhosis. As with % of CD89 positive monocytes no difference 
was found to be statistically significant between the mean values for the 
patient and control groups. The horizontal bar is the mean for the values 
obtained within each group and this shows that the percentage of CD89 
positive neutrophils in patients with cirrhosis is reduced when compared 
with the median value for the other groups. This may be due to the 
activated state found in this group's granulocytes. 
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looked at the expression of CD89 receptors in patients with primary and hepatic IgAN 
and their controls as well as measuring the percentage of CD89 positive PBMCs. 
Our findings do not support the results of previous investigators who have either 
shown elevated or reduced CD89 expression in peripheral blood cells of patients with 
IgAN and cirrhosis. We have found no differences in either direction between the 
groups. There was no difference in the surface CD89 expression in either monocytes 
or neutrophils but we did find a trend towards reduced receptor expression in patients 
with PIgAN and cirrhosis but this did not achieve statistical significance. When 
examining the percentage of CD89 positive cells, it appears that the values for 
percentage receptor positivity in monocytes in all groups show a wide scatter about 
the mean with no significant difference between the groups. This suggests that in any 
one group, the monocyte population is quite heterogeneous with regards to the 
presence of CD89 receptors on the cell surface. Conversely a high percentage of 
CD89 positivity existed in the neutrophils of normal controls, patients with GN and 
HIgAN with only a few individuals in each group showing lower levels of receptor 
positivity. The patients with cirrhosis and to lesser extent patients with primary IgAN 
on the whole had a lower percentage of CD89 positive neutrophils. These findings did 
not achieve statistical significance which may be explained by the small numbers of 
patients especially in the cirrhosis group. 
Given the standardised experimental procedure, it is unlikely that the lack of 
significant differences between groups in CD89 expression is due to the presence of 
different variables affecting the results during the course of our experiments. The 
standardised protocol was applied consistently to every set of experimental sample 
and conditions were optinýiised for minimal leukocyte activation. Furthermore, the 
populations of lymphocytes, monocytes and polymorph nuclear cells were live-gated 
according to FSc and SSc characteristics and the accuracy of these gates confirmed by 
back-gating using CD14 and CD45 staining. The conjugated antibodies used for cell 
staining were all standard commercial ones with high levels of specificity for their 
receptors. For accurate quantitation the amount of antibodies used was of saturating 
level. The appropriate amount was determined empirically prior to these experiments. 
The flow cytometer was calibrated daily for fluorescence and light scatter with 
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microbead standards (Dako FluoroSpheres, Dako Ltd). During the time course of the 
study no significant change in calibration was seen. 
The other aspect of the methodology which may account for the discrepancies in the 
findings by different researchers is the antibody technique used to stain the cells under 
examination. Kashem et al (1996) had used indirect immunofluorescence (EF) in their 
experiments which may cause cross-linking by the secondary antibody in the EF assay. 
This in turn could cause clustering of the receptor resulting in falsely elevated 
fluorescence intensity. Grossetete et al 1998 used direct antibody binding to the 
receptor to avoid this problem. In fact they did report a difference in their results 
depending on which technique they utilized. A direct assay with a fluorochrome 
labelled anti-CD89 antibody showed significantly decreased fluorescence intensity 
(FI) whereas repeating the same experiment with an indirect assay yielded a slightly 
increased FI value in IgAN. However, having used the same direct fluorochrome 
conjugated anti-CD89 monoclonal antibody, we have not found statistically 
significant decrease in surface expression of CD89 in circulating monocytes and 
neutrophils. 
We did find some evidence of cell activation from the data assessing side scatter in 
granulocytes. 'Me only groups that were statistically different in terms of granularity 
were those patients with cirrhosis without renal involvement. It is unlikely that this is 
due to samples from these patients being handled differently during the course of the 
study as no statistically significant correlation was found between the neutrophil 
CD89 expression and the side scatter for the samples. It is most likely that these 
patients' cells were activated in vivo. 71bis finding however does not explain the lack 
of difference in the receptor expression in neutrophils in the different patient groups. 
Previous studies of CD89 receptor expression on monocyte cell lines (U937) suggest 
that cells activated with PMA show increased intensity of surface staining up to 3-4 
fold, consistent with activation induced by IgA binding up-regulation. One 
explanation for finding the reverse in our cirrhotic patients may be the occupation of 
these receptors by IgA immune complexes which are found in abundance in the 
circulation of these patients, thus decreasing monoclonal antibody binding and hence 
staining of the cell surface receptors. In our results however, we did not find a 
correlation between total serum IgA levels in patients and fluorescence intensity. 
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In summary, our experiments did not show statistically significant over expression or 
under expression of CD89 in neutrophils and monocytes in our study groups when 
compared with normal and other relevant controls. These findings effectively negate 
the hypothesis that the differences in the serum IgA levels in patients with IgAN and 
liver disease are due to altered expression of and clearance via the monocyte and 
neutrophil CD89 receptor. Our study did show a trend towards reduced CD89 
expression on neutrophils in primary IgAN and cirrhosis as well as lower percentage 
of CD89 positive neutrophils in these two patient groups, but these findings did not 
achieve statistical significance. This may be due to small numbers of patients in the 
hepatic groups. 
The differences in the results between the different studies presented in this thesis 
may ultimately be due to the study of vastly different populations of patients with 
different genetic characteristics. IgA nephropathy in itself is a heterogeneous disease 
and this per se renders extrapolation from one study performed in one population to 
another with vastly different racial and genetic backgrounds problematic. However, 
based on our findings, it is reasonable to conclude that CD89 expression does not play 
a key role in determining the levels of serum IgA in IgAN and hepatic cirrhosis and 
the predisposition to tissue IgA deposition. Other factors such as the ASGPR function 
and the state of immune activation and over-production of IgA are a more likely 
explanation of the finding of raised IgA levels in these conditions. Our studies of IgA 
production in these patients are presented in the following chapter (7). 
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Chapter 7: IgA Production in IgA nephropathies 
7.1 Human IgA production 
Despite the marked predominance of mucosal IgA production, appreciable quantities 
of IgA are also made in systemic immune sites, most notably the bone marrow. In 
health this IgA is nearly entirely monomeric IgAl, which is secreted into the 
circulation (Kerr 1990). There have been reports of increased serum IgA levels in the 
primary IgA nephropathy literature (d'Amico 1988). The ratio of polymeric to 
monomeric IgA in the circulation although within the normal range, is reported as 
increased when compared to normal subjects (Layward et al 1992; Ots et al 1999). 
Both patients with cirrhosis and hepatic IgAN are said to have elevated circulating 
IgA levels (Feehally 1988; Pouria and Feehally 2000). Whilst in normal individuals 
and those with primary IgAN the circulating IgA is predominantly of the IgAl sub- 
type, in cirrhosis both IgAl and IgA2 levels are elevated, the latter being the more 
markedly raised. 
In this chapter the data from studies assessing the characteristics of serum IgA and its 
production, as set out in the aims of the thesis are presented. These experiments were 
performed to address the following points: 
1. In order to assess any differences in IgA production between the patient and 
control groups serum IgG, IgA, and IgA sub-class (IgAI and 2) levels in both 
primary and secondary IgAN and their respective controls were measured as 
pcr protocols dcscribed in chaptcr 3. 
2. We also measured total IgA, IgG and IgM levels in the supernatant produced 
by peripheral blood mononuclear cells in stimulated and unstimulated cultures 
to find if there were any differences in immunoglobulin production between 
the groups in vitro. 
3. We measured the levels of IgA monomer and polymer in the serum of the 
different groups by size exclusion chromatography looking for differences in 




7.2.1 Serum immunoglobulin levels 
Z2.1.1 Serum total IgA: Total serum IgA levels were measured in 23 normal controls, 
15 patients with PlgAN, 10 patients with other glomerulonephritides, 6 patients with 
hepatic IgAN and II patients with alcoholic cirrhosis. Total IgA levels obtained by 
ELISA in normal controls were between 1.7 and 7.5 mg/mI with a mean and standard 
deviation of 4.4: 0.8. Patients with IgA nephropathy (both primary and hepatic) had 
significantly elevated total IgA levels as expected. The range for the former was 
between a minimum of 3.9 and a maximum of 15.4 mg/ml and in the latter between 5 
and 16.6 mg/ml. Patients with cirrhosis with no renal disease had the highest IgA 
levels of all the groups as previously reported in the literature, with a range of 4-31.7 
mg/ml and a mean of 17.7±7.9 mghnl. Unexpectedly we found that even patients with 
non-IgA glornerulonephritis had a modest but statistically significant elevation in their 
total serum IgA levels with a range of 3.6-12.5 and a mean of 6.6±2.7mg/ml. These 
results are summarised in Table 7.1 and depicted in the graph in figure 7.1. 
The serum IgA levels measured using ELISA in our hands in the laboratory were 
higher than the range quoted from our hospital laboratories. We found that on average 
the levels were greater by 2-4 fold. We speculate that this arose as a result of a 
commercial RID kit being used by the hospital laboratories. The higher sensitivity of 
the ELISA probably explains this difference. Nevertheless as demonstrated by the 
dot-plot graph in Figure 7.2, there is a good correlation between the laboratory values 
measured by us and using the hospital immunology RID kit. 
Z2.1.2 Serum IgAI: Serum IgAl samples were measured by ELISA as per methods 
outlined in chapter I Samples were analysed from the same patient groups as before. 
The normal range for serum IgAl was between 0.4 to 5.8 mg/ml. with a mean of 3.1 ± 
1.6. IgAl levels were significantly elevated in all the patient and control groups 
except for HIgAN where the increased mean IgAl value did not reach statistical 
significance due to small sample size. These changes were particularly marked in 
patients with cirrhosis with no renal disease although we did find a very wide scatter 
around the mean. A summary of these results is shown in Figure 7.3 and Table 7.2. 
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Normal PIgAN GN HIgAN Cirrhosis 
Number 23 15 10 6 11 
Mean 4.32 8.10 6.57 10.37 17.73 
SD 1.75 2.98 2.66 4.23 7.86 
SEM 0.36 0.77 0.84 1.73 2.37 
P value N/A 0.000 1 0.01* 0.00 1 0.000 1 
Table 7.1 Statistical analyses of values obtained for total serum IgA and the 
differences between different patient groups. Serum total IgA levels were significantly 
elevated in all groups as compared with normal. The data were analysed using a Mann 
Whitney U test with confidence intervals of greater than 95%. 
:=- P<0.000 I P<0.0001* 
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Normals PlgAN GN HIgAN Cirrhosis 
Figure 7.1 A graph comparing total serum IgA levels in the different 
patient groups, showing statistically significant elevation in all patient 








Laboratory RID IgA values (mg/ml) 
Figure 7.2 A dot plot of the correlation between serum total IgA 
values in 35 patients and controls, obtained by ELISA in our 
laboratories as compared with the levels obtained from the same 
samples when analysed by a commercial RID kit in the hospital 
laboratory. 
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Normal HIgAN Cirrhosis 
Figure 7.3 Graph showing elevated serum IgAl in patients as opposed to 
normal controls in PIgAN, GN, HIgAN and Cirrhosis. Despite the elevated 
mean value of IgA the results in the HIgAN group did not reach statistical 
significance due to low patient numbers. Analyses were performed using Mann 
Whitney U test with p values < 0.05 deemed significant. 












Normal PIgAN GN HIgAN Cirrhosis 
Number 25 14 10 6 11 
Mean 3.10 4.43 5.61 6.20 12.81 
SD. 1.53 2.20 3.12 3.83 6.47 
SEM 0.31 0.59 0.99 1.57 1.95 
p value N/A 0.039* 0.03 1 0.054 0.0001* 
Table 7.2 Table showing differences in serum IgAl levels between different patient 
groups. Patients with primary and not hepatic IgA nephropathy have statistically 
significant elevated levels of circulating IgAl, as do patients with other 
glomerulonephritis and cirrhotics with no renal disease. 
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Z2.1.3 Serum IgA2: Serum IgA2 levels were measured by ELISA in the same patient 
and control groups as per the protocol described in chapter 3. The normal levels 
ranged between 0.2 and 8mg/mI with a mean of 1.9 ± 2. IgA2 levels were elevated in 
patients with cirrhosis but not those with hepatic IgAN. Whilst patients with primary 
IgAN did not have a statistically significant increase in their serum IgA2 levels 
compared with normal controls, patients with non-IgA glomerulonephritis did. Once 
the Bonferroni test was applied to the results of this experiment, the only truly 
significant difference was in the cirrhotic group when compared with normal subjects. 
These findings are presented in Figure 7.4 and Table 7.3. 
7.2.1.4 Ratio of serum IgA]flgA2 levels: These results show that the ratio of paired 
serum IgAl to IgA2 levels is similar in all patient and control groups. No statistically 
significant differences were found using the Mann Whitney U test as shown in rigure 
7.5. 
Z2.1.5 Serum IgG: Serum IgG levels were measured in 26 normal controls, 16 
patients with primary IgAN, 10 patients with other glomerulonephritides, 5 patients 
with hepatic IgAN and II patients with alcoholic cirrhosis with no glomerular 
disease. The results show that serum IgG levels from normal serum had a range 
between 7.2 to 33 mghnl with a mean of 18 mg/ml. Only patients with primary IgAN 
and cirrhosis when compared to normal controls appear to have a statistically 
significant increase in their serum IgG levels whereas those with other 
glomerulonephritides and secondary IgAN do not when the Mann Whitney U test is 
applied alone. The difference between PIgAN and GN is also statistically significant 
suggesting that the raised IgG levels are not related to renal disease per se but specific 
to PlgAN. We conclude that the rise in IgG levels may be a result of inflammation per 
se and not necessarily a feature of either liver or renal disease since patients with 
hepatic IgAN seem to have levels within the normal range. Figure 7.6 and Table 7.4 
show the details of the results of this experiment. 
7.2.2 PolyLneric and monomeric TgA production 
Serum IgAl purified by jacalin affinity chromatography was used for this study as 














0-: 0. -M AA 
Normal PlgAN GN HIgAN Cirrhosis 
Subjects 
Figure 7.4 Graph showing serum IgA2 levels in different patients. IgA2 
levels were significantly elevated in patients with cirrhosis and patients 
with non-IgA glomerulonephritis and not in primary or hepatic IgANs. 
Once the Bonferroni test was applied to the results, the only significant 
result was in the difference found between patients with cirrhosis and 
normal controls. 
Normal PIgAN GN HIgAN Cirrhosis 
Number 23 14 10 6 11 
Mean 1.86 2.47 2.93 2.97 6.07 
Std. Dev. 2.00 2.04 1.55 1.81 3.41 
Std. Error 0.42 0.54 0.49 0.74 1.03 
p value N/A 0.194 0.023* 0.101 0.0005* 
Table 73 Table summarising the statistical analyses on results from serum 
IgA2 levels and the differences found between different patient groups. (N: 
normal controls, P: PIgAN, G: other gl omeru I onephri tides, H: hepatic IgAN, 
C: cirrhosis, * denotes statistical significance by the MWU test) 
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Figure 7.5 Graph depicting the ratio of IgA I to IgA2 in serum from 
the different patient and control groups. The horizontal bar is the 
mean value for each group. There was no statistically significant 
difference between the means in any of the patient groups when 
compared with normal controls. The data were analysed by a Mann 
Whitney U test 
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Normal PlgAN GN HIgAN Cirrhosis 
n<0.033 
















Normal PlgAN GN HIgAN Cirrhosis 
Figure 7.6 shows a scatter graph of the serum IgG levels in the different 
patient groups: 26 normal controls, 16 patients with PIgAN, 10 patients 
with other glomerulonephritides, 5 patients with HIgAN, and II with 
cirrhosis. The level of IgG production was significantly elevated cirrhosis 
when analysed by the Mann Whitney U followed by the Bonferroni test. 
The difference between the PIgAN and GN groups was also statistically 
significant. The p values shown are for patients compared with normal 
controls. 
Normal PIgAN GN HIgAN Cirrhosis 
Number 26 16 10 5 11 
Mean 18 23 16 19 26 
SD 6.3 7.8 6 6.9 9 
SEM 1.2 2 1.9 3.1 2.7 
p value N/A 0.02* 0.57 0.79 0.01* 
Table 7.4 Statistical analyses of the serum IgG levels: Tables showing 
statistical differences in serum IgG levels between different patient groups. 
(N: normal controls, P: PIgAN, GN: other glomerulonephritides, H: hepatic 
IgAN, C: cirrhosis, * denotes statistically significant p value with 95% 
confidence intervals using Mann Whitney U test) 
199 
previous patient and control groups. Additionally, serum samples from patients with 
IgA myeloma and HSP secondary to myeloma were also used. Two samples of breast 
milk from lactating normal female controls were also collected and processed to 
isolate mucosal IgAl as described in chapter 3. Paired samples of serum were taken 
from the same individuals at the same time. This was used as a mucosal control to 
allow comparison between the mucosal and systemic IgA polymer and monomer 
levels. Results are expressed as the ratio between monomeric and polymeric IgA I. 
In this experiment we found the ratio of monomer to polymer in normal controls to be 
between 2.3 to 5 with a mean value of 3.4. In the PIgAN samples, this ratio was 
reduced with a mean of 3. Previous studies have suggested that serum IgA in primary 
IgA nephropathy has higher levels of circulating polymeric IgA and that these form 
the bulk of immune complexes in their blood. Although our results showed a trend 
towards lower monomeric forms in the serum, they did not achieve statistical 
significance. We found no difference between patients with other 
glomerulonephritides and the normal and the same holds true for hepatic IgAN. 
Patients with cirrhosis however had a much lower monomer/polymer ratio with a 
mean of 2.2. This was highly significant with p<0.001 1. 
Ile patients with HSP and myeloma had normal monomeric/polymeric IgAl ratios 
where as patients with IgA multiple myeloma had very high levels of polymeric IgAl 
and therefore a much reduced monomeric/polymeric ratio of 0.96. The breast milk 
contained very low levels of monomer, with one sample having an m/p ratio of 0.13 
and the other 0.5 (mean--0.34). This finding is to be expected given that the majority 
of secretory IgA is known to be polymeric. The results of these studies are shown in 
Table 7.5 and Figure 7.7. 
7.2.3 Supgmatant immunoglobulin production 
In our study, no differences were found between the patient groups in their ability to 
produce immunoglobulins of any of the IgA, IgG or IgM classes. Basal IgA 
production levels were virtually similar in all groups (Figure 7.8). Whilst we found 
that stimulation with pokeweed mitogen did increase the amount of IgA found in the 
supernatant of the cultured PBMCs, there was again no significant difference between 
the groups (Figure 7.9). 
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p<0.08 P<1.00 p<C, [)<0.0011* 
0 
Subjects 
Figure 7.7 Graph showing the ratio of monomeric to polymeric IgA in 
different patients. In addition to the 5 patient and control groups 2 samples 
of breast milk (13M) from 2 lactating normal females (mucosal IgA), 2 
samples of serum from patients with Henoch-Sch6nlein Purpura secondary to 
an IgA Myeloma (HSPM) and 4 samples from patients with different IgA 
myelomas were used. (BM: breast milk; HSPM: Henoch-Schonlein Purpura 
secondary to Myeloma). 
Normal PIgAN GN HIgAN Cirrhosis 
Number 21 33 11 7 9 
Mean 3.40 2.98 3.35 2.93 2.16 
Std. Dev. 0.65 0.99 0.88 0.72 0.82 
Std. Error 0.14 0.17 0.27 0.27 0.27 
p value N/A 0.08 1 0.22 0.00 11* 
Table 7.5 shows the analyses on the ratio of monomeric to polymeric IgA I 
by size exclusion chromatography in the different patient groups. Only 
patients with cirrhosis have statistically significant reduction in the ratio of 
monomeric to polymeric IgA in their circulation. Although the ratio was 
reduced in patients with both primary and hepatic IgAN, this did not attain 
statistical significance by the Mann Whitney U test. Statistical analyses were 
not carried out on the myeloma patients and the 2 samples of breast milk due 
to the small numbers of cases. 
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Figure 7.8 Graph showing the amount of IgA production in culture from 
unstimulated PBMCs in different groups. No statistically significant 




p<0.70 ; )- 0.5-, p<0.79 
Figure 7.9 Graph showing the level of IgA production from PBMCs stimulated 
in culture with pokeweed mitogen in the different patient groups. No 
statistically significant differences were found between the different groups. 
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Normal P19AN GN HIgAN Cirrhosis 
Subjects 
Normal P19AN GN HIgAN Cirrhosis 
Subjects 
Similarly the results of experiments looking at basal and stimulated IgG production 
did not highlight any differences between the groups (Figures 7.10 and 7.11). In all 
the groups except for GN, there appeared to be two separate subpopulations with 
different levels of unstimulated supernatant IgG production, but the relatively small 
numbers in each group did not allow a meaningful statistical analysis of the 
differences between them. These differences were also found in the PWM stimulated 
groups. Finally JgM production in both unstimulated and stimulated culture was found 
to be similar in all groups with no significant differences observed between the groups 
(Figures 7.12 and 7.13). 
7.3 Discussion 
Our findings in these series of experiments support previous reports that total IgA 
levels are generally elevated in patients with cirrhosis and in primary IgAN. We also 
found a significant increase in total serum IgA levels in patients with hepatic IgAN. 
However the finding that IgA levels are elevated in patients with other types of 
glomerulonephritis was surprising and may suggest mechanisms involved in serum 
IgA elevation which are not specific to IgA nephropathies. Some of the previous 
studies of serum IgA levels in IgA nephropathy have not used controls that have non- 
IgA renal glomerular disease (Layward et al 1993). The underlying mechanism for 
raised IgA levels is not known in this group of patients and one might speculate that 
the aetiology of these non-IgA glomerulonephritides may have factors that are 
common with primary IgAN. Ibis may be due to irregularities in the mucosal immune 
function in this patient group, which contrary to PIgAN do not lead to deposition of 
IgA in the glomeruli. On the other hand the presence of higher IgA levels may be 
quite a non-specific finding. 
In the analysis of the sub-classes of IgA, all the different patient and control groups 
had elevated IgA I levels as compared with normal controls. This was not expected in 
patients with non-IgA glomerulonephritis. Interestingly these patients showed 
significantly elevated IgA2 levels as compared with normals even when these levels 
were found to be normal in patients with primary and hepatic IgAN. Patients with 
cirrhosis also had highly elevated IgA2 levels. This has been previously reported in 
the literature (Kutteh et al 1982). 
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Normal PlgAN GN HlgAN Cirrhosis 
Subjects 
Figure 7.10 IgG levels produced by PBMCs in unstimulated culture medium 
showing no statistical differences between the patient and control groups. 
There was a bimodal distfibution of IgG levels within each individual group 
suggesting the presence of sub-populations with different IgG producing 
capacity. 
r)<0.3 p<0.7 p, 1 P<0.5 
E 
C 
Figure 7.11 IgG levels in supernatant produced by cultured PBMCs 
stimulated with PWM. There was no significant difference in the results 
between the different groups. The same bi-modal distribution as that found 
in basal IgG secretion is visible in stimulated IgG production, with the 
exception of the results from the normal controls. 
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r%-n i ný-l nn c nel 
Figure 7.12 IgM levels in supernatant produced by cells cultured in 
unstimulated RPMI medium. There were no significant differences in 





Normal PlgAN GN HIgAN Cirrhosis 
Subject 
Figure 7.13 Graph showing the IgM levels produced in the supernatant 
of PBMCs cultured in RPMI containing pokeweed mitogen. No 
statistically significant differences were found between the different 
groups. 
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p<0.95 , )--0.72 ;)f: ý 'I , ý" I- p<0.50 
Total serum IgG levels were found to be increased in patients with primary IgAN as 
compared with normal and renal controls. This has been previously reported during 
episodes of acute disease exacerbation in IgAN (Rostoker et al 1989). The same group 
have reported a disproportionate increase in circulating immune complexes containing 
IgGI and IgG3 in these patients. Patients with cirrhosis showed marked elevation of 
serum IgG, which in view of the high levels of IgG immune complexes in their 
circulation is not unexpected. This was not the case in patients with hepatic IgAN and 
may be a reflection of differences in the severity of the liver disease in the two 
different patient groups. Even though we have attempted to match the two groups for 
severity of- liver disease, the absence of a reliable marker of hepatic function makes 
this quite difficult. 
Although not all observers agree, a number of previous studies have reported 
increased IgA production and IgA system hyperactivity in vitro studies of PBMCs 
cultured in stimulated and unstimulated medium. We did not find any differences in 
the different patient and control groups for any of the three immunoglobulin classes. 
This could on the one hand be due to our particular experimental technique, or on the 
other hand it may reflect the fact that raised IgA levels are not a result of over 
production but rather a result of defective clearance from the circulation. 
Finally, our experiments measuring the ratio of polymeric versus monomeric IgA 
using size-exclusion chromatography confirms the previously reported increase in the 
polymeric fraction of serum IgA levels in patients with primary IgAN. Although this 
did not achieve statistical significance, the trend is definitely towards increased 
polymer. 'Me changes in the polymeric IgA levels appear to be modest in some 
studies examining both primary IgAN and also cirrhosis of the liver. One study 
suggested that this elevation was a consequence of the overt increase in serum IgA 
levels and found that the monomeric IgA levels were also markedly elevated 
(Newkirk et al 1983). They did however find selective rise in polymeric IgA in 
alcoholic cirrhosis. Other studies have not found a marked increase in polymeric IgA 
in IgAN and in one study of antigen specific antibodies (Russell et al 1986) three 
patterns of predominant polymer, predominant monomer, and equal amounts of 
polymer and monomer were found. One group did find significantly higher polymeric 
IgA levels in IgAN versus patients with non-IgA renal disease and normal controls 
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(Tomino et al 1984). However the numbers of patients in each group were very small. 
Czerkinsky et al (1986) found that in a third of patients both monomeric and 
polymeric forms of IgA immune complexes were raised in IgAN. 
The absence of a significant result in our study may also be due to less than optimal 
resolution of the various peaks obtained. The results none the less were highly 
significant in patients with cirrhosis and confirm the findings from previous reports of 
elevated polymeric IgA levels in this group. We would have expected patients with 
hepatic IgAN to show a similar trend but found no significant change as compared 
with the normal polymer to monomer ratio. This may be due to insufficient number of 
patients in this group. 
7.4 Conclusion 
In conclusion our results support the previous findings of elevated IgA levels in 
patients with primary and hepatic IgAN and cirrhosis. In addition we have found that 
this is also the case in patients with other types of glomerulonephritis. The PBMC 
studies did not support the previously reported hyperactivity of the IgA producing 
plasma cells in IgA nephropathy. Furthermore, raised IgA levels are in no way 
specific to IgA nephropathies when compared to the relevant disease controls. 
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Chapter 8: Discussion 
This thesis has examined the production, clearance and structural characteristics of 
human IgA in a number of IgA-mediated diseases. The main purpose of this study 
was to elucidate the mechanisms involved in IgAl mesangial deposition choosing the 
IgAl hinge region 0-glycosylation pattern as its main focus. We believe no single 
aetiological factor is responsible for IgA deposition in IgAN and that several 
contributory factors are required for this diverse condition to develop in its various 
forms. An important strength of this study has been the use of samples from patients 
not only with primary IgAN, but also those with IgAN secondary to hepatic disease. 
Furthermore, appropriate renal and hepatic controls were employed which permitted 
the variations in both normals and other renal and hepatic disease groups to be 
determined. 
The glycan content of the IgAl hinge glycopeptide was determined using mass 
spectrometry. Having optimised the current MS techniques for performing 0- 
glycosylation analyses, the spectra obtained were used to compare the glycan content 
of serum IgAl in all patient and control groups. IgA production was assessed in vitro 
using PBMCs in culture and PBMC CD89 expression was studied by flow cytometry 
to assess one of its known clearance routes. Studying patients with secondary IgAN 
and patients with liver disease, has allowed us to examine a wide spectrum of 
conditions where IgA system anomalies have been identified, thus deepening our 
understanding of wider mechanisms underlying different subsets of patients in a 
disease which characteristically has a variable phenotype. 
IgAN is recognised as the commonest type of glomerulonephritis in the Western 
world (Julian et al 1988). Since Berger and Hinglais first described lgý, N in 1968, the 
condition has come to be known in a variety of heterogeneous clinical forms spanning 
a wide and disparate clinical spectrum (Nicholls et al 1985; Chauveau and Droz 
1993). Such is the diversity of the clinical presentation, course, and outcome of IgAN 
in different individuals and populations that classing it all as one disease may be an 
over-simplification and highly questionable. The one feature that unifies these 
variable clinicopathological entities is the detection of mesangial IgA deposits on 
immunofluorescence associated with variable degrees of mesangial matrix deposition 
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and cellular proliferation (d'Amico 1988). A review of the literature covering the 
natural history of IgAN highlights the existence of extreme variability in both the 
clinical course and the rate of progression in patients labelled with this disease 
(d'Amico 2000). The risk factors that are associated with poor outcome and disease 
progression are not really specific to IgAN and are generic to most other types of 
renal disease. The conflicting and controversial results of hundreds of studies 
published claiming universal parameters for prognostication in this disease suggests 
that IgAN should be regarded more as a syndrome rather than a unified disease 
(Clarkson et al 1984). The majority of clinical studies of 19AN so far have primarily 
been in non-selective cohorts of patients (Koyoma et al 1997; Radford et al 1997; 
Nicholls et al 1984; d'Amico et al 1986). Perhaps future studies should focus on 
selected sub-groups with well-defined characteristics in order to highlight the nuances 
in the phenotypes of individuals in terms of their presentation, clinical course, risk 
factors for progression, and the underlying aetiology of IgA nephropathy in all its 
guises. 
It is apparent from both clinical and laboratory studies of IgAN that there are as many 
permutations in the pathological and immunological profiles of these patients as there 
are in the clinical features (Emancipator and Lamm 1989). This, we believe is another 
strength of our study where we have assessed both primary and secondary forms of 
IgAN, describing the laboratory features of the individual types of the primary and 
hepatic forms of the disease as well as a number of cases of myeloma and HSP. Ibis 
allows us to move away from an over-simplified 'one-size fits all' approach to the 
pathogenesis of such a heterogeneous syndrome. 
The mechanisms of IgA deposition and the consequent initiation of glomerular injury 
in IgAN remain unknown and the unravelling of its aetiology continues to present us 
with a scientific challenge. Given that IgAN is distinguished from other mesangio- 
proliferative diseases by the presence of IgA deposits in the mesangium. on 
immunofluorescence, one key to our understanding of the disease process must be a 
clearer appreciation of the factors leading to the deposition of IgA in the different 
forms of the disease. It follows that in studying these factors we appreciate the 
existence of different mechanisms leading to IgA deposition in different patients. The 
course the disease takes may to some extent be dictated by the individuals' genetic 
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predispositions to other factors such as hypertension or renal fibrosis. Elevated IgA 
levels and aberrant glycosylation of IgAl in IgA nephropathies have been reported 
and may be the starting point in the development of the disease (Andre et al 1990; 
d'Amico 1988; Tomana et al 1997; Allen et al 1995; Mestecky et al 1997). They 
therefore warrant detailed investigation and characterisation in the process of 
unravelling the pathogenesis of IgA nephropathies. 
Identification of the factors leading to IgA deposition and the initiation of the 
inflammatory process have been hampered both by the absence of good animal 
models of IgA disease (Allen 1999), general paucity of information on human IgAl 
0-glycan structure due to inherent technical difficulties, and confusion and 
contradiction within the literature concerning various aspects of IgA metabolism 
(Allen 1999). The relative lack of detailed information on human IgA glycosylation 
has been in part due to the presence of a variety of glycoforms of IgAl in any one 
individual as well as the complexity of the potential permutations of 0-glycosylation 
in the hinge region (Reviewed in Novak et al 2001). This is changing, with increasing 
information becoming available from mass spectrometry as the technology has 
become more and more sophisticated and accessible, replacing less reliable techniques 
such as lectin binding and gas chromatography in the study of IgA structure (Odani et 
al 2000). Despite this, there are still many discrepancies in the literature regarding the 
mechanisms behind the production, clearance and physicochernical characteristics of 
IgA and the glycosylation pattern of the hinge region of IgAl. I will address some of 
the questions arising from these discrepancies in the light of our findings. 
8.1 Summary of Key Findings 
e Patients with primary IgAN have mass spectrometric evidence of significantly 
reduced serum IgAl sialylation with a slight decrease in galactosylation as 
well as lower numbers of GaINAc residues. 
* Patients with HIgAN also have marked undersialylation but increased 
galactose content compared with normal controls. Cirrhotics with no 
glomerular lesions have a greater proportion of undersialylated IgAl in their 
circulation but the galactose and GaINAc content remains unaltered when 
compared with normal controls. 
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9 The finding of altered glycosylation is not specific to renal diseases with IgA 
deposition. Patients with other glomerulonephritides also showed changes in 
their glycosylation pattern. Furthermore, when comparing the PIgAN and GN 
groups, no statistical differences were found between the two. 
9 Our patients with myelorna and HSP secondary to myeloma also showed 
changes in the IgA I glycan composition. 
We found elevated total serum IgA levels in all the groups compared with 
normals. The finding of elevated total IgA levels in our renal (GN) control 
group was unexpected. IgAl levels were elevated in primary and hepatic 
IgAN as well as patients with cirrhosis and non-IgA glomerulonephritis. IgA2 
levels were high in patients with cirrhosis and GN. The ratio of polymeric to 
monomeric IgA was only increased in patients with cirrhosis without renal 
involvement. 
* No significant changes were found in CD89 expression on peripheral blood 
mononuclear cells in any of the groups. 
8.2 IgAl O-Glycosylation 
8.2.1 Glycosylation results 
Previous attempts at obtaining spectra from the heavily sialylated IgAl hinge 
glycopeptide has been met with variable success. The only group who has previously 
succeeded in isolating the hinge glycopeptide and studi ed it by mass spectrometry 
have been unable to obtain baseline resolved, discrete spectra that allowed 
quantitative analyses to be performed (Figure 4.1) (lwase et al 1999; Hiki et al 1999; 
Odani et al 2000; Hiki et al 2001; Horie et al 2003). Their best spectra were obtained 
when the specimens were subjected to enzymatic cleavage of their sialic acid residues, 
thus producing spectra that were informative only about the galactose and GaINAc 
content of the peptide (Hiki et al 1998). 
We have successfully established a methodology for assessing the intact IgAl hinge 
glycopeptide using MALDI-ToF-MS. This allowed us to study the native IgAl hinge 
region in detail without having to enzymatically desialylate the species under 
examination. I'llis revealed a hitherto undiscovered 6th GaINAc substitution of the 
hinge glycopeptide in all patient and control samples (Tarelli et al 2004). The MS 
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results corroborated with the lectin binding data from studies performed on the same 
samples, confirming the robustness of our results (Figures 5.18). 
When this technique was applied to the various IgA I samples obtained from the sera 
of patient and control groups (including those with IgA myeloma and HSP secondary 
to IgA myeloma), a number of interesting structural features of the IgAl HGP 0- 
glycans became apparent (Table 5.6). The most striking changes in IgAl 0- 
glycosylation were in the degree of sialylation of the hinge region (Tables 5.5 and 
8.1). Patients with primary and hepatic IgAN as well as those with cirrhosis were 
found to have a statistically significant reduction in the number of sialic acid residues 
in the hinge region. The most marked changes were in those patients with cirrhosis. 
interestingly and rather unexpectedly, patients with non-IgA GN also showed, albeit 
to a lesser degree, evidence of under-sialylation but this was not statistically 
significant. 
GaINAc Galactose Sialic acid 






Table 8.1 A summary of glycosylation changes in the IgA I HGP 
in the patient and control groups. The numbers represent the 
average glycan residues per IgA molecule calculated from the 
values obtained from the normal controls. T elevated glycan 
content compare with normal, I reduced glycan content 
compared with normal, *-* unchanged. 
212 
A minor reduction in the percentage galactosylation of GaINAc residues on the HGP 
was observed which was only statistically significant in patients with primary IgA 
nephropathy (Table 5.4). Patients with hepatic IgAN in fact showed a slight increase 
in percentage galactosylation. 
We discovered a 6th GaINAc substitution in between 5-10% of the HGP species in 
normals and all patient groups with the exception of those with myeloma. In addition, 
we discovered the presence of differences in the number of GaINAc substitutions 
between the groups (Table 53). Patients with primary and secondary IgAN and not 
their renal or hepatic controls had a larger proportion of glycoforms containing 3 
GaINAc substitutions corresponding to a reduction in the mean GaINAc number. 
Those with myeloma and HSP myeloma had a trend towards higher mean numbers of 
GaINAc substitutions. There was no difference between mucosal or systemic IgA I in 
this respect when comparing the glycan content of serum and breast milk IgA. 
The most strikingly unusual 0-glycans found in patients with PIgAN were found in 
the least abundant species. When presented in rank order, the data suggest that there is 
little difference in the ranking of the major (top 10) glycoforms between the primary 
IgAN and the normal and renal controls (Table 5.5). However a number of minor 
glycoforms were identified in the primary IgAN group which were totally absent in 
the controls. These were also absent from the renal controls (GN group) (Table 5.7). 
The significance of this finding is two-fold. Firstly it suggests that mesangial 
deposition of IgAl may be mediated by a small but highly abnormal and pathogenic 
group of IgAl glycoforms. Secondly, it raises the technical possibility that the most 
pathogenic glycoforms, may not be retained by the jacalin affinity columns due to their 
highly unusual glycosylation and may be lost during sample purification and 
processing. 
Our results do not support the findings of previous studies that have claimed reduced 
galactose content as the salient distinguishing feature of IgAl 0-glycosylation in 
primary IgAN based on lectin binding and HPLC techniques (Allen et al. 1995, 
Tomana et al 1997). In one review article, the IgA HGP in IgAN has been firmly 
labelled as being 'Gal-deficient' quoting studies where the techniques used do not 
give as accurate or direct information about the structure of these glycans as mass 
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spectrometry (Novak et al 2001). Where they quoted the mass spectrometry data, they 
omitted to mention the findings pointing to de-sialylation of the HGP (Novak et al 
2001). Our data presents further evidence of complex global changes in the glycan 
content and composition in the patients and controls we have studied. The 
significance of these findings is discussed below. 
8.2.2 Inte[pretation of Glycosylation findings 
IgAl 0-glycosylation is altered in both primary and hepatic IgANs but also in other 
non-IgA glomerulonephritides. Patients with IgA myeloma with and without the 
presence of renal disease also exhibit changes in their glycosylation as compared with 
normal but the pattern of change is distinct from those with IgA nephropathies and 
may reflect the particular clonal expansion unique to each case. This is the first report 
of alterations in the glycosylation of IgA I in other GNs. 
These findings could be interpreted in a number of ways. Firstly, altered 
glycosylation may be a symptom rather than a cause of IgA nephropathies and as such 
reduced IgAl 0-glycosylation may not be singularly implicated in their pathogenesis. 
The presence of altered IgAl 0-glycosylation in other renal diseases supports the 
hypothesis that these changes are not specific to IgAN per se. The glycan profile 
obtained for the different groups of patients and controls showed shifts in the 
preponderance of the various species rather than distinct changes in glycoform 
composition. In IgAN, the most commonly represented glycoforms were found to be 
almost identical to those of other GNs in terms of ranking and percentage of total peak 
area. We therefore cannot solely attribute the pathogenesis of IgANs to subtle shifts in 
the overall glycosylation pattern. Furthermore, there was no correlation between the 
degree of renal dysfunction and the degree of change in glycosylation (See Figures 
5.19 and 5.20). 'Ibis makes the presence of under-glycosylation an unlikely single 
pathogenic factor in the aetiology or natural history of the disease. Nevertheless, these 
findings do not rule out a role for glycosylation changes as a trigger in a chain of 
events leading to the development of renal inflammatory disease in a subset of 
patients. 
The idea that IgA nephropathies are heterogeneous diseases with different aetiological 
factors may also explain these findings. The example of IgA system changes in 
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hepatic IgAN and also in patients with cirrhosis demonstrates that under-sialylation 
can be due to the failure of the IgA clearance mechanisms of the liver. 71bis may lead 
to accumulation of de-sialylated IgA in the circulation and lead to tissue deposition 
but not necessarily renal disease. So IgAN, which is really a morphological diagnosis 
with variable presentation and natural history, may also have diverse pathogeneses. 
Another interpretation of our results may be that the presence of specific pathogenic 
IgAl glycoforms, such as those found in small quantities in patients with primary 
IgAN may be capable of triggering an inflammatory process once deposited in the 
mesangium of genetically susceptible individuals. These particular species were 
absent in normal controls as well as those with other GNs. These striking differences 
although quantitatively small may be aetiologically significant. It may be these 
quantitatively insignificant glycoforms that represent the pathogenic glycans with a 
higher propensity to mesangial deposition in this disease. Whether the low level is due 
to tissue deposition or due to losses during jacalin affinity chromatography is not 
clear. One may speculate that the most pathogenic glycoforms, are so abnormal that 
their binding to jacalin is significantly altered and therefore lost in the process of 
purification. The good correlations between our lectin binding results on serum IgA 
and the spectra obtained from purified IgAl mitigates against there being a technical 
problem with our methodology. 
In one study Hiki et al (2001) used MALDI mass spectrometry to assess the 
glycosylation of IgA deposited in the mesangium of patients with primary IgAN. 
ribey were able to characterise some of the glycosylation features of the deposited 
IgA. Interestingly, they identified some of the unusual glycoforms that we specifically 
found in the serum of our patients with IgAN (the asialo-species 320,400, and 420). 
This finding lends support to the hypothesis that these atypical glycoforms found in 
low quantities in the serum have a stronger affinity for the mesangiurn. and may play a 
crucial role in the pathogenesis of IgAN. This also directs us towards the glycoforms 
to be studied in the future both in terms of their binding properties when isolated from 
serum and their ability to trigger an inflammatory response in the glomerulus. 
The literature covering the various techniques in IgAN so far has suggested different 
glycan candidates for the pathogenic role in IgAN. Lectin binding studies in IgAN on 
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the whole have shown evidence of under-galactosylation (Ander et al 1990, Allen et 
al 1995, Baharaki et al 1996, Tomana et al 1997, Allen et al 2001). However a 
number of studies did not support these findings and in fact found the opposite to be 
true (Tomino et al, 1995, Hiki et al 1996) and one paper contained conflicting results 
when different lectins were used within the same study (Allen et al 1995). A study by 
Hiki et a] (1996) using gas-phase hydrazinolysis showed increased asialo- 
GalPl, 3GalNAc, residues. Fluorofore assisted carbohydrate electrophoresis has 
demonstrated truncated IgAl 0-glycans with increased terminal GaINAc (Allen et al 
1999). Mass spectrometry has provided more evidence for both under-galactosylation 
and under-sialylation. Some authors have concluded from work based on gas 
chromatography that under-galactosylation in IgAN is the consequence of over- 
sialylation and over-activity of the sialyl-transferases (Tomana et al 1997). None of 
the studies has suggested aberrant GaINAc substitutions. 
So which glycan abnormalities are specific to IgAN and are they pathogenic? Our 
data confirm the earlier finding of under-galactosylation and under-sialylation of 
IgA I. Our findings highlighted a global decrease in glycosylation in all three residues 
particularly in sialic acid numbers. We have found differences in the number of 
GaINAc substitutions and a small but significant decrease in the percentage 
galactosylation. Given that patients with cirrhosis have strikingly under-sialylated IgA 
and very high serum concentrations of IgAl with and without renal disease, it is 
unlikely that pure under-sialylation per se is the cause of progressive renal disease in 
hepatic or primary IgAN. This does not rule out the role of under-sialylated species in 
the initial formation of the deposits nor does it negate the potential role for specific 
under-glycosylated pathogenic glycoforms in the pathogenesis of the disease. I 
believe that the role of so-called 'Gal-deficient' HGP has been over-stated in the 
literature (Tomana 1997, Novak 2001) without much direct evidence for its existence 
in a sufficiently large cohort of patients. 
How have the findings of this thesis contributed to our understanding of the 
pathogenesis of IgAN? Our study has analysed the greatest number of patients with 
IgAN and normal controls by mass spectrometry, engaging the appropriate normal 
and diseased controls. 71be real strength of the project has been in assessing defined 
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groups of patients with different characteristics and aetiologies, using tools that inform 
us directly and accurately of the underlying structure of the IgAl molecule. The study 
therefore has the power to draw definitive conclusions about the glycan content of 
IgAl and its potential role in renal diseases. 
The observation that IgA I O-glycosylation alterations in themselves are not specific 
to IgAN, and in light of the discovery of changes in all 3 glycans, the stated 
importance of glycosylation per se in the pathogenesis of IgANs now needs to be 
reassessed. The presence of similar changes in glycoforms in diverse diseases 
invalidates automatic assumptions about the biological properties and the pathological 
role of 0-glycans in the pathogenesis of IgANs even though they may have a share in 
its multi-factorial pathogenesis. The development and progression of the disease may 
require the interaction between a number of triggers and predisposing factors in any 
one individual. 
One possibility is that the presence of a small number of highly pathogenic 'sticky' 
glycoforms, over a period of time in the circulation will lead to mesangial deposition 
and trigger inflammation. One may hypothesise that IgAN manifests itself when an 
excess of undersialylated glycoforms, such as those found in the glomeruli of IgAN 
patients described by Hiki et al (2001) and those exclusively identified in the serum of 
patients with IgAN in this study are deposited in the renal mesangium. The 
progression of disease will depend on the genetic make-up of individual patients and 
their predisposition to other co-morbid factors such as hypertension. Perhaps different 
IgAl glycoforms have variable inflammatory and pathogenic potential and the 
presentation of the patients depends on the mix of glycans present within the deposits 
(Kokubo et al 1999; Kokubo et al 2000). Ibis could be supported by finding positive 
correlations between markers of progressive renal disease such as raised serum 
creatinine and the type of glycoforms encountered in the any one individual. We 
found no such correlation in our study. 
Alternatively it is likely that the unusual IgAl O-glycosylation is a consequence of 
the diseases we have studied. One can hypothesise that in patients with inflammatory 
diseases affecting the kidneys and liver, the metabolic and immunological changes 
resulting from cirrhosis or glomerulonephritis may affect immunoglobulin glycan 
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structure. Increasing evidence of glycosylation abnormalities in other autoimmune 
diseases such as rheumatoid arthritis may be a reflection of a universal change in post- 
translational modification of glycoproteins in an inflammatory milieu. The type of 
inflammatory process and the organs involved may dictate the exact nature of ihese 
changes. 
Finally, in light of the variable descriptions of its clinical and morphological features, 
the natural history, as well as the contradictory findings regarding its aetiology by 
various researchers, IgAN probably needs to be viewed as a heterogeneous disease 
with a common histological appearance and not under the umbrella of a unified 
diagnosis. 71be literature derives its information from patients studied with diverse 
racial backgrounds from the Pacific Rim, through Europe to America. Therefore the 
different genetic influences should be taken into account when interpreting the 
findings of such studies. The cohorts studied are also not homogeneous with respect 
to the clinical features of the patients and present vast clinical diversity. It may be that 
the presence of a certain pathogenic subset of glycoforms in a cohort of patients with 
specific racial and genetic predispositions and characteristics are required for IgA 
nephropathy to manifest itself in a particular phenotype and with a course unique to 
itself. This hypothesis may be tested by isolating those aberrant forms we found 
exclusively in patients with IgAN and those found in the deposits of IgAN patients in 
the paper by Hiki et al (2001) and assessing their binding properties in vitro and in 
vivo to mesangial cells, their receptors, and extra cellular matrix components. 
However, any findings from such studies should be viewed in the context of the 
individual patients genetic, racial, and immunological characteristics. 
8.2.3 Limitations of the MS stud 
The main significant limitation of our glycosylation studies are whether the results of 
experiments on serum IgA are truly a reflection of the tissue IgA within the renal 
mesangium. So far only two studies have addressed this issue (Allen et al 2001; Hiki 
et al 2001). Obtaining renal tissue from patients with IgAN for the elution of IgA is 
difficult. One study has eluted IgAl from 3 nephrectomy samples and examined the 
glycosylation pattern by lectin binding whilst another eluted the IgAl from renal 
biopsy samples and analysed them by MALDI ToF MS. The former found elevated 
lectin binding to Helix aspersa and Vicia villosa in all three tissue samples as 
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compared with the serum from the same patients and other patient and controls 
suggesting the presence of the under-sialylated and under-galactosylated forms in the 
glomeruli of these patients (Allen et al 2001). Hiki et al (2001) found decreased 
galactosylation and sialylation of the deposited IgAl compared with serum IgA from 
IgAN patients and normal controls. 
The concern about the use of jacalin in glycosylation studies and its implication in 
terms of selectivity for different glycoforms has been addressed earlier in chapter 5. 
Our results may be biased towards the least pathogenic glycoforms if there is an 
inherent inability of jacalin to bind the most aberrantly glycosylated species. However 
the concordance between our mass spectrometric findings and those of the lectin 
binding studies are reassuring that no significant glycoforms have been lost through 
the use of this method. The lectin binding assays were performed on whole serum not 
purified IgAl. The IgA was captured on anti-IgA coated plates before applying the 
lectins. These were done in duplicate plates that were developed with anti-IgAl to 
ensure the wells were saturated with IgAl and that the differences in lectin binding 
were not due to different amounts of IgAl being present in the wells. 'Me mass 
spectrometry was, on the other hand performed, on samples of purified IgA I. The fact 
that the two sets of studies and results show good correlation is highly significant 
because it suggests that the purified IgAl on which the MS has been done is 
representative of the whole array of glycoforms in the sera and that there have been no 
major loss of glycoforms. 
One further technical criticism may be directed at the differential ability of various 
glycoforms to 'fly' in the mass spectrometer vacuum chamber due to different masses. 
Thus for example under-sialylated species may be over represented as compared with 
more heavily glycosylated glycopeptides. Whilst the absolute percentages of the 
various glycoforms may be inaccurate, the differences between the groups should 
remain robust. 
This study has provided detailed information about the overall carbohydrate moieties' 
numbers in the hinge region. However it does not provide any information about 
amino acid specific substitutions of the glycoforms and this kind of structural analysis 
will need to follow. The increasingly sophisticated mass spectrometry technologies 
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now available should allow the exact structure of the glycoproteins to be identified. 
With the expansion of the new MS techniques, there is much room for optimism for 
progress to be made in this area. Already Novak et al have presented exciting new 
results by identifying the sugar substituted amino acids in the tryptic fragments of the 
hinge region of an IgAl myeloma protein. The desialylated spectra were obtained 
from a high resolution Fourier transform ion cyclotron resonance (FI7-ICR) mass 
spectrometer (Novak et al 2004). 
8.2.4 Future strategies in glycoform analysis 
We are currently planning de-glycosylation studies to re-assess the galactose content 
of the hinge glycopeptide samples that have been already studied. The bulk of 
evidence in the literature that proposes IgAl under-galactosylation is the hallmark of 
IgAN has not utilised mass spectrometry to assess its glycan content. We need to 
clarify this using our samples by a gold standard technique such as mass 
spectrometry. By removing heavy sialyl groups from the outer surface of the 
molecule, the core sugars and in particular actual galactose numbers will become 
more readily quantifiable. This should clarify the contribution of the different glycans 
in the make up of IgA I in PIgAN. 
Having described the relative carbohydrate content of the IgAl HGP in detail, we 
would like to perform qualitative analyses of the amino acid positions where 
substitutions by glycans in the IgAl hinge region have occurred. We now have access 
to the surface-enhanced laser desorption and ionisation (SELDI) MS technology, 
coupled with other facilities which should allow us to look at the exact structure of the 
molecule. 
Whilst the one MS study of the renal mesangial deposits shed some light on the type 
of glycoforms in the kidney, technically it did not produce optimal spectra for 
performing a definitive analysis of the deposits (Hiki et al 2001). We would therefore 
like to repeat this study using nanotechnologies that require the minimum amount of 
sample to assess IgAl glycoforms eluted from renal biopsy samples. It is now 
possible using single glomerular isolation techniques to perform such studies without 
requiring large quantities of biopsy tissue. Once specific deposited glycan changes are 
identified, it may then be possible to delve into the cause of the specific glycosylation 
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changes. The study of glycoform profiles for both serum and mesangial IgAl could 
reveal more information about the role of IgAl 0-glycosylation in this disease. 
Furthermore, the chemical properties of the under-glycosylated glycoforms could be 
compared with the normal controls. A number of studies described earlier have looked 
at the binding properties of de-sialylated IgA on columns lined with ECM and also 
their deposition when injected into experimental animals. Further analyses of the 
properties of glycoforms presumed to be pathogenic and found in the sera and 
mesangium of IgAN will be desirable. Likewise, the ability of these glycoforms to 
trigger an immune response will be of interest. 
Another interesting aspect of the glycosylation of IgA about which very little is 
known is the mechanism and site of glycosylation. Information on the factors 
controlling the number and order of glycan substitutions on a particular glycoform is 
scanty. Unravelling these processes is not only of academic interest but also opens 
potential routes for therapeutic interventions to alter glycosylation in the future. 
83 IgA production and sub-class profile 
8.3.1 Findings of the studies 
Serum IgA levels were found to be elevated in all study groups as compared with 
normal controls. Whilst this confirmed previous findings in patients with primary and 
hepatic IgAN as well as those with alcoholic cirrhosis, it was an unexpected finding in 
patients with glomerulonephritis of non-IgA aetiology. IgAl levels were also elevated 
in patients with IgAN, HIgAN and cirrhosis and again in patients with other GN. The 
IgA2 levels however were only significantly raised in patients with cirrhosis and 
rather unexpectedly again in GN. In keeping with previous findings of changes in the 
IgG immune system, serum IgG levels were also found to be higher in patients with 
IgAN and cirrhosis compared with normal controls and other GN (Schena et al 1986; 
Giron et al 1992). 
The ratio of polymeric to monomeric IgA was increased significantly in patients with 
cirrhosis as compared with normal controls. In IgAN, although the trend was towards 
the presence of higher polymer forms of IgA, this change in ratio did not reach 
statistical significance compared with normals and renal controls. 
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Despite elevated levels of total serum IgA in all our patient groups and diseased 
controls, no differences in IgA production by PBMCs in culture, neither in the resting 
nor stimulated state, were found. Given that the stimulated cultures produced higher 
levels of immunoglobulins of all three (IgG, A, and M) classes compared with the 
unstimulated group, it is unlikely that the lack of differences between the groups is 
due to an experimental artefact. 71bese findings bring the significance of IgA levels as 
a marker of disease under question. Furthermore, the presence of elevated IgA levels 
in renal diseases not mediated by IgA makes serum total IgA levels an unreliable 
diagnostic marker. 
IgA production in vitro is sensitive to many different culture conditions that will 
inevitably vary from one investigation to another. The fact that many researchers 
report conflicting results regarding IgA hyperactivity in vitro may be down to lack of 
uniform culture conditions used in different studies (Toyabe et al 2001; Layward et al 
1994; Hale et al 1986; Egido, et al 1983; Linne and Wasserman 1985; Feehally et al 
1986; Cagnoli et al 1985). The artificial tissue culture environment and lack of normal 
intercellular signalling pathways may also affect the growth and development of 
PBMCs in vitro. The choice of PWM may not reflect the true in vivo stimuli that 
trigger inappropriate production of IgA by natural food or infective antigens (Russell 
et al 1986). Our findings therefore do not rule out in vivo IgA over-production. 
We cannot draw definitive conclusions from the slight but statistically non-significant 
predominance of polymeric IgA over monomeric IgA in the serum of our patients 
with IgAN. Our findings support other research where absolute levels of serum 
polymeric IgA were increased, but levels of polymeric IgA relative to total serum IgA 
were in fact lower in IgAN when compared with normal controls (van der Boog et al 
2004). This study also found no significant correlation between serum concentrations 
of polymeric IgA and clinical parameters of disease. These data support the notion 
that size alone is not the key factor for mesangial deposition, while the 
physicochernical composition of the macromolecular IgA may be. 
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8.3.2 Limitations of I&A levels and production studies 
As with any clinical study, the patient groups may not be necessarily uniform in terms 
of degree of renal or hepatic dysfunction. Every effort was made to select patients 
with near normal renal function. However a number of patients with renal failure were 
also included in the study. A number of clinical parameters for each group of patients 
were observed, such as serum creatinine levels, 7GT levels, urine dipstik analysis, and 
24-hour protein levels. Assessment of hepatic function is more challenging and again 
as far as possible, patients with cirrhosis did not have decompensated liver failure. 
Although none of our patients were on immunosuppression, matching was not 
possible for other medications and most patients were on anti-hypertensive drugs and 
ACE inhibitors. It was not possible to match the study groups for gender due to 
preponderance of males in the IgAN and HIgAN patients. One further clinical 
criticism involves the study being carried out at a single time point. Whilst every 
effort was made to rule out acute infections or inflammation at the time of 
recruitment, it is difficult to generalise the results from the study at a single point in 
the natural history of the disease. Ideally one would want to repeat these studies over 
a period of time to look for changes with ageing and with acute inflammatory 
episodes. 
Finally, at the onset of this project, we assumed, based on the current literature, that 
patients with hepatic IgAN generally have a more benign course and do not develop 
renal failure. They would therefore act as a control group with a good prognosis for 
patients with primary IgAN. The literature suggests that ESRF in HIgAN is 
exceedingly rare. In our unit, out of 8 cases that were identified with HIgAN, 4 
developed end-stage renal disease, and another 2 had severe chronic renal failure. One 
had mild renal failure with only one case with normal renal function after a4 year 
follow up period. In effect, we did not have a 'benign control group' as had been 
anticipated at the outset. This does, however, suggest that HIgAN is not as innocuous 
a renal condition as it has been supposed. We may have selected the most aggressive 
cases by virtue of the fact that we only included patients if they had biopsy proven 
HIgAN. Given that patients without significant renal impairment would not have been 
biopsied, our sample may not truly represent the HIgAN population. 
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8.4 IgA clearance mechanisms 
We did not demonstrate any statistically significant differences in CD89 receptor 
expression on either monocytes or neutrophils in any of the study groups. The 
percentage of CD89 positive neutrophils and monocytes were also found to be 
uniform between the patient and control groups. This did not appear to be a reflection 
of differences in technique or the state of activation of the cells. It is unlikely that in 
IgAN, altered CD89 expression per se is a significant reason for a potential defect in 
the clearance of IgA and its immune complexes. This does not rule out the possibility 
of defective clearance due to altered interaction between the ligand and its receptor. 
As more and more Fca receptors are identified, it may be that other clearance 
mechanisms within the reticulo-endothelial system attain greater significance and 
studying such routes may prove more instructive. 
In patients with hepatic cirrhosis, it is more likely that the cirrhotic liver and the 
damaged hepatocytes are unable to perform their normal clearance of IgAl 
macromolecules and that this leads to IgA accumulation within the circulation. One 
study by Burgess et al (1992) showed that the changes in polarity in cirrhotic 
hepatocytes altered the position of the ASGP-R. This may in turn affect the 
accessibility of IgA to the receptor for clearance. Further studies of these disease 
specific mechanisms in these patients are warranted to assess the structure and 
function of these receptors and their interactions with their ligand using liver biopsy 
material. 
Finally, we are interested in studying the role of hepatocyte clearance of IgA and the 
interactions between glycan structure and the ASGP-R. This may be done either using 
immortalised cell lines such as the HepG2 that express the ASGP-R or using liver 
biopsy material from patients with primary and hepatic IgAN. 
8.5 Final Remarks 
This project aimed to study IgA biology as relevant to IgAN. In order to test the 
hypothesis that IgAl 0-glycosylation plays a role in the pathogenesis of IgAN, we 
analysed the various glycoforms of IgAl by devising a refined technique for the HGP 
purification and analysis by MALDI. This allowed us to successfully identify a 
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myriad glycoforms, which represent the normal spectrum of permutations in the IgAl 
HGP O-glycans, obtained from a large sample of normal volunteers. We subsequently 
compared different patient and control groups with this normal group using a Java 
programme created for this purpose. We also aimed to study the characteristics of 
serum IgA which we performed by measuring total IgA, IgAl, and IgA2 as well as 
the ratio of polymeric to monomeric IgA. IgA metabolism was also examined by 
looking for any differences in IgA production by plasma cells in vitro as well as IgA 
clearance via the CD89 receptor by measuring CD89 expression on peripheral blood 
mononuclear cells. 
The major contribution of this thesis to our understanding of the pathogenesis of IgA 
nephropathies is in our mass spectrometry findings of IgAl structure. We accurately 
identified and presented the vastly heterogeneous glycoforms that form the bulk of 
normal and diseased IgAl. Normal IgAl glycosylation has not been previously 
assessed in such large numbers of volunteers. We have thus created a baseline for 
normal IgAl glycosylation as well as defining the changes in the other patient and 
control groups. We also successfully compared the groups and found significant 
differences in both the core and surface glycans of IgAl. Our findings have proven 
the glycosylation changes in the IgAl molecule as a global phenomenon in the 
populations we studied and as such not specific to IgAN. We did however identify 
certain highly abnormal glycoforms which were specific to patients with IgAN which 
warrant a closer examination as outlined above. We also confirmed the previous 
reports of IgAl undersialylation in IgAN and to a lesser degree under-galactosylation. 
Our findings do not suggest that galactose-deficient IgA HGP is the most 
characteristic glycoform present in IgAN. By studying different subsets of IgA 
mediated diseases, different glycan patterns emerged in each group. These patterns 
may account for the variable presentation, clinical course and final outcome in the 
different groups. Studying the different IgA-mediated diseases as separate groups has 
allowed for these subtle changes to become apparent whereas examining them under a 
unified category would have bluffed the differences observed. 
In reviewing the IgAN literature on IgA levels and metabolism, we have come across 
much confusion and controversy. In this regard, our study confirms that elevated total 
serum IgA and its subtypes are not specific to IgAN. In patients with other GN the 
225 
IgA2 levels were in fact higher than IgAN. These serum levels should not have a 
place as a marker for the diagnosis or progression of the disease. Our data do not 
support the view held by some researchers in this field that polymeric IgA is the 
predominant form present in the circulation of patients with IgAN. We can only say 
that in a proportion of patients there is an increase in the polymer to monomer ratio. 
Furthermore our results show that there is no intrinsic over-production of IgA in vitro 
and an alternative mechanism for elevated IgA levels should be pursued. Finally we 
showed quite clearly that monocyte and neutrophil CD89 expression is unaltered in 
IgAN and we cannot attribute raised IgA levels in any of the patient or control groups 
to decreased clearance via reduced CD89 expression. 
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